BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hidalgo M. Pancreatic cancer. N Engl J Med. 2010;362:1605-1617. [PMID: 20427809 DOI: 10.1056/nejmra0901557] [Cited by in Crossref: 1860] [Cited by in F6Publishing: 1135] [Article Influence: 155.0] [Reference Citation Analysis]
Number Citing Articles
1 Kim YJ, Hong YB, Cho CH, Seong YS, Bae I. Exploring protein kinase inhibitors: unveiling gemcitabine resistance in pancreatic cancer. Pancreas 2012;41:804-5. [PMID: 22695089 DOI: 10.1097/MPA.0b013e31823f3fcb] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
2 Wang H, Du S, Cai J, Wang J, Shen X. Apolipoprotein E2 Promotes the Migration and Invasion of Pancreatic Cancer Cells via Activation of the ERK1/2 Signaling Pathway. Cancer Manag Res 2020;12:13161-71. [PMID: 33376407 DOI: 10.2147/CMAR.S284115] [Reference Citation Analysis]
3 Lee ES, Lee JM. Imaging diagnosis of pancreatic cancer: A state-of-the-art review. World J Gastroenterol 2014; 20(24): 7864-7877 [PMID: 24976723 DOI: 10.3748/wjg.v20.i24.7864] [Cited by in CrossRef: 191] [Cited by in F6Publishing: 146] [Article Influence: 23.9] [Reference Citation Analysis]
4 Orozco CA, Martinez-Bosch N, Guerrero PE, Vinaixa J, Dalotto-Moreno T, Iglesias M, Moreno M, Djurec M, Poirier F, Gabius HJ, Fernandez-Zapico ME, Hwang RF, Guerra C, Rabinovich GA, Navarro P. Targeting galectin-1 inhibits pancreatic cancer progression by modulating tumor-stroma crosstalk. Proc Natl Acad Sci U S A 2018;115:E3769-78. [PMID: 29615514 DOI: 10.1073/pnas.1722434115] [Cited by in Crossref: 50] [Cited by in F6Publishing: 54] [Article Influence: 12.5] [Reference Citation Analysis]
5 Li H, Zhou W, Li L, Wu J, Liu X, Zhao L, Jia L, Sun Y. Inhibition of Neddylation Modification Sensitizes Pancreatic Cancer Cells to Gemcitabine. Neoplasia 2017;19:509-18. [PMID: 28535453 DOI: 10.1016/j.neo.2017.04.003] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
6 Guerra C, Barbacid M. Genetically engineered mouse models of pancreatic adenocarcinoma. Mol Oncol 2013;7:232-47. [PMID: 23506980 DOI: 10.1016/j.molonc.2013.02.002] [Cited by in Crossref: 102] [Cited by in F6Publishing: 93] [Article Influence: 11.3] [Reference Citation Analysis]
7 Cheng XB, Sato N, Kohi S, Koga A, Hirata K. 4-Methylumbelliferone inhibits enhanced hyaluronan synthesis and cell migration in pancreatic cancer cells in response to tumor-stromal interactions. Oncol Lett 2018;15:6297-301. [PMID: 29725394 DOI: 10.3892/ol.2018.8147] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
8 Mou Y, Li M, Hou S, Ren X, Tian B. Assessment of preoperative hypercoagulability in patients with pancreatic ductal adenocarcinoma (PDAC) using rapid thromboelastography (r-TEG). J Thromb Thrombolysis 2019;48:648-52. [PMID: 31250338 DOI: 10.1007/s11239-019-01908-8] [Reference Citation Analysis]
9 Cho YR, Lee JH, Kim JH, Lee SY, Yoo S, Jung MK, Kim SJ, Yoo HJ, Pack CG, Rho JK, Son J. Matrine suppresses KRAS-driven pancreatic cancer growth by inhibiting autophagy-mediated energy metabolism. Mol Oncol 2018;12:1203-15. [PMID: 29791786 DOI: 10.1002/1878-0261.12324] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
10 Schlitter AM, Esposito I. Definition of microscopic tumor clearance (r0) in pancreatic cancer resections. Cancers (Basel). 2010;2:2001-2010. [PMID: 24281214 DOI: 10.3390/cancers2042001] [Cited by in Crossref: 51] [Cited by in F6Publishing: 47] [Article Influence: 4.3] [Reference Citation Analysis]
11 Lyssiotis CA, Cantley LC. Targeting metabolic scavenging in pancreatic cancer. Clin Cancer Res 2014;20:6-8. [PMID: 24166909 DOI: 10.1158/1078-0432.CCR-13-2570] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
12 Tao L, Zhang L, Peng Y, Tao M, Li G, Xiu D, Yuan C, Ma C, Jiang B. Preoperative neutrophil-to-lymphocyte ratio and tumor-related factors to predict lymph node metastasis in patients with pancreatic ductal adenocarcinoma (PDAC). Oncotarget 2016;7:74314-24. [PMID: 27494847 DOI: 10.18632/oncotarget.11031] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.8] [Reference Citation Analysis]
13 Sahai V, Kumar K, Knab LM, Chow CR, Raza SS, Bentrem DJ, Ebine K, Munshi HG. BET bromodomain inhibitors block growth of pancreatic cancer cells in three-dimensional collagen. Mol Cancer Ther. 2014;13:1907-1917. [PMID: 24807963 DOI: 10.1158/1535-7163.mct-13-0925] [Cited by in Crossref: 62] [Cited by in F6Publishing: 39] [Article Influence: 7.8] [Reference Citation Analysis]
14 Shao S, Qin T, Qian W, Li X, Li W, Han L, Zhang D, Wang Z, Ma Q, Wu Z, Wu E, Lei J. Cav-1 Ablation in Pancreatic Stellate Cells Promotes Pancreatic Cancer Growth through Nrf2-Induced shh Signaling. Oxid Med Cell Longev 2020;2020:1868764. [PMID: 32377291 DOI: 10.1155/2020/1868764] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
15 Polvani S, Tarocchi M, Tempesti S, Galli A. Nuclear receptors and pathogenesis of pancreatic cancer. World J Gastroenterol 2014; 20(34): 12062-12081 [PMID: 25232244 DOI: 10.3748/wjg.v20.i34.12062] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 18] [Article Influence: 2.8] [Reference Citation Analysis]
16 Naghibzadeh-Tahami A, Marzban M, Yazdi-Feyzabadi V, Khazaei Z, Zahedi MJ, Moazed V, Haghdoost AA. Opium use as an independent risk factor for pancreatic cancer: A case-control study. Cancer Epidemiol 2021;75:102017. [PMID: 34626910 DOI: 10.1016/j.canep.2021.102017] [Reference Citation Analysis]
17 Springett GM, Husain K, Neuger A, Centeno B, Chen DT, Hutchinson TZ, Lush RM, Sebti S, Malafa MP. A Phase I Safety, Pharmacokinetic, and Pharmacodynamic Presurgical Trial of Vitamin E δ-tocotrienol in Patients with Pancreatic Ductal Neoplasia. EBioMedicine 2015;2:1987-95. [PMID: 26844278 DOI: 10.1016/j.ebiom.2015.11.025] [Cited by in Crossref: 39] [Cited by in F6Publishing: 35] [Article Influence: 5.6] [Reference Citation Analysis]
18 Choi YD, Jung JY, Baek M, Khan S, Song PI, Ryu S, Koo JY, Chauhan SC, Tsin A, Choi C, Kim WJ, Kim M. APE1 Promotes Pancreatic Cancer Proliferation through GFRα1/Src/ERK Axis-Cascade Signaling in Response to GDNF. Int J Mol Sci 2020;21:E3586. [PMID: 32438692 DOI: 10.3390/ijms21103586] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
19 Delgiorno KE, Hall JC, Takeuchi KK, Pan FC, Halbrook CJ, Washington MK, Olive KP, Spence JR, Sipos B, Wright CV, Wells JM, Crawford HC. Identification and manipulation of biliary metaplasia in pancreatic tumors. Gastroenterology 2014;146:233-44.e5. [PMID: 23999170 DOI: 10.1053/j.gastro.2013.08.053] [Cited by in Crossref: 64] [Cited by in F6Publishing: 65] [Article Influence: 7.1] [Reference Citation Analysis]
20 Wang J, Hussain SP. NO and Pancreatic Cancer: A Complex Interaction with Therapeutic Potential. Antioxid Redox Signal 2017;26:1000-8. [PMID: 27510096 DOI: 10.1089/ars.2016.6809] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
21 Fang Y, Zhao L, Xiao H, Cook KM, Bai Q, Herrick EJ, Chen X, Qin C, Zhu Z, Wakefield MR, Nicholl MB. IL-33 acts as a foe to MIA PaCa-2 pancreatic cancer. Med Oncol 2017;34:23. [PMID: 28058630 DOI: 10.1007/s12032-016-0880-3] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 2.6] [Reference Citation Analysis]
22 Zhao L, Zhao H, Yan H. Gene expression profiling of 1200 pancreatic ductal adenocarcinoma reveals novel subtypes. BMC Cancer 2018;18:603. [PMID: 29843660 DOI: 10.1186/s12885-018-4546-8] [Cited by in Crossref: 32] [Cited by in F6Publishing: 24] [Article Influence: 8.0] [Reference Citation Analysis]
23 Oziel-Taieb S, Faure M, Gilabert M, Autret A, Turrini O, Moureau-Zabotto L, Giovannini M, Rousseau F, Raoul JL. Treatment of Pancreatic Adenocarcinoma in Elderly Patients over 75 Years of Age: A Retrospective Series of 129 Patients. J Gastrointest Cancer 2016;47:15-9. [PMID: 26545612 DOI: 10.1007/s12029-015-9774-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
24 Tesfaye AA, Kamgar M, Azmi A, Philip PA. The evolution into personalized therapies in pancreatic ductal adenocarcinoma: challenges and opportunities. Expert Rev Anticancer Ther. 2018;18:131-148. [PMID: 29254387 DOI: 10.1080/14737140.2018.1417844] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
25 Hwang HJ, Oh MS, Lee DW, Kuh HJ. Multiplex quantitative analysis of stroma-mediated cancer cell invasion, matrix remodeling, and drug response in a 3D co-culture model of pancreatic tumor spheroids and stellate cells. J Exp Clin Cancer Res 2019;38:258. [PMID: 31200779 DOI: 10.1186/s13046-019-1225-9] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 8.3] [Reference Citation Analysis]
26 Barros AG, Pulido CF, Machado M, Brito MJ, Couto N, Sousa O, Melo SA, Mansinho H. Treatment optimization of locally advanced and metastatic pancreatic cancer (Review). Int J Oncol 2021;59:110. [PMID: 34859257 DOI: 10.3892/ijo.2021.5290] [Reference Citation Analysis]
27 Earl J, Garcia-Nieto S, Martinez-Avila JC, Montans J, Sanjuanbenito A, Rodríguez-Garrote M, Lisa E, Mendía E, Lobo E, Malats N. Circulating tumor cells (Ctc) and kras mutant circulating free Dna (cfdna) detection in peripheral blood as biomarkers in patients diagnosed with exocrine pancreatic cancer. BMC Cancer. 2015;15:797. [PMID: 26498594 DOI: 10.1186/s12885-015-1779-7] [Cited by in Crossref: 98] [Cited by in F6Publishing: 94] [Article Influence: 14.0] [Reference Citation Analysis]
28 Shen X, Cheng G, Xu L, Wu W, Chen Z, Du P. Jumonji AT-rich interactive domain 1B promotes the growth of pancreatic tumors via the phosphatase and tensin homolog/protein kinase B signaling pathway. Oncol Lett 2018;16:267-75. [PMID: 29928411 DOI: 10.3892/ol.2018.8618] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
29 Kanji ZS, Gallinger S. Diagnosis and management of pancreatic cancer. CMAJ. 2013;185:1219-1226. [PMID: 23610017 DOI: 10.1503/cmaj.121368] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 2.6] [Reference Citation Analysis]
30 Dókus LE, Lajkó E, Ranđelović I, Mező D, Schlosser G, Kőhidai L, Tóvári J, Mező G. Phage Display-Based Homing Peptide-Daunomycin Conjugates for Selective Drug Targeting to PANC-1 Pancreatic Cancer. Pharmaceutics 2020;12:E576. [PMID: 32580307 DOI: 10.3390/pharmaceutics12060576] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
31 Flammang I, Reese M, Yang Z, Eble JA, Dhayat SA. Tumor-Suppressive miR-192-5p Has Prognostic Value in Pancreatic Ductal Adenocarcinoma. Cancers (Basel) 2020;12:E1693. [PMID: 32630552 DOI: 10.3390/cancers12061693] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
32 Elias A, Chatzizacharias NA, Xanthis A, Corrie P, Davies S, Brais RJ, Jamieson NV, Praseedom RK, Huguet E, Harper SJF, Jah A. Salvage pancreaticoduodenectomy after complete response to chemoradiotherapy for a previously unresectable pancreatic adenosquamous carcinoma: a case report. Medicine (Baltimore) 2015;94:e499. [PMID: 25674740 DOI: 10.1097/MD.0000000000000499] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
33 Smith JP, Cooper TK, McGovern CO, Gilius EL, Zhong Q, Liao J, Molinolo AA, Gutkind JS, Matters GL. Cholecystokinin receptor antagonist halts progression of pancreatic cancer precursor lesions and fibrosis in mice. Pancreas. 2014;43:1050-1059. [PMID: 25058882 DOI: 10.1097/MPA.0000000000000194] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 3.3] [Reference Citation Analysis]
34 Bosetti C, Lucenteforte E, Silverman DT, Petersen G, Bracci PM, Ji BT, Negri E, Li D, Risch HA, Olson SH. Cigarette smoking and pancreatic cancer: an analysis from the International Pancreatic Cancer Case-Control Consortium (Panc4). Ann Oncol. 2012;23:1880-1888. [PMID: 22104574 DOI: 10.1093/annonc/mdr541] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
35 van Tienhoven G, Gouma DJ, Richel DJ. Neoadjuvant chemoradiotherapy has a potential role in pancreatic carcinoma. Ther Adv Med Oncol 2011;3:27-33. [PMID: 21789153 DOI: 10.1177/1758834010383150] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
36 Fels B, Nielsen N, Schwab A. Role of TRPC1 channels in pressure-mediated activation of murine pancreatic stellate cells. Eur Biophys J 2016;45:657-70. [PMID: 27670661 DOI: 10.1007/s00249-016-1176-4] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 4.3] [Reference Citation Analysis]
37 Kohyama A, Kim MJ, Yokoyama R, Sun S, Omar AM, Phan ND, Meselhy MR, Tsuge K, Awale S, Matsuya Y. Structure-activity relationship and mechanistic study on guggulsterone derivatives; Discovery of new anti-pancreatic cancer candidate. Bioorg Med Chem 2021;54:116563. [PMID: 34942553 DOI: 10.1016/j.bmc.2021.116563] [Reference Citation Analysis]
38 Wang H, Li D, Liu S, Liu R, Yuan H, Krasnoperov V, Shan H, Conti PS, Gill PS, Li Z. Small-Animal PET Imaging of Pancreatic Cancer Xenografts Using a 64Cu-Labeled Monoclonal Antibody, MAb159. J Nucl Med 2015;56:908-13. [PMID: 25908833 DOI: 10.2967/jnumed.115.155812] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
39 Gong YF, Zhou QB, Liao YD, Mai C, Chen TJ, Tang YQ, Chen RF. Optimized construction of MUC1-VNTRn DNA vaccine and its anti-pancreatic cancer efficacy. Oncol Lett 2017;13:2198-206. [PMID: 28454381 DOI: 10.3892/ol.2017.5717] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
40 Liu P, Ying Q, Liu H, Yu SQ, Bu LP, Shao L, Li XY. Curcumin enhances anti‑cancer efficacy of either gemcitabine or docetaxel on pancreatic cancer cells. Oncol Rep 2020;44:1393-402. [PMID: 32945513 DOI: 10.3892/or.2020.7713] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
41 Kusama K, Okamoto Y, Saito K, Kasahara T, Murata T, Ueno Y, Kobayashi Y, Kamada Y, Miyoshi E. Reevaluation of Pholiota squarrosa lectin-reactive haptoglobin as a pancreatic cancer biomarker using an improved ELISA system. Glycoconj J 2017;34:537-44. [PMID: 28455724 DOI: 10.1007/s10719-017-9772-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
42 Parajuli P, Nguyen TL, Prunier C, Razzaque MS, Xu K, Atfi A. Pancreatic cancer triggers diabetes through TGF-β-mediated selective depletion of islet β-cells. Life Sci Alliance 2020;3:e201900573. [PMID: 32371554 DOI: 10.26508/lsa.201900573] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
43 Lodestijn SC, van Neerven SM, Vermeulen L, Bijlsma MF. Stem Cells in the Exocrine Pancreas during Homeostasis, Injury, and Cancer. Cancers (Basel) 2021;13:3295. [PMID: 34209288 DOI: 10.3390/cancers13133295] [Reference Citation Analysis]
44 Gnoni A, Licchetta A, Scarpa A, Azzariti A, Brunetti AE, Simone G, Nardulli P, Santini D, Aieta M, Delcuratolo S, Silvestris N. Carcinogenesis of pancreatic adenocarcinoma: precursor lesions. Int J Mol Sci. 2013;14:19731-19762. [PMID: 24084722 DOI: 10.3390/ijms141019731] [Cited by in Crossref: 31] [Cited by in F6Publishing: 35] [Article Influence: 3.4] [Reference Citation Analysis]
45 Tingle SJ, Moir JA, White SA. Role of anti-stromal polypharmacy in increasing survival after pancreaticoduodenectomy for pancreatic ductal adenocarcinoma. World J Gastrointest Pathophysiol 2015; 6(4): 235-242 [PMID: 26600982 DOI: 10.4291/wjgp.v6.i4.235] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
46 Cui L, Xie R, Dang S, Zhang Q, Mao S, Chen J, Qu J, Zhang J. NOV promoted the growth and migration of pancreatic cancer cells. Tumour Biol 2014;35:3195-201. [PMID: 24258112 DOI: 10.1007/s13277-013-1418-3] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
47 Shields MA, Dangi-Garimella S, Krantz SB, Bentrem DJ, Munshi HG. Pancreatic cancer cells respond to type I collagen by inducing snail expression to promote membrane type 1 matrix metalloproteinase-dependent collagen invasion. J Biol Chem. 2011;286:10495-10504. [PMID: 21288898 DOI: 10.1074/jbc.m110.195628] [Cited by in Crossref: 79] [Cited by in F6Publishing: 63] [Article Influence: 7.2] [Reference Citation Analysis]
48 Barton S, Li B, Siuta M, Vaibhav J, Song J, Holt CM, Tomono T, Ukawa M, Kumagai H, Tobita E, Wilson K, Sakuma S, Pham W. SPECIFIC MOLECULAR RECOGNITION AS A STRATEGY TO DELINEATE TUMOR MARGIN USING TOPICALLY APPLIED FLUORESCENCE EMBEDDED NANOPARTICLES. Precis Nanomed 2018;1:194-207. [PMID: 31773101 DOI: 10.33218/prnano1(3).181009.1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
49 Shin SW, Jung W, Choi C, Kim SY, Son A, Kim H, Lee N, Park HC. Fucoidan-Manganese Dioxide Nanoparticles Potentiate Radiation Therapy by Co-Targeting Tumor Hypoxia and Angiogenesis. Mar Drugs 2018;16:E510. [PMID: 30558324 DOI: 10.3390/md16120510] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 4.5] [Reference Citation Analysis]
50 Elbanna KY, Jang HJ, Kim TK. Imaging diagnosis and staging of pancreatic ductal adenocarcinoma: a comprehensive review. Insights Imaging. 2020;11:58. [PMID: 32335790 DOI: 10.1186/s13244-020-00861-y] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 6.5] [Reference Citation Analysis]
51 Awasthi N, Monahan S, Stefaniak A, Schwarz MA, Schwarz RE. Inhibition of the MEK/ERK pathway augments nab-paclitaxel-based chemotherapy effects in preclinical models of pancreatic cancer. Oncotarget 2018;9:5274-86. [PMID: 29435178 DOI: 10.18632/oncotarget.23684] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
52 Basso D, Bozzato D, Padoan A, Moz S, Zambon CF, Fogar P, Greco E, Scorzeto M, Simonato F, Navaglia F, Fassan M, Pelloso M, Dupont S, Pedrazzoli S, Fassina A, Plebani M. Inflammation and pancreatic cancer: molecular and functional interactions between S100A8, S100A9, NT-S100A8 and TGFβ1. Cell Commun Signal 2014;12:20. [PMID: 24670043 DOI: 10.1186/1478-811X-12-20] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]
53 Funamizu N, Hu C, Lacy C, Schetter A, Zhang G, He P, Gaedcke J, Ghadimi MB, Ried T, Yfantis HG, Lee DH, Subleski J, Chan T, Weiss JM, Back TC, Yanaga K, Hanna N, Alexander HR, Maitra A, Hussain SP. Macrophage migration inhibitory factor induces epithelial to mesenchymal transition, enhances tumor aggressiveness and predicts clinical outcome in resected pancreatic ductal adenocarcinoma. Int J Cancer 2013;132:785-94. [PMID: 22821831 DOI: 10.1002/ijc.27736] [Cited by in Crossref: 62] [Cited by in F6Publishing: 71] [Article Influence: 8.9] [Reference Citation Analysis]
54 Fang WB, Yao M, Cheng N. Priming cancer cells for drug resistance: role of the fibroblast niche. Front Biol (Beijing) 2014;9:114-26. [PMID: 25045348 DOI: 10.1007/s11515-014-1300-8] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 3.0] [Reference Citation Analysis]
55 Tatarian T, Jiang W, Leiby BE, Grigoli A, Jimbo M, Dabbish N, Neoptolemos JP, Greenhalf W, Costello E, Ghaneh P, Halloran C, Palmer D, Buchler M, Yeo CJ, Winter JM, Brody JR. Cytoplasmic HuR Status Predicts Disease-free Survival in Resected Pancreatic Cancer: A Post-hoc Analysis From the International Phase III ESPAC-3 Clinical Trial. Ann Surg. 2018;267:364-369. [PMID: 27893535 DOI: 10.1097/sla.0000000000002088] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 5.7] [Reference Citation Analysis]
56 Lee JW, Lee JH, Park Y, Kwon J, Lee W, Song KB, Hwang DW, Kim SC. Prognostic Impact of Perioperative CA19-9 Levels in Patients with Resected Perihilar Cholangiocarcinoma. J Clin Med 2021;10:1345. [PMID: 33805079 DOI: 10.3390/jcm10071345] [Reference Citation Analysis]
57 Mohammed A, Janakiram NB, Pant S, Rao CV. Molecular Targeted Intervention for Pancreatic Cancer. Cancers (Basel) 2015;7:1499-542. [PMID: 26266422 DOI: 10.3390/cancers7030850] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
58 Bruera G, Massacese S, Candria S, Galvano A, Manetta R, Giordano AV, Carducci S, Di Sibio A, Ciacco E, Russo A, Ricevuto E; Oncology Network ASL1 Abruzzo, Italy. Real life triplet FIr/FOx chemotherapy in first-line metastatic pancreatic ductal adenocarcinoma patients: recommended schedule for expected activity and safety and phase II study. Oncotarget 2018;9:31861-76. [PMID: 30159128 DOI: 10.18632/oncotarget.25870] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
59 Vroomen LGPH, Scheffer HJ, Melenhorst MCAM, de Jong MC, van den Bergh JE, van Kuijk C, van Delft F, Kazemier G, Meijerink MR. MR and CT imaging characteristics and ablation zone volumetry of locally advanced pancreatic cancer treated with irreversible electroporation. Eur Radiol. 2017;27:2521-2531. [PMID: 27659702 DOI: 10.1007/s00330-016-4581-2] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 4.7] [Reference Citation Analysis]
60 Dooley J, Lagou V, Goveia J, Ulrich A, Rohlenova K, Heirman N, Karakach T, Lampi Y, Khan S, Wang J, Dresselaers T, Himmelreich U, Gunter MJ, Prokopenko I, Carmeliet P, Liston A. Heterogeneous Effects of Calorie Content and Nutritional Components Underlie Dietary Influence on Pancreatic Cancer Susceptibility. Cell Rep 2020;32:107880. [PMID: 32668252 DOI: 10.1016/j.celrep.2020.107880] [Reference Citation Analysis]
61 Huang J, Qian W, Wang L, Wu H, Zhou H, Wang AY, Chen H, Yang L, Mao H. Functionalized milk-protein-coated magnetic nanoparticles for MRI-monitored targeted therapy of pancreatic cancer. Int J Nanomedicine 2016;11:3087-99. [PMID: 27462153 DOI: 10.2147/IJN.S92722] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
62 Koutsounas I, Giaginis C, Patsouris E, Theocharis S. Current evidence for histone deacetylase inhibitors in pancreatic cancer. World J Gastroenterol 2013; 19(6): 813-828 [PMID: 23430136 DOI: 10.3748/wjg.v19.i6.813] [Cited by in CrossRef: 29] [Cited by in F6Publishing: 27] [Article Influence: 3.2] [Reference Citation Analysis]
63 Hwang HK, Kim HI, Kim SH, Choi J, Kang CM, Kim KS, Lee WJ. Prognostic impact of the tumor-infiltrating regulatory T-cell (Foxp3(+))/activated cytotoxic T lymphocyte (granzyme B(+)) ratio on resected left-sided pancreatic cancer. Oncol Lett. 2016;12:4477-4484. [PMID: 28105157 DOI: 10.3892/ol.2016.5252] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 3.3] [Reference Citation Analysis]
64 Kim CH, Ling DC, Wegner RE, Flickinger JC, Heron DE, Zeh H, Moser AJ, Burton SA. Stereotactic body radiotherapy in the treatment of pancreatic adenocarcinoma in elderly patients. Radiat Oncol. 2013;8:240. [PMID: 24131503 DOI: 10.1186/1748-717x-8-240] [Cited by in Crossref: 28] [Cited by in F6Publishing: 15] [Article Influence: 3.1] [Reference Citation Analysis]
65 Wu CH, Cao C, Kim JH, Hsu CH, Wanebo HJ, Bowen WD, Xu J, Marshall J. Trojan-horse nanotube on-command intracellular drug delivery. Nano Lett 2012;12:5475-80. [PMID: 23030797 DOI: 10.1021/nl301865c] [Cited by in Crossref: 78] [Cited by in F6Publishing: 73] [Article Influence: 7.8] [Reference Citation Analysis]
66 Carper MB, Denvir J, Boskovic G, Primerano DA, Claudio PP. RGS16, a novel p53 and pRb cross-talk candidate inhibits migration and invasion of pancreatic cancer cells. Genes Cancer 2014;5:420-35. [PMID: 25568667 DOI: 10.18632/genesandcancer.43] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
67 Kato S, Lippman SM, Flaherty KT, Kurzrock R. The Conundrum of Genetic "Drivers" in Benign Conditions. J Natl Cancer Inst 2016;108:djw036. [PMID: 27059373 DOI: 10.1093/jnci/djw036] [Cited by in Crossref: 74] [Cited by in F6Publishing: 63] [Article Influence: 12.3] [Reference Citation Analysis]
68 Yang YH, Liu JB, Gui Y, Lei LL, Zhang SJ. Relationship between autophagy and perineural invasion, clinicopathological features, and prognosis in pancreatic cancer. World J Gastroenterol 2017; 23(40): 7232-7241 [PMID: 29142470 DOI: 10.3748/wjg.v23.i40.7232] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
69 Jun E, Koo B, Kim EJ, Hwang DW, Lee JH, Song KB, Lee W, Park Y, Hong S, Shin Y, Kim SC. Analysis of KRAS Mutation Subtype in Tissue DNA and Cell-Free DNA Using Droplet Digital PCR and the Function of Cell-Free DNA as a Recurrence Predictive Marker in Pancreatic Cancer. Biomedicines 2021;9:1599. [PMID: 34829828 DOI: 10.3390/biomedicines9111599] [Reference Citation Analysis]
70 Shimasaki T, Kitano A, Motoo Y, Minamoto T. Aberrant glycogen synthase kinase 3β in the development of pancreatic cancer. J Carcinog 2012;11:15. [PMID: 23230392 DOI: 10.4103/1477-3163.100866] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
71 Ali A, Brown V, Denley S, Jamieson NB, Morton JP, Nixon C, Graham JS, Sansom OJ, Carter CR, McKay CJ, Duthie FR, Oien KA. Expression of KOC, S100P, mesothelin and MUC1 in pancreatico-biliary adenocarcinomas: development and utility of a potential diagnostic immunohistochemistry panel. BMC Clin Pathol. 2014;14:35. [PMID: 25071419 DOI: 10.1186/1472-6890-14-35] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
72 Garrido-Laguna I, Uson M, Rajeshkumar NV, Tan AC, de Oliveira E, Karikari C, Villaroel MC, Salomon A, Taylor G, Sharma R, Hruban RH, Maitra A, Laheru D, Rubio-Viqueira B, Jimeno A, Hidalgo M. Tumor engraftment in nude mice and enrichment in stroma- related gene pathways predict poor survival and resistance to gemcitabine in patients with pancreatic cancer. Clin Cancer Res 2011;17:5793-800. [PMID: 21742805 DOI: 10.1158/1078-0432.CCR-11-0341] [Cited by in Crossref: 148] [Cited by in F6Publishing: 97] [Article Influence: 13.5] [Reference Citation Analysis]
73 Pekala KR, Ma X, Kropp PA, Petersen CP, Hudgens CW, Chung CH, Shi C, Merchant NB, Maitra A, Means AL, Gannon MA. Loss of HNF6 expression correlates with human pancreatic cancer progression. Lab Invest 2014;94:517-27. [PMID: 24638272 DOI: 10.1038/labinvest.2014.47] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
74 Frese KK, Neesse A, Cook N, Bapiro TE, Lolkema MP, Jodrell DI, Tuveson DA. nab-Paclitaxel potentiates gemcitabine activity by reducing cytidine deaminase levels in a mouse model of pancreatic cancer. Cancer Discov. 2012;2:260-269. [PMID: 22585996 DOI: 10.1158/2159-8290.cd-11-0242] [Cited by in Crossref: 261] [Cited by in F6Publishing: 151] [Article Influence: 26.1] [Reference Citation Analysis]
75 Kutkowska J, Strzadala L, Rapak A. Sorafenib in Combination with Betulinic Acid Synergistically Induces Cell Cycle Arrest and Inhibits Clonogenic Activity in Pancreatic Ductal Adenocarcinoma Cells. Int J Mol Sci 2018;19:E3234. [PMID: 30347681 DOI: 10.3390/ijms19103234] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
76 Vincent A, Herman J, Schulick R, Hruban RH, Goggins M. Pancreatic cancer. Lancet. 2011;378:607-620. [PMID: 21620466 DOI: 10.1016/so140-6736(10)62307-0] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
77 Navarrete A, Armitage EG, Musteanu M, García A, Mastrangelo A, Bujak R, López-Casas PP, Hidalgo M, Barbas C. Metabolomic evaluation of Mitomycin C and rapamycin in a personalized treatment of pancreatic cancer. Pharmacol Res Perspect 2014;2:e00067. [PMID: 25505613 DOI: 10.1002/prp2.67] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
78 Oyasiji T, Ma WW. Novel adjuvant therapies for pancreatic adenocarcinoma. J Gastrointest Oncol 2015;6:430-5. [PMID: 26261729 DOI: 10.3978/j.issn.2078-6891.2015.031] [Reference Citation Analysis]
79 Yamamoto K, Opina A, Sail D, Blackman B, Saito K, Brender JR, Malinowski RM, Seki T, Oshima N, Crooks DR, Kishimoto S, Saida Y, Otowa Y, Choyke PL, Ardenkjær-Larsen JH, Mitchell JB, Linehan WM, Swenson RE, Krishna MC. Real-Time insight into in vivo redox status utilizing hyperpolarized [1-13C] N-acetyl cysteine. Sci Rep 2021;11:12155. [PMID: 34108512 DOI: 10.1038/s41598-021-90921-0] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
80 Cheng G, Zielonka J, McAllister D, Tsai S, Dwinell MB, Kalyanaraman B. Profiling and targeting of cellular bioenergetics: inhibition of pancreatic cancer cell proliferation. Br J Cancer. 2014;111:85-93. [PMID: 24867695 DOI: 10.1038/bjc.2014.272] [Cited by in Crossref: 58] [Cited by in F6Publishing: 57] [Article Influence: 7.3] [Reference Citation Analysis]
81 Pan Y, Rhea P, Tan L, Cartwright C, Lee HJ, Ravoori MK, Addington C, Gagea M, Kundra V, Kim SJ, Newman RA, Yang P. PBI-05204, a supercritical CO₂ extract of Nerium oleander, inhibits growth of human pancreatic cancer via targeting the PI3K/mTOR pathway. Invest New Drugs 2015;33:271-9. [PMID: 25476893 DOI: 10.1007/s10637-014-0190-6] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.4] [Reference Citation Analysis]
82 Yuan C, Qian ZR, Babic A, Morales-Oyarvide V, Rubinson DA, Kraft P, Ng K, Bao Y, Giovannucci EL, Ogino S, Stampfer MJ, Gaziano JM, Sesso HD, Buring JE, Cochrane BB, Chlebowski RT, Snetselaar LG, Manson JE, Fuchs CS, Wolpin BM. Prediagnostic Plasma 25-Hydroxyvitamin D and Pancreatic Cancer Survival. J Clin Oncol. 2016;34:2899-2905. [PMID: 27325858 DOI: 10.1200/jco.2015.66.3005] [Cited by in Crossref: 30] [Cited by in F6Publishing: 19] [Article Influence: 5.0] [Reference Citation Analysis]
83 Ansari D, Chen BC, Dong L, Zhou MT, Andersson R. Pancreatic cancer: Translational research aspects and clinical implications. World J Gastroenterol 2012; 18(13): 1417-1424 [PMID: 22509073 DOI: 10.3748/wjg.v18.i13.1417] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 16] [Article Influence: 1.4] [Reference Citation Analysis]
84 Ono H, Basson MD, Ito H. PTK6 promotes cancer migration and invasion in pancreatic cancer cells dependent on ERK signaling. PLoS One 2014;9:e96060. [PMID: 24788754 DOI: 10.1371/journal.pone.0096060] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 2.8] [Reference Citation Analysis]
85 Yabuuchi S, Pai SG, Campbell NR, de Wilde RF, De Oliveira E, Korangath P, Streppel MM, Rasheed ZA, Hidalgo M, Maitra A. Notch signaling pathway targeted therapy suppresses tumor progression and metastatic spread in pancreatic cancer. Cancer Lett. 2013;335:41-51. [PMID: 23402814 DOI: 10.1016/j.canlet.2013.01.054] [Cited by in Crossref: 94] [Cited by in F6Publishing: 83] [Article Influence: 10.4] [Reference Citation Analysis]
86 Wang YN, Lee HH, Hung MC. A novel ligand-receptor relationship between families of ribonucleases and receptor tyrosine kinases. J Biomed Sci 2018;25:83. [PMID: 30449278 DOI: 10.1186/s12929-018-0484-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
87 Leshchiner ES, Parkhitko A, Bird GH, Luccarelli J, Bellairs JA, Escudero S, Opoku-Nsiah K, Godes M, Perrimon N, Walensky LD. Direct inhibition of oncogenic KRAS by hydrocarbon-stapled SOS1 helices. Proc Natl Acad Sci U S A 2015;112:1761-6. [PMID: 25624485 DOI: 10.1073/pnas.1413185112] [Cited by in Crossref: 99] [Cited by in F6Publishing: 91] [Article Influence: 14.1] [Reference Citation Analysis]
88 Shields MA, Krantz SB, Bentrem DJ, Dangi-Garimella S, Munshi HG. Interplay between β1-integrin and Rho signaling regulates differential scattering and motility of pancreatic cancer cells by snail and Slug proteins. J Biol Chem 2012;287:6218-29. [PMID: 22232555 DOI: 10.1074/jbc.M111.308940] [Cited by in Crossref: 47] [Cited by in F6Publishing: 37] [Article Influence: 4.7] [Reference Citation Analysis]
89 Sohrabi E, Rezaie E, Heiat M, Sefidi-Heris Y. An Integrated Data Analysis of mRNA, miRNA and Signaling Pathways in Pancreatic Cancer. Biochem Genet 2021. [PMID: 33813720 DOI: 10.1007/s10528-021-10062-x] [Reference Citation Analysis]
90 Jakstaite A, Maziukiene A, Silkuniene G, Kmieliute K, Gulbinas A, Dambrauskas Z. HuR mediated post-transcriptional regulation as a new potential adjuvant therapeutic target in chemotherapy for pancreatic cancer. World J Gastroenterol 2015; 21(46): 13004-13019 [PMID: 26675757 DOI: 10.3748/wjg.v21.i46.13004] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 16] [Article Influence: 3.1] [Reference Citation Analysis]
91 Riquelme E, Zhang Y, Zhang L, Montiel M, Zoltan M, Dong W, Quesada P, Sahin I, Chandra V, San Lucas A, Scheet P, Xu H, Hanash SM, Feng L, Burks JK, Do KA, Peterson CB, Nejman D, Tzeng CD, Kim MP, Sears CL, Ajami N, Petrosino J, Wood LD, Maitra A, Straussman R, Katz M, White JR, Jenq R, Wargo J, McAllister F. Tumor Microbiome Diversity and Composition Influence Pancreatic Cancer Outcomes. Cell 2019;178:795-806.e12. [PMID: 31398337 DOI: 10.1016/j.cell.2019.07.008] [Cited by in Crossref: 240] [Cited by in F6Publishing: 233] [Article Influence: 120.0] [Reference Citation Analysis]
92 de Jesus VHF, Camandaroba MPG, Calsavara VF, Riechelmann RP. Systematic review and meta-analysis of gemcitabine-based chemotherapy after FOLFIRINOX in advanced pancreatic cancer.Ther Adv Med Oncol. 2020;12:1758835920905408. [PMID: 32165927 DOI: 10.1177/1758835920905408] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
93 Santana-Codina N, Roeth AA, Zhang Y, Yang A, Mashadova O, Asara JM, Wang X, Bronson RT, Lyssiotis CA, Ying H, Kimmelman AC. Oncogenic KRAS supports pancreatic cancer through regulation of nucleotide synthesis. Nat Commun 2018;9:4945. [PMID: 30470748 DOI: 10.1038/s41467-018-07472-8] [Cited by in Crossref: 86] [Cited by in F6Publishing: 74] [Article Influence: 21.5] [Reference Citation Analysis]
94 Adiseshaiah PP, Crist RM, Hook SS, McNeil SE. Nanomedicine strategies to overcome the pathophysiological barriers of pancreatic cancer. Nat Rev Clin Oncol 2016;13:750-65. [PMID: 27531700 DOI: 10.1038/nrclinonc.2016.119] [Cited by in Crossref: 115] [Cited by in F6Publishing: 113] [Article Influence: 19.2] [Reference Citation Analysis]
95 Kudgus RA, Szabolcs A, Khan JA, Walden CA, Reid JM, Robertson JD, Bhattacharya R, Mukherjee P. Inhibiting the growth of pancreatic adenocarcinoma in vitro and in vivo through targeted treatment with designer gold nanotherapeutics. PLoS One 2013;8:e57522. [PMID: 23483913 DOI: 10.1371/journal.pone.0057522] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 2.3] [Reference Citation Analysis]
96 Awaji M, Saxena S, Wu L, Prajapati DR, Purohit A, Varney ML, Kumar S, Rachagani S, Ly QP, Jain M, Batra SK, Singh RK. CXCR2 signaling promotes secretory cancer-associated fibroblasts in pancreatic ductal adenocarcinoma. FASEB J 2020;34:9405-18. [PMID: 32453916 DOI: 10.1096/fj.201902990R] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
97 Iancu I, Bartoș A, Cioltean CL, Breazu C, Iancu C, Bartoș D. Role of radio-ablative technique for optimizing the survival of patients with locally advanced pancreatic adenocarcinoma (Review). Exp Ther Med 2021;22:853. [PMID: 34178126 DOI: 10.3892/etm.2021.10285] [Reference Citation Analysis]
98 Haruki K, Shiba H, Shimada Y, Shirai Y, Iwase R, Fujiwara Y, Uwagawa T, Ohashi T, Yanaga K. Glycogen synthase kinase-3β activity plays a key role in the antitumor effect of nafamostat mesilate in pancreatic cancer cells. Ann Gastroenterol Surg 2018;2:65-71. [PMID: 29863120 DOI: 10.1002/ags3.12025] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
99 Kamil F, Rowe JH. How does the tumor microenvironment play a role in hepatobiliary tumors? J Gastrointest Oncol 2018;9:180-95. [PMID: 29564184 DOI: 10.21037/jgo.2017.06.09] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
100 Chen Q, Yuan H, Shi GD, Wu Y, Liu DF, Lin YT, Chen L, Ge WL, Jiang K, Miao Y. Association between NR5A2 and the risk of pancreatic cancer, especially among Caucasians: a meta-analysis of case-control studies. Onco Targets Ther 2018;11:2709-23. [PMID: 29785120 DOI: 10.2147/OTT.S157759] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
101 Cho IK, Kim H, Lee JC, Lee J, Kim J, Ahn S, Park H, Hwang JH. Higher Tumor Cellularity in Resected Pancreatic Ductal Adenocarcinoma Is a Negative Prognostic Indicator. Gut Liver 2020;14:521-8. [PMID: 31615191 DOI: 10.5009/gnl19180] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
102 Halfdanarson TR, Haraldsdottir S, Borad MJ. Advances in systemic therapy for advanced pancreatobiliary malignancies. F1000Res 2013;2:105. [PMID: 24327864 DOI: 10.12688/f1000research.2-105.v1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
103 Ciernikova S, Earl J, García Bermejo ML, Stevurkova V, Carrato A, Smolkova B. Epigenetic Landscape in Pancreatic Ductal Adenocarcinoma: On the Way to Overcoming Drug Resistance? Int J Mol Sci 2020;21:E4091. [PMID: 32521716 DOI: 10.3390/ijms21114091] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
104 Chung MJ, Kang H, Kim HG, Hyun JJ, Lee JK, Lee KH, Noh MH, Kang DH, Lee SH, Bang S, Pancreatobiliary Cancer Study Group of Korean Society of Gastrointestinal Cancer. Multicenter phase II trial of modified FOLFIRINOX in gemcitabine-refractory pancreatic cancer. World J Gastrointest Oncol 2018; 10(12): 505-515 [PMID: 30595804 DOI: 10.4251/wjgo.v10.i12.505] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
105 Tao L, Zhang L, Peng Y, Tao M, Li L, Xiu D, Yuan C, Ma Z, Jiang B. Neutrophils assist the metastasis of circulating tumor cells in pancreatic ductal adenocarcinoma: A new hypothesis and a new predictor for distant metastasis. Medicine (Baltimore) 2016;95:e4932. [PMID: 27684834 DOI: 10.1097/MD.0000000000004932] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 4.8] [Reference Citation Analysis]
106 Wong SK, Gondara L, Renouf DJ, Lim HJ, Loree JM, Davies JM, Gill S. Impact of surveillance among patients with resected pancreatic cancer following adjuvant chemotherapy. J Gastrointest Oncol 2021;12:446-54. [PMID: 34012638 DOI: 10.21037/jgo-20-422] [Reference Citation Analysis]
107 Chen J, Guo XZ, Li HY, Wang D, Shao XD. Comparison of cytotoxic T lymphocyte responses against pancreatic cancer induced by dendritic cells transfected with total tumor RNA and fusion hybrided with tumor cell. Exp Biol Med (Maywood). 2015;240:1310-1318. [PMID: 25736302 DOI: 10.1177/1535370215571884] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
108 Yang Y, Sun Y, Wang H, Li H, Zhang M, Zhou L, Meng X, Wu Y, Liu P, Liu X, Zhang J, Tan X. MicroRNA-221 induces autophagy through suppressing HDAC6 expression and promoting apoptosis in pancreatic cancer. Oncol Lett 2018;16:7295-301. [PMID: 30546469 DOI: 10.3892/ol.2018.9513] [Cited by in Crossref: 4] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
109 Pencovich N, Orbach L, Lessing Y, Elazar A, Barnes S, Berman P, Blachar A, Nachmany I, Sagie B. Palliative bypass surgery for patients with advanced pancreatic adenocarcinoma: experience from a tertiary center. World J Surg Oncol 2020;18:63. [PMID: 32238149 DOI: 10.1186/s12957-020-01828-5] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
110 Zhou RT, He M, Yu Z, Liang Y, Nie Y, Tai S, Teng CB. Baicalein inhibits pancreatic cancer cell proliferation and invasion via suppression of NEDD9 expression and its downstream Akt and ERK signaling pathways. Oncotarget 2017;8:56351-63. [PMID: 28915595 DOI: 10.18632/oncotarget.16912] [Cited by in Crossref: 28] [Cited by in F6Publishing: 21] [Article Influence: 5.6] [Reference Citation Analysis]
111 Li T, Wang YN, Khokhlova TD, D'Andrea S, Starr F, Chen H, McCune JS, Risler LJ, Mashadi-Hossein A, Hingorani SR, Chang A, Hwang JH. Pulsed High-Intensity Focused Ultrasound Enhances Delivery of Doxorubicin in a Preclinical Model of Pancreatic Cancer. Cancer Res. 2015;75:3738-3746. [PMID: 26216548 DOI: 10.1158/0008-5472.can-15-0296] [Cited by in Crossref: 41] [Cited by in F6Publishing: 25] [Article Influence: 5.9] [Reference Citation Analysis]
112 Kamposioras K, Geraghty J, Appleyard J, Dawod M, Papadimitriou K, Lamarca A, Anthoney A. Pancreaticobiliary Malignancies in the Emergency Room: Management of Acute Complications and Oncological Emergencies. J Gastrointest Cancer 2021. [PMID: 34648136 DOI: 10.1007/s12029-021-00718-7] [Reference Citation Analysis]
113 Olson MT, Ly QP, Mohs AM. Fluorescence Guidance in Surgical Oncology: Challenges, Opportunities, and Translation. Mol Imaging Biol. 2019;21:200-218. [PMID: 29942988 DOI: 10.1007/s11307-018-1239-2] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 6.7] [Reference Citation Analysis]
114 Vaziri-Gohar A, Zarei M, Brody JR, Winter JM. Metabolic Dependencies in Pancreatic Cancer. Front Oncol. 2018;8:617. [PMID: 30631752 DOI: 10.3389/fonc.2018.00617] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 7.0] [Reference Citation Analysis]
115 Mackenzie R, Kommoss S, Winterhoff BJ, Kipp BR, Garcia JJ, Voss J, Halling K, Karnezis A, Senz J, Yang W, Prigge ES, Reuschenbach M, Doeberitz MV, Gilks BC, Huntsman DG, Bakkum-Gamez J, McAlpine JN, Anglesio MS. Targeted deep sequencing of mucinous ovarian tumors reveals multiple overlapping RAS-pathway activating mutations in borderline and cancerous neoplasms. BMC Cancer 2015;15:415. [PMID: 25986173 DOI: 10.1186/s12885-015-1421-8] [Cited by in Crossref: 78] [Cited by in F6Publishing: 63] [Article Influence: 11.1] [Reference Citation Analysis]
116 Luu AM, Belyaev O, Höhn P, Praktiknjo M, Janot M, Uhl W, Braumann C. Late recurrences of pancreatic cancer in patients with long-term survival after pancreaticoduodenectomy. J Gastrointest Oncol 2021;12:474-83. [PMID: 34012641 DOI: 10.21037/jgo-20-433] [Reference Citation Analysis]
117 McCarroll J, Teo J, Boyer C, Goldstein D, Kavallaris M, Phillips PA. Potential applications of nanotechnology for the diagnosis and treatment of pancreatic cancer. Front Physiol 2014;5:2. [PMID: 24478715 DOI: 10.3389/fphys.2014.00002] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 4.0] [Reference Citation Analysis]
118 Schmahl MJ, Regan DP, Rivers AC, Joesten WC, Kennedy MA. NMR-based metabolic profiling of urine, serum, fecal, and pancreatic tissue samples from the Ptf1a-Cre; LSL-KrasG12D transgenic mouse model of pancreatic cancer. PLoS One 2018;13:e0200658. [PMID: 30016349 DOI: 10.1371/journal.pone.0200658] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
119 Singh PK, Deorukhkar AA, Venkatesulu BP, Li X, Tailor R, Bomalaski JS, Krishnan S. Exploiting Arginine Auxotrophy with Pegylated Arginine Deiminase (ADI-PEG20) to Sensitize Pancreatic Cancer to Radiotherapy via Metabolic Dysregulation. Mol Cancer Ther 2019;18:2381-93. [PMID: 31395686 DOI: 10.1158/1535-7163.MCT-18-0708] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
120 Zhai S, Liu Y, Lu X, Qian H, Tang X, Cheng X, Wang Y, Shi Y, Deng X. INPP4B As A Prognostic And Diagnostic Marker Regulates Cell Growth Of Pancreatic Cancer Via Activating AKT. Onco Targets Ther 2019;12:8287-99. [PMID: 31632078 DOI: 10.2147/OTT.S223221] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
121 Pitarresi JR, Liu X, Sharma SM, Cuitiño MC, Kladney RD, Mace TA, Donohue S, Nayak SG, Qu C, Lee J, Woelke SA, Trela S, LaPak K, Yu L, McElroy J, Rosol TJ, Shakya R, Ludwig T, Lesinski GB, Fernandez SA, Konieczny SF, Leone G, Wu J, Ostrowski MC. Stromal ETS2 Regulates Chemokine Production and Immune Cell Recruitment during Acinar-to-Ductal Metaplasia. Neoplasia 2016;18:541-52. [PMID: 27659014 DOI: 10.1016/j.neo.2016.07.006] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
122 Leal AD, Messersmith WA, Lieu CH. Neoadjuvant treatment of localized pancreatic adenocarcinoma. J Gastrointest Oncol 2021;12:2461-74. [PMID: 34790407 DOI: 10.21037/jgo-20-250] [Reference Citation Analysis]
123 Yoshida M, Miyasaka Y, Ohuchida K, Okumura T, Zheng B, Torata N, Fujita H, Nabae T, Manabe T, Shimamoto M, Ohtsuka T, Mizumoto K, Nakamura M. Calpain inhibitor calpeptin suppresses pancreatic cancer by disrupting cancer-stromal interactions in a mouse xenograft model. Cancer Sci 2016;107:1443-52. [PMID: 27487486 DOI: 10.1111/cas.13024] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
124 Wang ZD, Cui YF. Several key issues in surgical treatment of distal pancreatic cancer. Shijie Huaren Xiaohua Zazhi 2015; 23(16): 2515-2522 [DOI: 10.11569/wcjd.v23.i16.2515] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
125 Guo Y, Zhang Z, Kim DH, Li W, Nicolai J, Procissi D, Huan Y, Han G, Omary RA, Larson AC. Photothermal ablation of pancreatic cancer cells with hybrid iron-oxide core gold-shell nanoparticles. Int J Nanomedicine. 2013;8:3437-3446. [PMID: 24039426 DOI: 10.2147/ijn.s47585] [Cited by in Crossref: 42] [Cited by in F6Publishing: 15] [Article Influence: 4.7] [Reference Citation Analysis]
126 Son J, Lyssiotis CA, Ying H, Wang X, Hua S, Ligorio M, Perera RM, Ferrone CR, Mullarky E, Shyh-Chang N, Kang Y, Fleming JB, Bardeesy N, Asara JM, Haigis MC, DePinho RA, Cantley LC, Kimmelman AC. Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway. Nature. 2013;496:101-105. [PMID: 23535601 DOI: 10.1038/nature12040] [Cited by in Crossref: 1034] [Cited by in F6Publishing: 973] [Article Influence: 114.9] [Reference Citation Analysis]
127 Irigoyen A, Jimenez-Luna C, Benavides M, Caba O, Gallego J, Ortuño FM, Guillen-Ponce C, Rojas I, Aranda E, Torres C, Prados J. Integrative multi-platform meta-analysis of gene expression profiles in pancreatic ductal adenocarcinoma patients for identifying novel diagnostic biomarkers. PLoS One 2018;13:e0194844. [PMID: 29617451 DOI: 10.1371/journal.pone.0194844] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 2.8] [Reference Citation Analysis]
128 Guo JC, Li J, Zhou L, Yang JY, Zhang ZG, Liang ZY, Zhou WX, You L, Zhang TP, Zhao YP. CXCL12-CXCR7 axis contributes to the invasive phenotype of pancreatic cancer. Oncotarget. 2016;7:62006-62018. [PMID: 27542220 DOI: 10.18632/oncotarget.11330] [Cited by in Crossref: 20] [Cited by in F6Publishing: 25] [Article Influence: 5.0] [Reference Citation Analysis]
129 Hsieh CC, Shyr YM, Liao WY, Chen TH, Wang SE, Lu PC, Lin PY, Chen YB, Mao WY, Han HY, Hsiao M, Yang WB, Li WS, Sher YP, Shen CN. Elevation of β-galactoside α2,6-sialyltransferase 1 in a fructoseresponsive manner promotes pancreatic cancer metastasis. Oncotarget 2017;8:7691-709. [PMID: 28032597 DOI: 10.18632/oncotarget.13845] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 7.8] [Reference Citation Analysis]
130 Conway JR, Herrmann D, Evans TJ, Morton JP, Timpson P. Combating pancreatic cancer with PI3K pathway inhibitors in the era of personalised medicine. Gut 2019;68:742-58. [PMID: 30396902 DOI: 10.1136/gutjnl-2018-316822] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 5.3] [Reference Citation Analysis]
131 Li D, Xie K, Wolff R, Abbruzzese JL. Pancreatic cancer. The Lancet 2004;363:1049-57. [DOI: 10.1016/s0140-6736(04)15841-8] [Cited by in Crossref: 1360] [Cited by in F6Publishing: 672] [Article Influence: 75.6] [Reference Citation Analysis]
132 Lonardo E, Cioffi M, Sancho P, Sanchez-Ripoll Y, Trabulo SM, Dorado J, Balic A, Hidalgo M, Heeschen C. Metformin targets the metabolic achilles heel of human pancreatic cancer stem cells. PLoS One. 2013;8:e76518. [PMID: 24204632 DOI: 10.1371/journal.pone.0076518] [Cited by in Crossref: 100] [Cited by in F6Publishing: 108] [Article Influence: 11.1] [Reference Citation Analysis]
133 Protti MP, De Monte L. Cross-talk within the tumor microenvironment mediates Th2-type inflammation in pancreatic cancer. Oncoimmunology 2012;1:89-91. [PMID: 22720220 DOI: 10.4161/onci.1.1.17939] [Cited by in Crossref: 40] [Cited by in F6Publishing: 38] [Article Influence: 40.0] [Reference Citation Analysis]
134 Hummel D, Aggarwal A, Borka K, Bajna E, Kállay E, Horváth HC. The vitamin D system is deregulated in pancreatic diseases. J Steroid Biochem Mol Biol 2014;144 Pt B:402-9. [PMID: 25090635 DOI: 10.1016/j.jsbmb.2014.07.011] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 2.5] [Reference Citation Analysis]
135 Hornick JR, Spitzer D, Goedegebuure P, Mach RH, Hawkins WG. Therapeutic targeting of pancreatic cancer utilizing sigma-2 ligands. Surgery 2012;152:S152-6. [PMID: 22763259 DOI: 10.1016/j.surg.2012.05.014] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 2.2] [Reference Citation Analysis]
136 Gao J, Wang M, Li T, Liu Q, You L, Liao Q. Up-regulation of CDHR5 expression promotes malignant phenotype of pancreatic ductal adenocarcinoma. J Cell Mol Med 2020;24:12726-35. [PMID: 33025744 DOI: 10.1111/jcmm.15856] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
137 Karamitopoulou E, Zlobec I, Gloor B, Kondi-Pafiti A, Lugli A, Perren A. Loss of Raf-1 kinase inhibitor protein (RKIP) is strongly associated with high-grade tumor budding and correlates with an aggressive phenotype in pancreatic ductal adenocarcinoma (PDAC). J Transl Med 2013;11:311. [PMID: 24330423 DOI: 10.1186/1479-5876-11-311] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
138 Yuan C, Bao Y, Wu C, Kraft P, Ogino S, Ng K, Qian ZR, Rubinson DA, Stampfer MJ, Giovannucci EL, Wolpin BM. Prediagnostic body mass index and pancreatic cancer survival. J Clin Oncol. 2013;31:4229-4234. [PMID: 24145341 DOI: 10.1200/jco.2013.51.7532] [Cited by in Crossref: 78] [Cited by in F6Publishing: 44] [Article Influence: 8.7] [Reference Citation Analysis]
139 Ma C, Nong K, Zhu H, Wang W, Huang X, Yuan Z, Ai K. H19 promotes pancreatic cancer metastasis by derepressing let-7’s suppression on its target HMGA2-mediated EMT. Tumor Biol 2014;35:9163-9. [DOI: 10.1007/s13277-014-2185-5] [Cited by in Crossref: 183] [Cited by in F6Publishing: 186] [Article Influence: 22.9] [Reference Citation Analysis]
140 Demirkol Canlı S, Dedeoğlu E, Akbar MW, Küçükkaraduman B, İşbilen M, Erdoğan ÖŞ, Erciyas SK, Yazıcı H, Vural B, Güre AO. A novel 20-gene prognostic score in pancreatic adenocarcinoma. PLoS One 2020;15:e0231835. [PMID: 32310997 DOI: 10.1371/journal.pone.0231835] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
141 Dai H, Chen H, Liu W, You Y, Tan J, Yang A, Lai X, Bie P. Effects of Raf kinase inhibitor protein expression on pancreatic cancer cell growth and motility: an in vivo and in vitro study. J Cancer Res Clin Oncol 2016;142:2107-17. [PMID: 27444299 DOI: 10.1007/s00432-016-2206-4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
142 Sun Q, Zhang Y, Liu M, Ye Z, Yu X, Xu X, Qin Y. Prognostic and diagnostic significance of galectins in pancreatic cancer: a systematic review and meta-analysis. Cancer Cell Int 2019;19:309. [PMID: 31832021 DOI: 10.1186/s12935-019-1025-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
143 Peng F, Li X, Jiang JX, Wang M, Tian R, Xu M, Guo XJ, Qin RY. Staurosporine inhibits cell proliferation and induces apoptosis in pancreatic cancer cell line Panc-1. Shijie Huaren Xiaohua Zazhi 2013; 21(25): 2578-2584 [DOI: 10.11569/wcjd.v21.i25.2578] [Reference Citation Analysis]
144 Goel G, Sun W. Novel approaches in the management of pancreatic ductal adenocarcinoma: potential promises for the future. J Hematol Oncol. 2015;8:44. [PMID: 25935754 DOI: 10.1186/s13045-015-0141-5] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 3.6] [Reference Citation Analysis]
145 Ye H, Zhou Q, Zheng S, Li G, Lin Q, Ye L, Wang Y, Wei L, Zhao X, Li W, Fu Z, Liu Y, Li Z, Chen R. FEZF1-AS1/miR-107/ZNF312B axis facilitates progression and Warburg effect in pancreatic ductal adenocarcinoma. Cell Death Dis 2018;9:34. [PMID: 29348628 DOI: 10.1038/s41419-017-0052-1] [Cited by in Crossref: 26] [Cited by in F6Publishing: 29] [Article Influence: 6.5] [Reference Citation Analysis]
146 Pantel K, Alix-Panabières C. Bone marrow as a reservoir for disseminated tumor cells: a special source for liquid biopsy in cancer patients. Bonekey Rep 2014;3:584. [PMID: 25419458 DOI: 10.1038/bonekey.2014.79] [Cited by in Crossref: 53] [Cited by in F6Publishing: 50] [Article Influence: 6.6] [Reference Citation Analysis]
147 Kim SM. Cellular and Molecular Mechanisms of 3,3'-Diindolylmethane in Gastrointestinal Cancer. Int J Mol Sci 2016;17:E1155. [PMID: 27447608 DOI: 10.3390/ijms17071155] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
148 Niyaz M, Khan MS, Mudassar S. Hedgehog Signaling: An Achilles' Heel in Cancer. Transl Oncol 2019;12:1334-44. [PMID: 31352196 DOI: 10.1016/j.tranon.2019.07.004] [Cited by in Crossref: 26] [Cited by in F6Publishing: 20] [Article Influence: 8.7] [Reference Citation Analysis]
149 La Torre M, Nigri G, Lo Conte A, Mazzuca F, Tierno SM, Salaj A, Marchetti P, Ziparo V, Ramacciato G. Is a preoperative assessment of the early recurrence of pancreatic cancer possible after complete surgical resection? Gut Liver 2014;8:102-8. [PMID: 24516708 DOI: 10.5009/gnl.2014.8.1.102] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 2.3] [Reference Citation Analysis]
150 Jin L, Zou Y, Ruan S, Han H, Zhang Y, Chen Z, Jin H, Shi N. Score for predicting overall survival in pancreatic adenocarcinoma patients with positive lymph nodes after surgery: a novel nomogram-based risk assessment. Gland Surg 2021;10:529-40. [PMID: 33708536 DOI: 10.21037/gs-20-597] [Reference Citation Analysis]
151 Takahashi K, Ehata S, Miyauchi K, Morishita Y, Miyazawa K, Miyazono K. Neurotensin receptor 1 signaling promotes pancreatic cancer progression. Mol Oncol 2021;15:151-66. [PMID: 33034134 DOI: 10.1002/1878-0261.12815] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
152 Kozinn SI, Harty NJ, Delong JM, Deliyiannis C, Logvinenko T, Summerhayes IC, Libertino JA, Holway AH, Rieger-Christ KM. MicroRNA Profile to Predict Gemcitabine Resistance in Bladder Carcinoma Cell Lines. Genes Cancer 2013;4:61-9. [PMID: 23946872 DOI: 10.1177/1947601913484495] [Cited by in Crossref: 19] [Cited by in F6Publishing: 23] [Article Influence: 2.1] [Reference Citation Analysis]
153 Noll EM, Eisen C, Stenzinger A, Espinet E, Muckenhuber A, Klein C, Vogel V, Klaus B, Nadler W, Rösli C, Lutz C, Kulke M, Engelhardt J, Zickgraf FM, Espinosa O, Schlesner M, Jiang X, Kopp-Schneider A, Neuhaus P, Bahra M, Sinn BV, Eils R, Giese NA, Hackert T, Strobel O, Werner J, Büchler MW, Weichert W, Trumpp A, Sprick MR. CYP3A5 mediates basal and acquired therapy resistance in different subtypes of pancreatic ductal adenocarcinoma. Nat Med 2016;22:278-87. [PMID: 26855150 DOI: 10.1038/nm.4038] [Cited by in Crossref: 127] [Cited by in F6Publishing: 105] [Article Influence: 21.2] [Reference Citation Analysis]
154 Adalsteinsson VA, Love JC. Towards Engineered Processes for Sequencing-Based Analysis of Single Circulating Tumor Cells. Curr Opin Chem Eng 2014;4:97-104. [PMID: 24839591 DOI: 10.1016/j.coche.2014.01.011] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
155 Goto Y, Ashida R, Nakamura A, Itasaka S, Shibuya K, Akimoto M, Mukumoto N, Matsumoto S, Kanai M, Isoda H, Masui T, Kodama Y, Nakamura M, Takaori K, Mizowaki T, Hiraoka M. Clinical results of dynamic tumor tracking intensity-modulated radiotherapy with real-time monitoring for pancreatic cancers using a gimbal mounted linac. Oncotarget 2018;9:23628-35. [PMID: 29805762 DOI: 10.18632/oncotarget.25310] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
156 Xu H, Paxton JW, Wu Z. Development of Long-Circulating pH-Sensitive Liposomes to Circumvent Gemcitabine Resistance in Pancreatic Cancer Cells. Pharm Res 2016;33:1628-37. [PMID: 26964546 DOI: 10.1007/s11095-016-1902-8] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 2.5] [Reference Citation Analysis]
157 Smits FJ, van Santvoort HC, Besselink MG, Batenburg MCT, Slooff RAE, Boerma D, Busch OR, Coene PPLO, van Dam RM, van Dijk DPJ, van Eijck CHJ, Festen S, van der Harst E, de Hingh IHJT, de Jong KP, Tol JAMG, Borel Rinkes IHM, Molenaar IQ; Dutch Pancreatic Cancer Group. Management of Severe Pancreatic Fistula After Pancreatoduodenectomy. JAMA Surg. 2017;152:540-548. [PMID: 28241220 DOI: 10.1001/jamasurg.2016.5708] [Cited by in Crossref: 47] [Cited by in F6Publishing: 38] [Article Influence: 9.4] [Reference Citation Analysis]
158 An Y, Chen XM, Yang Y, Mo F, Jiang Y, Sun DL, Cai HH. LncRNA DLX6-AS1 promoted cancer cell proliferation and invasion by attenuating the endogenous function of miR-181b in pancreatic cancer. Cancer Cell Int 2018;18:143. [PMID: 30250401 DOI: 10.1186/s12935-018-0643-7] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 5.3] [Reference Citation Analysis]
159 Ma W, Li T, Wu S, Li J, Wang X, Li H. LOX and ACSL5 as potential relapse markers for pancreatic cancer patients. Cancer Biol Ther 2019;20:787-98. [PMID: 30712446 DOI: 10.1080/15384047.2018.1564565] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
160 Zhu H, Wei M, Xu J, Hua J, Liang C, Meng Q, Zhang Y, Liu J, Zhang B, Yu X, Shi S. PARP inhibitors in pancreatic cancer: molecular mechanisms and clinical applications. Mol Cancer 2020;19:49. [PMID: 32122376 DOI: 10.1186/s12943-020-01167-9] [Cited by in Crossref: 40] [Cited by in F6Publishing: 41] [Article Influence: 20.0] [Reference Citation Analysis]
161 Venkatesulu BP, Hsieh CE, Sanders KL, Krishnan S. Recent advances in radiation therapy of pancreatic cancer. F1000Res 2018;7:F1000 Faculty Rev-1931. [PMID: 30613390 DOI: 10.12688/f1000research.16272.1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
162 Pan T, Zhang Y, Zhou N, He X, Chen C, Liang L, Duan X, Lin Y, Wu K, Zhang H. A recombinant chimeric protein specifically induces mutant KRAS degradation and potently inhibits pancreatic tumor growth. Oncotarget 2016;7:44299-309. [PMID: 27322423 DOI: 10.18632/oncotarget.9996] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
163 Ying H, Elpek KG, Vinjamoori A, Zimmerman SM, Chu GC, Yan H, Fletcher-Sananikone E, Zhang H, Liu Y, Wang W. PTEN is a major tumor suppressor in pancreatic ductal adenocarcinoma and regulates an NF-κB-cytokine network. Cancer Discov. 2011;1:158-169. [PMID: 21984975 DOI: 10.1158/2159-8290.cd-11-0031] [Cited by in Crossref: 135] [Cited by in F6Publishing: 107] [Article Influence: 12.3] [Reference Citation Analysis]
164 Kishimoto S, Brender JR, Crooks DR, Matsumoto S, Seki T, Oshima N, Merkle H, Lin P, Reed G, Chen AP, Ardenkjaer-Larsen JH, Munasinghe J, Saito K, Yamamoto K, Choyke PL, Mitchell J, Lane AN, Fan TW, Linehan WM, Krishna MC. Imaging of glucose metabolism by 13C-MRI distinguishes pancreatic cancer subtypes in mice. Elife 2019;8:e46312. [PMID: 31408004 DOI: 10.7554/eLife.46312] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 3.7] [Reference Citation Analysis]
165 Neuzillet C, Hentic O, Rousseau B, Rebours V, Bengrine-Lefèvre L, Bonnetain F, Lévy P, Raymond E, Ruszniewski P, Louvet C, Hammel P. FOLFIRI regimen in metastatic pancreatic adenocarcinoma resistant to gemcitabine and platinum-salts. World J Gastroenterol 2012; 18(33): 4533-4541 [PMID: 22969226 DOI: 10.3748/wjg.v18.i33.4533] [Cited by in CrossRef: 23] [Cited by in F6Publishing: 26] [Article Influence: 2.3] [Reference Citation Analysis]
166 Schultz NA, Christensen IJ, Werner J, Giese N, Jensen BV, Larsen O, Bjerregaard JK, Pfeiffer P, Calatayud D, Nielsen SE. Diagnostic and Prognostic Impact of Circulating YKL-40, IL-6, and CA 19.9 in Patients with Pancreatic Cancer. PLoS One. 2013;8:e67059. [PMID: 23840582 DOI: 10.1371/journal.pone.0067059] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 2.4] [Reference Citation Analysis]
167 Park I, Choi SJ, Kim YS, Ahn HK, Hong J, Sym SJ, Park J, Cho EK, Lee JH, Shin YJ, Shin DB. Prognostic Factors for Risk Stratification of Patients with Recurrent or Metastatic Pancreatic Adenocarcinoma Who Were Treated with Gemcitabine-Based Chemotherapy. Cancer Res Treat 2016;48:1264-73. [PMID: 27034148 DOI: 10.4143/crt.2015.250] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 3.7] [Reference Citation Analysis]
168 Harada A, Matsumoto S, Yasumizu Y, Shojima K, Akama T, Eguchi H, Kikuchi A. Localization of KRAS downstream target ARL4C to invasive pseudopods accelerates pancreatic cancer cell invasion. Elife 2021;10:e66721. [PMID: 34590580 DOI: 10.7554/eLife.66721] [Reference Citation Analysis]
169 Hu M, Xiong S, Chen Q, Zhu S, Zhou X. Novel role of microRNA-126 in digestive system cancers: From bench to bedside. Oncol Lett 2019;17:31-41. [PMID: 30655735 DOI: 10.3892/ol.2018.9639] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
170 Xu B, Jin DY, Lou WH, Wang DS. Lipocalin-2 is associated with a good prognosis and reversing epithelial-to-mesenchymal transition in pancreatic cancer. World J Surg. 2013;37:1892-1900. [PMID: 23539193 DOI: 10.1007/s00268-013-2009-6] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
171 Firuzi O, Che PP, El Hassouni B, Buijs M, Coppola S, Löhr M, Funel N, Heuchel R, Carnevale I, Schmidt T, Mantini G, Avan A, Saso L, Peters GJ, Giovannetti E. Role of c-MET Inhibitors in Overcoming Drug Resistance in Spheroid Models of Primary Human Pancreatic Cancer and Stellate Cells. Cancers (Basel) 2019;11:E638. [PMID: 31072019 DOI: 10.3390/cancers11050638] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 6.7] [Reference Citation Analysis]
172 Haeno H, Gonen M, Davis MB, Herman JM, Iacobuzio-Donahue CA, Michor F. Computational modeling of pancreatic cancer reveals kinetics of metastasis suggesting optimum treatment strategies. Cell. 2012;148:362-375. [PMID: 22265421 DOI: 10.1016/j.cell.2011.11.060.computational] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
173 Luu AM, Herzog T, Hoehn P, Reinacher-Schick A, Munding J, Uhl W, Braumann C. FOLFIRINOX treatment leading to pathologic complete response of a locally advanced pancreatic cancer. J Gastrointest Oncol 2018;9:E9-E12. [PMID: 29755782 DOI: 10.21037/jgo.2018.01.07] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
174 Zhu T, Gao YF, Chen YX, Wang ZB, Yin JY, Mao XY, Li X, Zhang W, Zhou HH, Liu ZQ. Genome-scale analysis identifies GJB2 and ERO1LB as prognosis markers in patients with pancreatic cancer. Oncotarget 2017;8:21281-9. [PMID: 28177904 DOI: 10.18632/oncotarget.15068] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 5.2] [Reference Citation Analysis]
175 Cheon YK, Koo JK, Lee YS, Lee TY, Shim CS. Elevated hemoglobin A1c levels are associated with worse survival in advanced pancreatic cancer patients with diabetes. Gut Liver. 2014;8:205-214. [PMID: 24672663 DOI: 10.5009/gnl.2014.8.2.205] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
176 Luu AM, Hoehn P, Vogel SR, Reinacher-Schick A, Munding J, Uhl W, Braumann C. Pathologic Complete Response of Pancreatic Cancer following Neoadjuvant FOLFIRINOX Treatment in Hepatic Metastasized Pancreatic Cancer. Visc Med 2019;35:387-91. [PMID: 31934588 DOI: 10.1159/000497827] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
177 Pelzer U, Sinn M, Stieler J, Riess H. [Multimodal treatment of pancreatic cancer]. Internist (Berl). 2014;55:31-36. [PMID: 24399472 DOI: 10.1007/s00108-013-3316-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
178 Veenstra VL, Damhofer H, Waasdorp C, van Rijssen LB, van de Vijver MJ, Dijk F, Wilmink HW, Besselink MG, Busch OR, Chang DK, Bailey PJ, Biankin AV, Kocher HM, Medema JP, Li JS, Jiang R, Pierce DW, van Laarhoven HWM, Bijlsma MF. ADAM12 is a circulating marker for stromal activation in pancreatic cancer and predicts response to chemotherapy. Oncogenesis 2018;7:87. [PMID: 30442938 DOI: 10.1038/s41389-018-0096-9] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 3.8] [Reference Citation Analysis]
179 Kauffmann EF, Napoli N, Menonna F, Vistoli F, Amorese G, Campani D, Pollina LE, Funel N, Cappelli C, Caramella D, Boggi U. Robotic pancreatoduodenectomy with vascular resection. Langenbecks Arch Surg. 2016;401:1111-1122. [PMID: 27553112 DOI: 10.1007/s00423-016-1499-8] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 5.0] [Reference Citation Analysis]
180 Tataranni T, Agriesti F, Pacelli C, Ruggieri V, Laurenzana I, Mazzoccoli C, Sala GD, Panebianco C, Pazienza V, Capitanio N, Piccoli C. Dichloroacetate Affects Mitochondrial Function and Stemness-Associated Properties in Pancreatic Cancer Cell Lines. Cells 2019;8:E478. [PMID: 31109089 DOI: 10.3390/cells8050478] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 5.7] [Reference Citation Analysis]
181 Lahat G, Sever R, Lubezky N, Nachmany I, Gerstenhaber F, Ben-Haim M, Nakache R, Koriansky J, Klausner JM. Pancreatic cancer: surgery is a feasible therapeutic option for elderly patients. World J Surg Oncol. 2011;9:10. [PMID: 21272335 DOI: 10.1186/1477-7819-9-10] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 2.2] [Reference Citation Analysis]
182 Liby KT, Royce DB, Risingsong R, Williams CR, Maitra A, Hruban RH, Sporn MB. Synthetic triterpenoids prolong survival in a transgenic mouse model of pancreatic cancer. Cancer Prev Res (Phila) 2010;3:1427-34. [PMID: 20959520 DOI: 10.1158/1940-6207.CAPR-10-0197] [Cited by in Crossref: 59] [Cited by in F6Publishing: 43] [Article Influence: 4.9] [Reference Citation Analysis]
183 Chen SJ, Chen YT, Zeng LJ, Zhang QB, Lian GD, Li JJ, Yang KG, Huang CM, Li YQ, Chu ZH, Huang KH. Bmi1 combines with oncogenic KRAS to induce malignant transformation of human pancreatic duct cells in vitro. Tumour Biol 2016;37:11299-309. [PMID: 26951514 DOI: 10.1007/s13277-016-4840-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
184 Camelo F, Le A. The Intricate Metabolism of Pancreatic Cancers. Adv Exp Med Biol 2021;1311:77-88. [PMID: 34014535 DOI: 10.1007/978-3-030-65768-0_5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
185 Lemke J, Schmidt SA, Kornmann M, Orend KH, Henne-Bruns D. Challenging the limits in pancreatic surgery: A case report. Int J Surg Case Rep 2016;29:151-4. [PMID: 27855353 DOI: 10.1016/j.ijscr.2016.10.062] [Reference Citation Analysis]
186 An XZ, Zhao ZG, Luo YX, Zhang R, Tang XQ, Hao D, Zhao X, Lv X, Liu D. Netrin-1 suppresses the MEK/ERK pathway and ITGB4 in pancreatic cancer. Oncotarget 2016;7:24719-33. [PMID: 27034160 DOI: 10.18632/oncotarget.8348] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 5.2] [Reference Citation Analysis]
187 Rathos MJ, Joshi K, Khanwalkar H, Manohar SM, Joshi KS. Molecular evidence for increased antitumor activity of gemcitabine in combination with a cyclin-dependent kinase inhibitor, P276-00 in pancreatic cancers. J Transl Med 2012;10:161. [PMID: 22873289 DOI: 10.1186/1479-5876-10-161] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 2.3] [Reference Citation Analysis]
188 Jun E, Song AY, Choi JW, Lee HH, Kim MY, Ko DH, Kang HJ, Kim SW, Bryceson Y, Kim SC, Kim HS. Progressive Impairment of NK Cell Cytotoxic Degranulation Is Associated With TGF-β1 Deregulation and Disease Progression in Pancreatic Cancer. Front Immunol 2019;10:1354. [PMID: 31281312 DOI: 10.3389/fimmu.2019.01354] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 5.7] [Reference Citation Analysis]
189 Bittoni A, Santoni M, Lanese A, Pellei C, Andrikou K, Stefano C. Neoadjuvant therapy in pancreatic cancer: an emerging strategy. Gastroenterol Res Pract 2014;2014:183852. [PMID: 25101123 DOI: 10.1155/2014/183852] [Cited by in Crossref: 24] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
190 Alemar B, Gregório C, Ashton-Prolla P. miRNAs As Diagnostic and Prognostic Biomarkers in Pancreatic Ductal Adenocarcinoma and Its Precursor Lesions: A Review. Biomark Insights 2015;10:113-24. [PMID: 26688661 DOI: 10.4137/BMI.S27679] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
191 Lee D, Komatsu S, Terashima K, Toyama H, Matsuo Y, Takahashi D, Suga M, Nishimura N, Tai K, Kido M, Demizu Y, Tokumaru S, Okimoto T, Sasaki R, Fukumoto T. Surgical spacer placement for proton radiotherapy in locally advanced pancreatic body and tail cancers: initial clinical results. Radiat Oncol 2021;16:3. [PMID: 33407648 DOI: 10.1186/s13014-020-01731-z] [Reference Citation Analysis]
192 Maier-Stocker C, Bitzer M, Malek NP, Plentz RR. Analysis of second-line chemotherapies for ductal pancreatic adenocarcinoma in a German single-center cohort. Scand J Gastroenterol 2014;49:1480-5. [PMID: 25390691 DOI: 10.3109/00365521.2014.978816] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
193 Sankpal UT, Goodison S, Jones-Pauley M, Hurtado M, Zhang F, Basha R. Tolfenamic acid-induced alterations in genes and pathways in pancreatic cancer cells. Oncotarget 2017;8:14593-603. [PMID: 28099934 DOI: 10.18632/oncotarget.14651] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
194 Parente P, Parcesepe P, Covelli C, Olivieri N, Remo A, Pancione M, Latiano TP, Graziano P, Maiello E, Giordano G. Crosstalk between the Tumor Microenvironment and Immune System in Pancreatic Ductal Adenocarcinoma: Potential Targets for New Therapeutic Approaches. Gastroenterol Res Pract. 2018;2018:7530619. [PMID: 30662458 DOI: 10.1155/2018/7530619] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.8] [Reference Citation Analysis]
195 Hamada S, Masamune A, Shimosegawa T. Alteration of pancreatic cancer cell functions by tumor-stromal cell interaction. Front Physiol. 2013;4:318. [PMID: 24198790 DOI: 10.3389/fphys.2013.00318] [Cited by in Crossref: 4] [Cited by in F6Publishing: 13] [Article Influence: 0.4] [Reference Citation Analysis]
196 Li CD, Ge M, Luo MY, Chen DJ. SiRNA-mediated silencing of the RPL31 gene inhibits proliferation of human pancreatic cancer PANC-1 cells. Shijie Huaren Xiaohua Zazhi 2012; 20(30): 2895-2901 [DOI: 10.11569/wcjd.v20.i30.2895] [Reference Citation Analysis]
197 Seo JW, Choi J, Lee SY, Sung S, Yoo HJ, Kang MJ, Cheong H, Son J. Autophagy is required for PDAC glutamine metabolism. Sci Rep 2016;6:37594. [PMID: 27892481 DOI: 10.1038/srep37594] [Cited by in Crossref: 33] [Cited by in F6Publishing: 38] [Article Influence: 5.5] [Reference Citation Analysis]
198 Lai X, Wang M, McElyea SD, Sherman S, House M, Korc M. A microRNA signature in circulating exosomes is superior to exosomal glypican-1 Levels for diagnosing pancreatic cancer. Cancer Lett. 2017;393:86-93. [PMID: 28232049 DOI: 10.1016/j.canlet.2017.02.019] [Cited by in Crossref: 144] [Cited by in F6Publishing: 148] [Article Influence: 28.8] [Reference Citation Analysis]
199 Idichi T, Seki N, Kurahara H, Fukuhisa H, Toda H, Shimonosono M, Yamada Y, Arai T, Kita Y, Kijima Y, Mataki Y, Maemura K, Natsugoe S. Involvement of anti-tumor miR-124-3p and its targets in the pathogenesis of pancreatic ductal adenocarcinoma: direct regulation of ITGA3 and ITGB1 by miR-124-3p. Oncotarget 2018;9:28849-65. [PMID: 29988949 DOI: 10.18632/oncotarget.25599] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 4.3] [Reference Citation Analysis]
200 Li W, Chen C, Zhao X, Ye H, Zhao Y, Fu Z, Pan W, Zheng S, Wei L, Nong T, Li Z, Chen R. HIF-2α regulates non-canonical glutamine metabolism via activation of PI3K/mTORC2 pathway in human pancreatic ductal adenocarcinoma. J Cell Mol Med 2017;21:2896-908. [PMID: 28544376 DOI: 10.1111/jcmm.13202] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
201 Zhang D, Zhang P, Li L, Tang N, Huang F, Kong X, Tan X, Shi G. Irisin functions to inhibit malignant growth of human pancreatic cancer cells via downregulation of the PI3K/AKT signaling pathway. Onco Targets Ther 2019;12:7243-9. [PMID: 31564907 DOI: 10.2147/OTT.S214260] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
202 Zhu L, Qin H, Li PY, Xu SN, Pang HF, Zhao HZ, Li DM, Zhao Q. Response gene to complement-32 enhances metastatic phenotype by mediating transforming growth factor beta-induced epithelial-mesenchymal transition in human pancreatic cancer cell line BxPC-3. J Exp Clin Cancer Res. 2012;31:29. [PMID: 22458379 DOI: 10.1186/1756-9966-31-29] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 2.1] [Reference Citation Analysis]
203 Huang L, Hu B, Ni J, Wu J, Jiang W, Chen C, Yang L, Zeng Y, Wan R, Hu G, Wang X. Transcriptional repression of SOCS3 mediated by IL-6/STAT3 signaling via DNMT1 promotes pancreatic cancer growth and metastasis. J Exp Clin Cancer Res 2016;35:27. [PMID: 26847351 DOI: 10.1186/s13046-016-0301-7] [Cited by in Crossref: 54] [Cited by in F6Publishing: 56] [Article Influence: 9.0] [Reference Citation Analysis]
204 Ahmed S, Bradshaw AD, Gera S, Dewan MZ, Xu R. The TGF-β/Smad4 Signaling Pathway in Pancreatic Carcinogenesis and Its Clinical Significance. J Clin Med 2017;6:E5. [PMID: 28067794 DOI: 10.3390/jcm6010005] [Cited by in Crossref: 56] [Cited by in F6Publishing: 62] [Article Influence: 11.2] [Reference Citation Analysis]
205 Geismann C, Grohmann F, Sebens S, Wirths G, Dreher A, Häsler R, Rosenstiel P, Hauser C, Egberts JH, Trauzold A, Schneider G, Sipos B, Zeissig S, Schreiber S, Schäfer H, Arlt A. c-Rel is a critical mediator of NF-κB-dependent TRAIL resistance of pancreatic cancer cells. Cell Death Dis 2014;5:e1455. [PMID: 25299780 DOI: 10.1038/cddis.2014.417] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 3.5] [Reference Citation Analysis]
206 Martin-Perez E, Domínguez-Muñoz JE, Botella-Romero F, Cerezo L, Matute Teresa F, Serrano T, Vera R. Multidisciplinary consensus statement on the clinical management of patients with pancreatic cancer. Clin Transl Oncol 2020;22:1963-75. [PMID: 32318964 DOI: 10.1007/s12094-020-02350-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
207 Miyashita T, Miki K, Kamigaki T, Makino I, Nakagawara H, Tajima H, Takamura H, Kitagawa H, Fushida S, Ahmed AK, Duncan MD, Harmon JW, Ohta T. Low-dose gemcitabine induces major histocompatibility complex class I-related chain A/B expression and enhances an antitumor innate immune response in pancreatic cancer. Clin Exp Med 2017;17:19-31. [PMID: 26449615 DOI: 10.1007/s10238-015-0394-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
208 Kohi S, Sato N, Cheng XB, Koga A, Higure A, Hirata K. A novel epigenetic mechanism regulating hyaluronan production in pancreatic cancer cells. Clin Exp Metastasis 2016;33:225-30. [PMID: 26589701 DOI: 10.1007/s10585-015-9771-9] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
209 Chang Z, Zhang Y, Liu J, Guan C, Gu X, Yang Z, Ye Q, Ding L, Liu R. GATA1 Promotes Gemcitabine Resistance in Pancreatic Cancer through Antiapoptotic Pathway. J Oncol 2019;2019:9474273. [PMID: 31093285 DOI: 10.1155/2019/9474273] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
210 Chiang KC, Yu CC, Chen JR, Huang YT, Huang CC, Yeh CN, Tsai CS, Chen LW, Chen HC, Hsu JT, Wang CH, Chen HY. Oncocytic-type intraductal papillary mucinous neoplasm (IPMN)-derived invasive oncocytic pancreatic carcinoma with brain metastasis - a case report. World J Surg Oncol 2012;10:138. [PMID: 22776211 DOI: 10.1186/1477-7819-10-138] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
211 Weng YC, Ma J, Zhang J, Wang JC. Long non-coding RNA LINC01133 silencing exerts antioncogenic effect in pancreatic cancer through the methylation of DKK1 promoter and the activation of Wnt signaling pathway. Cancer Biol Ther 2019;20:368-80. [PMID: 30580676 DOI: 10.1080/15384047.2018.1529110] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
212 Wang B, Fan P, Zhao J, Wu H, Jin X, Wu H. FBP1 loss contributes to BET inhibitors resistance by undermining c-Myc expression in pancreatic ductal adenocarcinoma. J Exp Clin Cancer Res 2018;37:224. [PMID: 30201002 DOI: 10.1186/s13046-018-0888-y] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
213 Stark JL, Mehla K, Chaika N, Acton TB, Xiao R, Singh PK, Montelione GT, Powers R. Structure and function of human DnaJ homologue subfamily a member 1 (DNAJA1) and its relationship to pancreatic cancer. Biochemistry 2014;53:1360-72. [PMID: 24512202 DOI: 10.1021/bi401329a] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 3.8] [Reference Citation Analysis]
214 O'Brien DP, Sandanayake NS, Jenkinson C, Gentry-Maharaj A, Apostolidou S, Fourkala EO, Camuzeaux S, Blyuss O, Gunu R, Dawnay A. Serum CA19-9 is significantly upregulated up to 2 years before diagnosis with pancreatic cancer: implications for early disease detection. Clin Cancer Res. 2015;21:622-631. [PMID: 24938522 DOI: 10.1158/1078-0432.ccr-14-0365] [Cited by in Crossref: 101] [Cited by in F6Publishing: 65] [Article Influence: 12.6] [Reference Citation Analysis]
215 Liu W, Deng L, Xu A, Xiong X, Tao J, Chang J, Xu Y, Zhou Z. Identifying a novel IRF3/circUHRF1/miR-1306-5p/ARL4C axis in pancreatic ductal adenocarcinoma progression. Cell Cycle 2022;:1-14. [PMID: 34983293 DOI: 10.1080/15384101.2021.2020450] [Reference Citation Analysis]
216 Hiraoka N, Ino Y, Hori S, Yamazaki-Itoh R, Naito C, Shimasaki M, Esaki M, Nara S, Kishi Y, Shimada K, Nakamura N, Torigoe T, Heike Y. Expression of classical human leukocyte antigen class I antigens, HLA-E and HLA-G, is adversely prognostic in pancreatic cancer patients. Cancer Sci 2020;111:3057-70. [PMID: 32495519 DOI: 10.1111/cas.14514] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
217 Shibata W, Kinoshita H, Hikiba Y, Sato T, Ishii Y, Sue S, Sugimori M, Suzuki N, Sakitani K, Ijichi H, Mori R, Endo I, Maeda S. Overexpression of HER2 in the pancreas promotes development of intraductal papillary mucinous neoplasms in mice. Sci Rep 2018;8:6150. [PMID: 29670173 DOI: 10.1038/s41598-018-24375-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
218 Etxeberria J, Goicoa T, López-Abente G, Riebler A, Ugarte MD. Spatial gender-age-period-cohort analysis of pancreatic cancer mortality in Spain (1990-2013). PLoS One 2017;12:e0169751. [PMID: 28199327 DOI: 10.1371/journal.pone.0169751] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.6] [Reference Citation Analysis]
219 Krantz SB, Shields MA, Dangi-Garimella S, Bentrem DJ, Munshi HG. Contribution of epithelial-mesenchymal transition to pancreatic cancer progression. Cancers (Basel). 2010;2:2084-2097. [PMID: 24281219 DOI: 10.3390/cancers2042084] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
220 Dreyer SB, Jamieson NB, Upstill-Goddard R, Bailey PJ, McKay CJ, Biankin AV, Chang DK; Australian Pancreatic Cancer Genome Initiative. Defining the molecular pathology of pancreatic body and tail adenocarcinoma. Br J Surg 2018;105:e183-91. [PMID: 29341146 DOI: 10.1002/bjs.10772] [Cited by in Crossref: 51] [Cited by in F6Publishing: 48] [Article Influence: 12.8] [Reference Citation Analysis]
221 Heinemann V, Vehling-Kaiser U, Waldschmidt D, Kettner E, Märten A, Winkelmann C, Klein S, Kojouharoff G, Gauler TC, von Weikersthal LF, Clemens MR, Geissler M, Greten TF, Hegewisch-Becker S, Rubanov O, Baake G, Höhler T, Ko YD, Jung A, Neugebauer S, Boeck S. Gemcitabine plus erlotinib followed by capecitabine versus capecitabine plus erlotinib followed by gemcitabine in advanced pancreatic cancer: final results of a randomised phase 3 trial of the 'Arbeitsgemeinschaft Internistische Onkologie' (AIO-PK0104). Gut 2013;62:751-9. [PMID: 22773551 DOI: 10.1136/gutjnl-2012-302759] [Cited by in Crossref: 71] [Cited by in F6Publishing: 66] [Article Influence: 7.1] [Reference Citation Analysis]
222 Song CY, Shen Y, Lu YQ. Role of routine check-up in the prognosis of patients with pancreatic cancer: A puzzling phenomenon. Hepatobiliary Pancreat Dis Int 2021;20:67-73. [PMID: 32631760 DOI: 10.1016/j.hbpd.2020.06.009] [Reference Citation Analysis]
223 Yang Z, LaRiviere MJ, Ko J, Till JE, Christensen T, Yee SS, Black TA, Tien K, Lin A, Shen H, Bhagwat N, Herman D, Adallah A, O'Hara MH, Vollmer CM, Katona BW, Stanger BZ, Issadore D, Carpenter EL. A Multianalyte Panel Consisting of Extracellular Vesicle miRNAs and mRNAs, cfDNA, and CA19-9 Shows Utility for Diagnosis and Staging of Pancreatic Ductal Adenocarcinoma. Clin Cancer Res 2020;26:3248-58. [PMID: 32299821 DOI: 10.1158/1078-0432.CCR-19-3313] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
224 Drosten M, Guerra C, Barbacid M. Genetically Engineered Mouse Models of K-Ras-Driven Lung and Pancreatic Tumors: Validation of Therapeutic Targets. Cold Spring Harb Perspect Med 2018;8:a031542. [PMID: 28778964 DOI: 10.1101/cshperspect.a031542] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
225 Huang S, Zheng J, Huang Y, Song L, Yin Y, Ou D, He S, Chen X, Ouyang X. Impact of S100A4 Expression on Clinicopathological Characteristics and Prognosis in Pancreatic Cancer: A Meta-Analysis. Dis Markers. 2016;2016:1-9. [PMID: 26903691 DOI: 10.1155/2016/8137378] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
226 Taniuchi K, Yawata T, Tsuboi M, Ueba T, Saibara T. Efficient delivery of small interfering RNAs targeting particular mRNAs into pancreatic cancer cells inhibits invasiveness and metastasis of pancreatic tumors. Oncotarget 2019;10:2869-86. [PMID: 31080558 DOI: 10.18632/oncotarget.26880] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
227 Osipov A, Blair AB, Liberto J, Wang J, Li K, Herbst B, Xu Y, Li S, Niu N, Rashid R, Ding D, Liu Y, Wang Z, Wolfgang CL, Burkhart RA, Laheru D, Zheng L. Inhibition of focal adhesion kinase enhances antitumor response of radiation therapy in pancreatic cancer through CD8+ T cells. Cancer Biol Med 2021;18:206-14. [PMID: 33628595 DOI: 10.20892/j.issn.2095-3941.2020.0273] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
228 Wang LM, Silva MA, D'Costa Z, Bockelmann R, Soonawalla Z, Liu S, O'Neill E, Mukherjee S, McKenna WG, Muschel R, Fokas E. The prognostic role of desmoplastic stroma in pancreatic ductal adenocarcinoma. Oncotarget 2016;7:4183-94. [PMID: 26716653 DOI: 10.18632/oncotarget.6770] [Cited by in Crossref: 56] [Cited by in F6Publishing: 57] [Article Influence: 9.3] [Reference Citation Analysis]
229 Granger JH, Granger MC, Firpo MA, Mulvihill SJ, Porter MD. Toward development of a surface-enhanced Raman scattering (SERS)-based cancer diagnostic immunoassay panel. Analyst 2013;138:410-6. [PMID: 23150876 DOI: 10.1039/c2an36128k] [Cited by in Crossref: 61] [Cited by in F6Publishing: 11] [Article Influence: 7.6] [Reference Citation Analysis]
230 Parajuli P, Singh P, Wang Z, Li L, Eragamreddi S, Ozkan S, Ferrigno O, Prunier C, Razzaque MS, Xu K, Atfi A. TGIF1 functions as a tumor suppressor in pancreatic ductal adenocarcinoma. EMBO J 2019;38:e101067. [PMID: 31268604 DOI: 10.15252/embj.2018101067] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
231 Duong HQ, You KS, Oh S, Kwak SJ, Seong YS. Silencing of NRF2 Reduces the Expression of ALDH1A1 and ALDH3A1 and Sensitizes to 5-FU in Pancreatic Cancer Cells. Antioxidants (Basel) 2017;6:E52. [PMID: 28671577 DOI: 10.3390/antiox6030052] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 5.2] [Reference Citation Analysis]
232 Jimenez-Luna C, Torres C, Ortiz R, Dieguez C, Martinez-Galan J, Melguizo C, Prados JC, Caba O. Proteomic biomarkers in body fluids associated with pancreatic cancer. Oncotarget. 2018;9:16573-16587. [PMID: 29662668 DOI: 10.18632/oncotarget.24654] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 4.5] [Reference Citation Analysis]
233 Galván JA, Zlobec I, Wartenberg M, Lugli A, Gloor B, Perren A, Karamitopoulou E. Expression of E-cadherin repressors SNAIL, ZEB1 and ZEB2 by tumour and stromal cells influences tumour-budding phenotype and suggests heterogeneity of stromal cells in pancreatic cancer. Br J Cancer 2015;112:1944-50. [PMID: 25989272 DOI: 10.1038/bjc.2015.177] [Cited by in Crossref: 99] [Cited by in F6Publishing: 95] [Article Influence: 14.1] [Reference Citation Analysis]
234 Wang L, Wang Y, Li PP, Wang R, Zhu Y, Zheng F, Li L, Cui JJ, Wang LW. Expression profile and prognostic value of SAV1 in patients with pancreatic ductal adenocarcinoma. Tumour Biol 2016. [PMID: 27747589 DOI: 10.1007/s13277-016-5457-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
235 Jeannot P, Callot C, Baer R, Duquesnes N, Guerra C, Guillermet-Guibert J, Bachs O, Besson A. Loss of p27Kip¹ promotes metaplasia in the pancreas via the regulation of Sox9 expression. Oncotarget 2015;6:35880-92. [PMID: 26416424 DOI: 10.18632/oncotarget.5770] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
236 Sharbeen G, Youkhana J, Mawson A, McCarroll J, Nunez A, Biankin A, Johns A, Goldstein D, Phillips P. MutY-Homolog (MYH) inhibition reduces pancreatic cancer cell growth and increases chemosensitivity. Oncotarget 2017;8:9216-29. [PMID: 27999205 DOI: 10.18632/oncotarget.13985] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
237 Nelson BS, Lin L, Kremer DM, Sousa CM, Cotta-Ramusino C, Myers A, Ramos J, Gao T, Kovalenko I, Wilder-Romans K, Dresser J, Davis M, Lee HJ, Nwosu ZC, Campit S, Mashadova O, Nicolay BN, Tolstyka ZP, Halbrook CJ, Chandrasekaran S, Asara JM, Crawford HC, Cantley LC, Kimmelman AC, Wahl DR, Lyssiotis CA. Tissue of origin dictates GOT1 dependence and confers synthetic lethality to radiotherapy. Cancer Metab 2020;8:1. [PMID: 31908776 DOI: 10.1186/s40170-019-0202-2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
238 Lee E, Horn-Ross PL, Rull RP, Neuhausen SL, Anton-Culver H, Ursin G, Henderson KD, Bernstein L. Reproductive factors, exogenous hormones, and pancreatic cancer risk in the CTS. Am J Epidemiol. 2013;178:1403-1413. [PMID: 24008905 DOI: 10.1093/aje/kwt154] [Cited by in Crossref: 38] [Cited by in F6Publishing: 34] [Article Influence: 4.2] [Reference Citation Analysis]
239 Herreros-Villanueva M, Bujanda L. Glypican-1 in exosomes as biomarker for early detection of pancreatic cancer. Ann Transl Med 2016;4:64. [PMID: 27004211 DOI: 10.3978/j.issn.2305-5839.2015.10.39] [Cited by in F6Publishing: 34] [Reference Citation Analysis]
240 Kamphorst JJ, Nofal M, Commisso C, Hackett SR, Lu W, Grabocka E, Vander Heiden MG, Miller G, Drebin JA, Bar-Sagi D, Thompson CB, Rabinowitz JD. Human pancreatic cancer tumors are nutrient poor and tumor cells actively scavenge extracellular protein. Cancer Res 2015;75:544-53. [PMID: 25644265 DOI: 10.1158/0008-5472.CAN-14-2211] [Cited by in Crossref: 400] [Cited by in F6Publishing: 278] [Article Influence: 57.1] [Reference Citation Analysis]
241 Yamaguchi K, Niwa Y, Nakabayashi T, Hiramatsu H. Generation of self-clusters of galectin-1 in the farnesyl-bound form. Sci Rep 2016;6:32999. [PMID: 27624845 DOI: 10.1038/srep32999] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
242 Xiong Y, Zhao Y, Han X, Chen G, Windsor J, Wu D, Qian J. Clinical characteristics and outcome of tumor-associated acute pancreatitis: a single-center cohort study. Ann Transl Med 2021;9:639. [PMID: 33987337 DOI: 10.21037/atm-20-7196] [Reference Citation Analysis]
243 Palagani V, El Khatib M, Kossatz U, Bozko P, Müller MR, Manns MP, Krech T, Malek NP, Plentz RR. Epithelial mesenchymal transition and pancreatic tumor initiating CD44+/EpCAM+ cells are inhibited by γ-secretase inhibitor IX. PLoS One. 2012;7:e46514. [PMID: 23094026 DOI: 10.1371/journal.pone.0046514] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 3.1] [Reference Citation Analysis]
244 Karamitopoulou E. Role of Epithelial-Mesenchymal Transition in Pancreatic Ductal Adenocarcinoma: Is Tumor Budding the Missing Link. Front Oncol. 2013;3:221. [PMID: 24062980 DOI: 10.3389/fonc.2013.00221] [Cited by in Crossref: 31] [Cited by in F6Publishing: 34] [Article Influence: 3.4] [Reference Citation Analysis]
245 Chen H, Ding C, Wild C, Liu H, Wang T, White MA, Cheng X, Zhou J. Efficient Synthesis of ESI-09, A Novel Non-cyclic Nucleotide EPAC Antagonist. Tetrahedron Lett 2013;54:1546-9. [PMID: 23459418 DOI: 10.1016/j.tetlet.2013.01.024] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 3.1] [Reference Citation Analysis]
246 Lankadasari MB, Mukhopadhyay P, Mohammed S, Harikumar KB. TAMing pancreatic cancer: combat with a double edged sword. Mol Cancer 2019;18:48. [PMID: 30925924 DOI: 10.1186/s12943-019-0966-6] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 8.3] [Reference Citation Analysis]
247 Zhao Y, Zheng Y, Zhu Y, Zhang Y, Zhu H, Liu T. M1 Macrophage-Derived Exosomes Loaded with Gemcitabine and Deferasirox against Chemoresistant Pancreatic Cancer. Pharmaceutics 2021;13:1493. [PMID: 34575569 DOI: 10.3390/pharmaceutics13091493] [Reference Citation Analysis]
248 Tao L, Zhou J, Yuan C, Zhang L, Li D, Si D, Xiu D, Zhong L. Metabolomics identifies serum and exosomes metabolite markers of pancreatic cancer. Metabolomics 2019;15:86. [PMID: 31147790 DOI: 10.1007/s11306-019-1550-1] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 10.7] [Reference Citation Analysis]
249 Jang WJ, Choi B, Song SH, Lee N, Kim DJ, Lee S, Jeong CH. Multi-omics analysis reveals that ornithine decarboxylase contributes to erlotinib resistance in pancreatic cancer cells. Oncotarget 2017;8:92727-42. [PMID: 29190951 DOI: 10.18632/oncotarget.21572] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
250 Singal AK, Ross WA, Guturu P, Varadhachary GR, Javle M, Jaganmohan SR, Raju RP, Fleming JB, Raju GS, Kuo YF, Lee JH. Self-expanding metal stents for biliary drainage in patients with resectable pancreatic cancer: single-center experience with 79 cases. Dig Dis Sci. 2011;56:3678-3684. [PMID: 21750930 DOI: 10.1007/s10620-011-1815-7] [Cited by in Crossref: 34] [Cited by in F6Publishing: 24] [Article Influence: 3.1] [Reference Citation Analysis]
251 Zeng J, Zhang H, Tan Y, Wang Z, Li Y, Yang X. Genetic alterations and functional networks of m6A RNA methylation regulators in pancreatic cancer based on data mining. J Transl Med 2021;19:323. [PMID: 34330301 DOI: 10.1186/s12967-021-03001-2] [Reference Citation Analysis]
252 Garrido-Laguna I, Tometich D, Hu N, Ying J, Geiersbach K, Whisenant J, Wang K, Ross JS, Sharma S. N of 1 case reports of exceptional responders accrued from pancreatic cancer patients enrolled in first-in-man studies from 2002 through 2012. Oncoscience 2015;2:285-93. [PMID: 25897431 DOI: 10.18632/oncoscience.141] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
253 Moningi S, Dholakia AS, Raman SP, Blackford A, Cameron JL, Le DT, De Jesus-Acosta AM, Hacker-Prietz A, Rosati LM, Assadi RK. The Role of Stereotactic Body Radiation Therapy for Pancreatic Cancer: A Single-Institution Experience. Ann Surg Oncol. 2015;22:2352-2358. [PMID: 25564157 DOI: 10.1245/s10434-014-4274-5] [Cited by in Crossref: 100] [Cited by in F6Publishing: 95] [Article Influence: 14.3] [Reference Citation Analysis]
254 Li S, Sun J, Yang J, Zhang L, Wang L, Wang X, Guo Z. XIAP expression is associated with pancreatic carcinoma outcome. Mol Clin Oncol 2013;1:305-8. [PMID: 24649165 DOI: 10.3892/mco.2013.58] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
255 Zhang F, Bai Z, Shi Y, Wang J, Li Y, Yang X. Interventional MRI-guided local delivery of agents into swine bile duct walls using MR-compatible needle-integrated balloon catheter system. NMR Biomed 2015;28:679-84. [PMID: 25900480 DOI: 10.1002/nbm.3308] [Reference Citation Analysis]
256 Fasano M, Della Corte CM, Vicidomini G, Scotti V, Rambaldi PF, Fiorelli A, Accardo M, De Vita F, Santini M, Ciardiello F, Morgillo F. Small bowel metastasis from pancreatic cancer in a long-term survival patient with synchronous advanced malignant pleural mesothelioma: A case report and literature review. Oncol Lett 2016;12:4505-9. [PMID: 28105159 DOI: 10.3892/ol.2016.5279] [Reference Citation Analysis]
257 Mattiucci GC, Morganti AG, Cellini F, Buwenge M, Casadei R, Farioli A, Alfieri S, Arcelli A, Bertini F, Calvo FA, Cammelli S, Fuccio L, Giaccherini L, Guido A, Herman JM, Macchia G, Maidment BW 3rd, Miller RC, Minni F, Regine WF, Reni M, Partelli S, Falconi M, Valentini V. Prognostic Impact of Presurgical CA19-9 Level in Pancreatic Adenocarcinoma: A Pooled Analysis. Transl Oncol 2019;12:1-7. [PMID: 30237099 DOI: 10.1016/j.tranon.2018.08.017] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
258 Vincent A, Herman J, Schulick R, Hruban RH, Goggins M. Pancreatic cancer. Lancet. 2011;378:607-620. [PMID: 21620466 DOI: 10.1016/s0140-6736(10)62307-0] [Cited by in Crossref: 1377] [Cited by in F6Publishing: 849] [Article Influence: 125.2] [Reference Citation Analysis]
259 Kanamori A, Matsubara D, Saitoh Y, Fukui Y, Gotoh N, Kaneko S, Seiki M, Murakami Y, Inoue JI, Sakamoto T. Mint3 depletion restricts tumor malignancy of pancreatic cancer cells by decreasing SKP2 expression via HIF-1. Oncogene 2020;39:6218-30. [PMID: 32826949 DOI: 10.1038/s41388-020-01423-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
260 Brunetto E, De Monte L, Balzano G, Camisa B, Laino V, Riba M, Heltai S, Bianchi M, Bordignon C, Falconi M, Bondanza A, Doglioni C, Protti MP. The IL-1/IL-1 receptor axis and tumor cell released inflammasome adaptor ASC are key regulators of TSLP secretion by cancer associated fibroblasts in pancreatic cancer. J Immunother Cancer 2019;7:45. [PMID: 30760333 DOI: 10.1186/s40425-019-0521-4] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 6.7] [Reference Citation Analysis]
261 Fernandez Y Viesca M, Arvanitakis M. Early Diagnosis And Management Of Malignant Distal Biliary Obstruction: A Review On Current Recommendations And Guidelines. Clin Exp Gastroenterol. 2019;12:415-432. [PMID: 31807048 DOI: 10.2147/ceg.s195714] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
262 Wolpin BM, Bao Y, Qian ZR, Wu C, Kraft P, Ogino S, Stampfer MJ, Sato K, Ma J, Buring JE. Hyperglycemia, insulin resistance, impaired pancreatic β-cell function, and risk of pancreatic cancer. J Natl Cancer Inst. 2013;105:1027-1035. [PMID: 23847240 DOI: 10.1093/jnci/djt123] [Cited by in Crossref: 102] [Cited by in F6Publishing: 91] [Article Influence: 11.3] [Reference Citation Analysis]
263 Walker EJ, Ko AH, Holly EA, Bracci PM. Metformin use among type 2 diabetics and risk of pancreatic cancer in a clinic-based case-control study. Int J Cancer. 2015;136:E646-E653. [PMID: 25091126 DOI: 10.1002/ijc.29120] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
264 Takahashi K, Ehata S, Koinuma D, Morishita Y, Soda M, Mano H, Miyazono K. Pancreatic tumor microenvironment confers highly malignant properties on pancreatic cancer cells. Oncogene 2018;37:2757-72. [PMID: 29511349 DOI: 10.1038/s41388-018-0144-0] [Cited by in Crossref: 39] [Cited by in F6Publishing: 39] [Article Influence: 9.8] [Reference Citation Analysis]
265 Baer R, Cintas C, Dufresne M, Cassant-Sourdy S, Schönhuber N, Planque L, Lulka H, Couderc B, Bousquet C, Garmy-Susini B. Pancreatic cell plasticity and cancer initiation induced by oncogenic Kras is completely dependent on wild-type PI 3-kinase p110α. Genes Dev. 2014;28:2621-2635. [PMID: 25452273 DOI: 10.1101/gad.249409.114] [Cited by in Crossref: 76] [Cited by in F6Publishing: 65] [Article Influence: 10.9] [Reference Citation Analysis]
266 Liu F, Korc M. Cdk4/6 inhibition induces epithelial-mesenchymal transition and enhances invasiveness in pancreatic cancer cells. Mol Cancer Ther 2012;11:2138-48. [PMID: 22869556 DOI: 10.1158/1535-7163.MCT-12-0562] [Cited by in Crossref: 71] [Cited by in F6Publishing: 51] [Article Influence: 7.1] [Reference Citation Analysis]
267 Feld FM, Nagel PD, Weissinger SE, Welke C, Stenzinger A, Möller P, Lennerz JK. GOT1/AST1 expression status as a prognostic biomarker in pancreatic ductal adenocarcinoma. Oncotarget 2015;6:4516-26. [PMID: 25595905 DOI: 10.18632/oncotarget.2799] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 2.1] [Reference Citation Analysis]
268 Tan XP, Dong WG, Zhang Q, Yang ZR, Lei XF, Ai MH. Potential effects of Mina53 on tumor growth in human pancreatic cancer. Cell Biochem Biophys 2014;69:619-25. [PMID: 24522517 DOI: 10.1007/s12013-014-9841-7] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
269 Zhang W, Yao JL, Dong SC, Hou FQ, Shi HP. SLPI knockdown induced pancreatic ductal adenocarcinoma cells proliferation and invasion. Cancer Cell Int 2015;15:37. [PMID: 25954138 DOI: 10.1186/s12935-015-0182-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
270 Singh VK, Haupt ME, Geller DE, Hall JA, Quintana Diez PM. Less common etiologies of exocrine pancreatic insufficiency. World J Gastroenterol 2017; 23(39): 7059-7076 [PMID: 29093615 DOI: 10.3748/wjg.v23.i39.7059] [Cited by in CrossRef: 46] [Cited by in F6Publishing: 30] [Article Influence: 9.2] [Reference Citation Analysis]
271 Onyeaghala G, Lane J, Pankratz N, Nelson HH, Thyagarajan B, Walcheck B, Anderson KE, Prizment AE. Association between MICA polymorphisms, s-MICA levels, and pancreatic cancer risk in a population-based case-control study. PLoS One 2019;14:e0217868. [PMID: 31166958 DOI: 10.1371/journal.pone.0217868] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
272 Breuer S, Maimon O, Appelbaum L, Peretz T, Hubert A. TL-118-anti-angiogenic treatment in pancreatic cancer: a case report. Med Oncol 2013;30:585. [PMID: 23609193 DOI: 10.1007/s12032-013-0585-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
273 Miyazono K, Katsuno Y, Koinuma D, Ehata S, Morikawa M. Intracellular and extracellular TGF-β signaling in cancer: some recent topics. Front Med 2018;12:387-411. [PMID: 30043220 DOI: 10.1007/s11684-018-0646-8] [Cited by in Crossref: 47] [Cited by in F6Publishing: 52] [Article Influence: 11.8] [Reference Citation Analysis]
274 Knight JC, Torres JB, Goldin R, Mosley M, Dias GM, Bravo LC, Kersemans V, Allen PD, Mukherjee S, Smart S, Cornelissen B. Early Detection in a Mouse Model of Pancreatic Cancer by Imaging DNA Damage Response Signaling. J Nucl Med 2020;61:1006-13. [PMID: 31862800 DOI: 10.2967/jnumed.119.234708] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
275 Sánchez-Bueno F, García-Pérez R, Claver Valderas MA, de la Peña Moral J, Frutos Esteban L, Ortiz Ruiz E, Fuster Quiñonero M, Parrilla Paricio P. Utility of 18 fludeoxyglucose in preoperative positon-emission tomography-computed tomography (PET-CT) in the early diagnosis of exocrine pancreatic cancer: A study of 139 resected cases. Cir Esp 2016;94:511-7. [PMID: 27712835 DOI: 10.1016/j.ciresp.2016.07.007] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
276 Li C, Morvaridi S, Lam G, Chheda C, Kamata Y, Katsumata M, Edderkaoui M, Yuan X, Nissen N, Pandol SJ, Wang Q. MSP-RON Signaling Is Activated in the Transition From Pancreatic Intraepithelial Neoplasia (PanIN) to Pancreatic Ductal Adenocarcinoma (PDAC). Front Physiol. 2019;10:147. [PMID: 30863319 DOI: 10.3389/fphys.2019.00147] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
277 Moravec R, Divi R, Verma M. Detecting circulating tumor material and digital pathology imaging during pancreatic cancer progression. World J Gastrointest Oncol 2017; 9(6): 235-250 [PMID: 28656074 DOI: 10.4251/wjgo.v9.i6.235] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
278 Cheng X, Wang B, Jin Z, Ma D, Yang W, Zhao R, Jing X, Shen B, Peng C, Qiu W. Pseudomonas aeruginosa-mannose-sensitive hemagglutinin inhibits pancreatic cancer cell proliferation and induces apoptosis via the EGFR pathway and caspase signaling. Oncotarget 2016;7:77916-25. [PMID: 27788491 DOI: 10.18632/oncotarget.12844] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
279 Park SJ, Kim H, Shin K, Lee MA, Hong TH. Oral chemotherapy for second-line treatment in patients with gemcitabine-refractory advanced pancreatic cancer. World J Gastrointest Oncol 2019; 11(11): 1021-1030 [PMID: 31798782 DOI: 10.4251/wjgo.v11.i11.1021] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
280 Qin R, Smyrk TC, Reed NR, Schmidt RL, Schnelldorfer T, Chari ST, Petersen GM, Tang AH. Combining clinicopathological predictors and molecular biomarkers in the oncogenic K-RAS/Ki67/HIF-1α pathway to predict survival in resectable pancreatic cancer. Br J Cancer 2015;112:514-22. [PMID: 25584484 DOI: 10.1038/bjc.2014.659] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 4.3] [Reference Citation Analysis]
281 Tao L, Su L, Yuan C, Ma Z, Zhang L, Bo S, Niu Y, Lu S, Xiu D. Postoperative metastasis prediction based on portal vein circulating tumor cells detected by flow cytometry in periampullary or pancreatic cancer. Cancer Manag Res 2019;11:7405-25. [PMID: 31496801 DOI: 10.2147/CMAR.S210332] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
282 Lehmann-Werman R, Neiman D, Zemmour H, Moss J, Magenheim J, Vaknin-Dembinsky A, Rubertsson S, Nellgård B, Blennow K, Zetterberg H, Spalding K, Haller MJ, Wasserfall CH, Schatz DA, Greenbaum CJ, Dorrell C, Grompe M, Zick A, Hubert A, Maoz M, Fendrich V, Bartsch DK, Golan T, Ben Sasson SA, Zamir G, Razin A, Cedar H, Shapiro AM, Glaser B, Shemer R, Dor Y. Identification of tissue-specific cell death using methylation patterns of circulating DNA. Proc Natl Acad Sci U S A 2016;113:E1826-34. [PMID: 26976580 DOI: 10.1073/pnas.1519286113] [Cited by in Crossref: 301] [Cited by in F6Publishing: 269] [Article Influence: 50.2] [Reference Citation Analysis]
283 Wang J, Xie Z, Liu Y, Zhang W, Ji T. MicroRNA-361 reduces the viability and migratory ability of pancreatic cancer cells via mediation of the MAPK/JNK pathway. Exp Ther Med 2021;22:1365. [PMID: 34659511 DOI: 10.3892/etm.2021.10799] [Reference Citation Analysis]
284 Koay EJ, Lee Y, Cristini V, Lowengrub JS, Kang Y, Lucas FAS, Hobbs BP, Ye R, Elganainy D, Almahariq M, Amer AM, Chatterjee D, Yan H, Park PC, Rios Perez MV, Li D, Garg N, Reiss KA, Yu S, Chauhan A, Zaid M, Nikzad N, Wolff RA, Javle M, Varadhachary GR, Shroff RT, Das P, Lee JE, Ferrari M, Maitra A, Taniguchi CM, Kim MP, Crane CH, Katz MH, Wang H, Bhosale P, Tamm EP, Fleming JB. A Visually Apparent and Quantifiable CT Imaging Feature Identifies Biophysical Subtypes of Pancreatic Ductal Adenocarcinoma. Clin Cancer Res 2018;24:5883-94. [PMID: 30082477 DOI: 10.1158/1078-0432.CCR-17-3668] [Cited by in Crossref: 40] [Cited by in F6Publishing: 22] [Article Influence: 10.0] [Reference Citation Analysis]
285 Zorde Khvalevsky E, Gabai R, Rachmut IH, Horwitz E, Brunschwig Z, Orbach A, Shemi A, Golan T, Domb AJ, Yavin E. Mutant KRAS is a druggable target for pancreatic cancer. Proc Natl Acad Sci USA. 2013;110:20723-20728. [PMID: 24297898 DOI: 10.1073/pnas.1314307110] [Cited by in Crossref: 163] [Cited by in F6Publishing: 152] [Article Influence: 18.1] [Reference Citation Analysis]
286 Zang W, Wang Y, Wang T, Du Y, Chen X, Li M, Zhao G. miR-663 attenuates tumor growth and invasiveness by targeting eEF1A2 in pancreatic cancer. Mol Cancer 2015;14:37. [PMID: 25744894 DOI: 10.1186/s12943-015-0315-3] [Cited by in Crossref: 48] [Cited by in F6Publishing: 52] [Article Influence: 6.9] [Reference Citation Analysis]
287 Martinez-Useros J, Li W, Cabeza-Morales M, Garcia-Foncillas J. Oxidative Stress: A New Target for Pancreatic Cancer Prognosis and Treatment. J Clin Med 2017;6:E29. [PMID: 28282928 DOI: 10.3390/jcm6030029] [Cited by in Crossref: 38] [Cited by in F6Publishing: 36] [Article Influence: 7.6] [Reference Citation Analysis]
288 Yuan C, Morales-Oyarvide V, Babic A, Clish CB, Kraft P, Bao Y, Qian ZR, Rubinson DA, Ng K, Giovannucci EL, Ogino S, Stampfer MJ, Gaziano JM, Sesso HD, Cochrane BB, Manson JE, Fuchs CS, Wolpin BM. Cigarette Smoking and Pancreatic Cancer Survival. J Clin Oncol. 2017;35:1822-1828. [PMID: 28358654 DOI: 10.1200/jco.2016.71.2026] [Cited by in Crossref: 46] [Cited by in F6Publishing: 33] [Article Influence: 9.2] [Reference Citation Analysis]
289 Yeo D, Huynh N, Beutler JA, Christophi C, Shulkes A, Baldwin GS, Nikfarjam M, He H. Glaucarubinone and gemcitabine synergistically reduce pancreatic cancer growth via down-regulation of P21-activated kinases. Cancer Lett. 2014;346:264-272. [PMID: 24491405 DOI: 10.1016/j.canlet.2014.01.001] [Cited by in Crossref: 40] [Cited by in F6Publishing: 33] [Article Influence: 5.0] [Reference Citation Analysis]
290 Jin L, Shi N, Ruan S, Hou B, Zou Y, Zou X, Jin H, Jian Z. The role of intraoperative radiation therapy in resectable pancreatic cancer: a systematic review and meta-analysis. Radiat Oncol 2020;15:76. [PMID: 32272945 DOI: 10.1186/s13014-020-01511-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
291 Zhao L, Liu Y, Zhao F, Jin Y, Feng J, Geng R, Sun J, Kang L, Yu L, Wei Y. Inhibition of Cholesterol Esterification Enzyme Enhances the Potency of Human Chimeric Antigen Receptor T Cells against Pancreatic Carcinoma. Mol Ther Oncolytics 2020;16:262-71. [PMID: 32181327 DOI: 10.1016/j.omto.2020.01.008] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
292 Augustyn A, Reed VI, Ahmad N, Bhutani MS, Bloom ES, Bowers JR, Chronowski GM, Das P, Holliday EB, Delclos ME, Huey RW, Koay EJ, Lee SS, Nelson CL, Taniguchi CM, Koong AC, Chun SG. Implementation of a stereotactic body radiotherapy program for unresectable pancreatic cancer in an integrated community academic radiation oncology satellite network. Clin Transl Radiat Oncol 2021;27:147-51. [PMID: 33665384 DOI: 10.1016/j.ctro.2021.02.004] [Reference Citation Analysis]
293 Wei F, Liu Y, Guo Y, Xiang A, Wang G, Xue X, Lu Z. miR-99b-targeted mTOR induction contributes to irradiation resistance in pancreatic cancer. Mol Cancer. 2013;12:81. [PMID: 23886294 DOI: 10.1186/1476-4598-12-81] [Cited by in Crossref: 42] [Cited by in F6Publishing: 42] [Article Influence: 4.7] [Reference Citation Analysis]
294 Stock K, Borrink R, Mikesch JH, Hansmeier A, Rehkämper J, Trautmann M, Wardelmann E, Hartmann W, Sperveslage J, Steinestel K. Overexpression and Tyr421-phosphorylation of cortactin is induced by three-dimensional spheroid culturing and contributes to migration and invasion of pancreatic ductal adenocarcinoma (PDAC) cells. Cancer Cell Int 2019;19:77. [PMID: 30976201 DOI: 10.1186/s12935-019-0798-x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
295 Ishii N, Araki K, Yokobori T, Hagiwara K, Gantumur D, Yamanaka T, Handa T, Tsukagoshi M, Igarashi T, Watanabe A, Kubo N, Harimoto N, Masamune A, Umezawa K, Kuwano H, Shirabe K. Conophylline suppresses pancreatic cancer desmoplasia and cancer-promoting cytokines produced by cancer-associated fibroblasts. Cancer Sci 2019;110:334-44. [PMID: 30353606 DOI: 10.1111/cas.13847] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 3.3] [Reference Citation Analysis]
296 Ramakrishnan P, Loh WM, Gopinath SCB, Bonam SR, Fareez IM, Mac Guad R, Sim MS, Wu YS. Selective phytochemicals targeting pancreatic stellate cells as new anti-fibrotic agents for chronic pancreatitis and pancreatic cancer. Acta Pharm Sin B 2020;10:399-413. [PMID: 32140388 DOI: 10.1016/j.apsb.2019.11.008] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
297 Campa D, Pastore M, Gentiluomo M, Talar-Wojnarowska R, Kupcinskas J, Malecka-Panas E, Neoptolemos JP, Niesen W, Vodicka P, Delle Fave G, Bueno-de-Mesquita HB, Gazouli M, Pacetti P, Di Leo M, Ito H, Klüter H, Soucek P, Corbo V, Yamao K, Hosono S, Kaaks R, Vashist Y, Gioffreda D, Strobel O, Shimizu Y, Dijk F, Andriulli A, Ivanauskas A, Bugert P, Tavano F, Vodickova L, Zambon CF, Lovecek M, Landi S, Key TJ, Boggi U, Pezzilli R, Jamroziak K, Mohelnikova-Duchonova B, Mambrini A, Bambi F, Busch O, Pazienza V, Valente R, Theodoropoulos GE, Hackert T, Capurso G, Cavestro GM, Pasquali C, Basso D, Sperti C, Matsuo K, Büchler M, Khaw KT, Izbicki J, Costello E, Katzke V, Michalski C, Stepien A, Rizzato C, Canzian F. Functional single nucleotide polymorphisms within the cyclin-dependent kinase inhibitor 2A/2B region affect pancreatic cancer risk. Oncotarget 2016;7:57011-20. [PMID: 27486979 DOI: 10.18632/oncotarget.10935] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 5.3] [Reference Citation Analysis]
298 Loc WS, Smith JP, Matters G, Kester M, Adair JH. Novel strategies for managing pancreatic cancer. World J Gastroenterol 2014; 20(40): 14717-14725 [PMID: 25356034 DOI: 10.3748/wjg.v20.i40.14717] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
299 Rossi ML, Rehman AA, Gondi CS. Therapeutic options for the management of pancreatic cancer. World J Gastroenterol 2014; 20(32): 11142-11159 [PMID: 25170201 DOI: 10.3748/wjg.v20.i32.11142] [Cited by in CrossRef: 75] [Cited by in F6Publishing: 68] [Article Influence: 9.4] [Reference Citation Analysis]
300 Koutsounas I, Giaginis C, Theocharis S. Histone deacetylase inhibitors and pancreatic cancer: Are there any promising clinical trials? World J Gastroenterol 2013; 19(8): 1173-1181 [PMID: 23482354 DOI: 10.3748/wjg.v19.i8.1173] [Cited by in CrossRef: 34] [Cited by in F6Publishing: 35] [Article Influence: 3.8] [Reference Citation Analysis]
301 Westphalen CB, Olive KP. Genetically engineered mouse models of pancreatic cancer. Cancer J 2012;18:502-10. [PMID: 23187836 DOI: 10.1097/PPO.0b013e31827ab4c4] [Cited by in Crossref: 64] [Cited by in F6Publishing: 39] [Article Influence: 7.1] [Reference Citation Analysis]
302 Hamada S, Masamune A, Yoshida N, Takikawa T, Shimosegawa T. IL-6/STAT3 Plays a Regulatory Role in the Interaction Between Pancreatic Stellate Cells and Cancer Cells. Dig Dis Sci 2016;61:1561-71. [PMID: 26738736 DOI: 10.1007/s10620-015-4001-5] [Cited by in Crossref: 43] [Cited by in F6Publishing: 41] [Article Influence: 7.2] [Reference Citation Analysis]
303 Cyr DP, Truong JL, Lam-McCulloch J, Cleary SP, Karanicolas PJ. Canadian practice patterns for pancreaticoduodenectomy. Can J Surg 2015;58:121-7. [PMID: 25799248 DOI: 10.1503/cjs.011714] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
304 Muniz VP, Barnes JM, Paliwal S, Zhang X, Tang X, Chen S, Zamba KD, Cullen JJ, Meyerholz DK, Meyers S, Davis JN, Grossman SR, Henry MD, Quelle DE. The ARF tumor suppressor inhibits tumor cell colonization independent of p53 in a novel mouse model of pancreatic ductal adenocarcinoma metastasis. Mol Cancer Res 2011;9:867-77. [PMID: 21636682 DOI: 10.1158/1541-7786.MCR-10-0475] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 1.6] [Reference Citation Analysis]
305 Zhang XW, Ma YX, Sun Y, Cao YB, Li Q, Xu CA. Gemcitabine in Combination with a Second Cytotoxic Agent in the First-Line Treatment of Locally Advanced or Metastatic Pancreatic Cancer: a Systematic Review and Meta-Analysis. Target Oncol 2017;12:309-21. [PMID: 28353074 DOI: 10.1007/s11523-017-0486-5] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
306 Veenstra VL, Damhofer H, Waasdorp C, Steins A, Kocher HM, Medema JP, van Laarhoven HW, Bijlsma MF. Stromal SPOCK1 supports invasive pancreatic cancer growth. Mol Oncol 2017;11:1050-64. [PMID: 28486750 DOI: 10.1002/1878-0261.12073] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
307 Damm M, Efremov L, Birnbach B, Terrero G, Kleeff J, Mikolajczyk R, Rosendahl J, Michl P, Krug S. Efficacy and Safety of Neoadjuvant Gemcitabine Plus Nab-Paclitaxel in Borderline Resectable and Locally Advanced Pancreatic Cancer-A Systematic Review and Meta-Analysis. Cancers (Basel) 2021;13:4326. [PMID: 34503138 DOI: 10.3390/cancers13174326] [Reference Citation Analysis]
308 Feisthammel J, Mössner J, Hoffmeister A. Palliative Endoscopic Treatment Options in Malignancies of the Biliopancreatic System. Viszeralmedizin 2014;30:238-43. [PMID: 26288596 DOI: 10.1159/000366145] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
309 Nakajima K, Ino Y, Naito C, Nara S, Shimasaki M, Ishimoto U, Iwasaki T, Doi N, Esaki M, Kishi Y, Shimada K, Hiraoka N. Neoadjuvant therapy alters the collagen architecture of pancreatic cancer tissue via Ephrin-A5. Br J Cancer 2021. [PMID: 34824448 DOI: 10.1038/s41416-021-01639-9] [Reference Citation Analysis]
310 Tan X, Liu P, Huang Y, Zhou L, Yang Y, Wang H, Yu B, Meng X, Zhang X, Gao F. Phosphoproteome Analysis of Invasion and Metastasis-Related Factors in Pancreatic Cancer Cells. PLoS One 2016;11:e0152280. [PMID: 27014871 DOI: 10.1371/journal.pone.0152280] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
311 Rodríguez-Pascual J, Sha P, García-García E, Rajeshkumar NV, De Vicente E, Quijano Y, Cubillo A, Angulo B, Hernando O, Hidalgo M. A preclinical and clinical study of mycophenolate mofetil in pancreatic cancer. Invest New Drugs 2013;31:14-9. [PMID: 22669334 DOI: 10.1007/s10637-012-9822-x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
312 Stoy C, Sundaram A, Rios Garcia M, Wang X, Seibert O, Zota A, Wendler S, Männle D, Hinz U, Sticht C, Muciek M, Gretz N, Rose AJ, Greiner V, Hofmann TG, Bauer A, Hoheisel J, Berriel Diaz M, Gaida MM, Werner J, Schafmeier T, Strobel O, Herzig S. Transcriptional co-factor Transducin beta-like (TBL) 1 acts as a checkpoint in pancreatic cancer malignancy. EMBO Mol Med 2015;7:1048-62. [PMID: 26070712 DOI: 10.15252/emmm.201404837] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
313 Ding Y, Campbell WG, Miften M, Vinogradskiy Y, Goodman KA, Schefter T, Jones BL. Quantifying Allowable Motion to Achieve Safe Dose Escalation in Pancreatic SBRT. Pract Radiat Oncol 2019;9:e432-42. [PMID: 30951868 DOI: 10.1016/j.prro.2019.03.006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
314 Chow CR, Ebine K, Knab LM, Bentrem DJ, Kumar K, Munshi HG. Cancer Cell Invasion in Three-dimensional Collagen Is Regulated Differentially by Gα13 Protein and Discoidin Domain Receptor 1-Par3 Protein Signaling. J Biol Chem 2016;291:1605-18. [PMID: 26589794 DOI: 10.1074/jbc.M115.669606] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
315 Li S, Tian B. Acute pancreatitis in patients with pancreatic cancer: Timing of surgery and survival duration. Medicine (Baltimore). 2017;96:e5908. [PMID: 28099352 DOI: 10.1097/md.0000000000005908] [Cited by in Crossref: 19] [Cited by in F6Publishing: 10] [Article Influence: 3.8] [Reference Citation Analysis]
316 Walters DM, Lindberg JM, Adair SJ, Newhook TE, Cowan CR, Stokes JB, Borgman CA, Stelow EB, Lowrey BT, Chopivsky ME, Gilmer TM, Parsons JT, Bauer TW. Inhibition of the growth of patient-derived pancreatic cancer xenografts with the MEK inhibitor trametinib is augmented by combined treatment with the epidermal growth factor receptor/HER2 inhibitor lapatinib. Neoplasia 2013;15:143-55. [PMID: 23441129 DOI: 10.1593/neo.121712] [Cited by in Crossref: 57] [Cited by in F6Publishing: 52] [Article Influence: 6.3] [Reference Citation Analysis]
317 Kooshkaki O, Rezaei Z, Rahmati M, Vahedi P, Derakhshani A, Brunetti O, Baghbanzadeh A, Mansoori B, Silvestris N, Baradaran B. MiR-144: A New Possible Therapeutic Target and Diagnostic/Prognostic Tool in Cancers. Int J Mol Sci 2020;21:E2578. [PMID: 32276343 DOI: 10.3390/ijms21072578] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
318 Chen J, Chen LJ, Yang RB, Xia YL, Zhou HC, Wu W, Lu Y, Hu LW, Zhao Y. Expression and clinical significance of apolipoprotein E in pancreatic ductal adenocarcinoma. Med Oncol. 2013;30:583. [PMID: 23609192 DOI: 10.1007/s12032-013-0583-y] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
319 Sakin A, Sahin S, Sakin A, Atci MM, Arici S, Yasar N, Demir C, Geredeli C, Cihan S. Factors affecting survival in operated pancreatic cancer: Does tumor localization have a significant effect on treatment outcomes? North Clin Istanb 2020;7:487-93. [PMID: 33163885 DOI: 10.14744/nci.2020.09735] [Reference Citation Analysis]
320 Liu Y, Bi T, Wang G, Dai W, Wu G, Qian L, Gao Q, Shen G. Lupeol inhibits proliferation and induces apoptosis of human pancreatic cancer PCNA-1 cells through AKT/ERK pathways. Naunyn Schmiedebergs Arch Pharmacol 2015;388:295-304. [PMID: 25418891 DOI: 10.1007/s00210-014-1071-4] [Cited by in Crossref: 36] [Cited by in F6Publishing: 34] [Article Influence: 4.5] [Reference Citation Analysis]
321 Lo JH, Hao L, Muzumdar MD, Raghavan S, Kwon EJ, Pulver EM, Hsu F, Aguirre AJ, Wolpin BM, Fuchs CS, Hahn WC, Jacks T, Bhatia SN. iRGD-guided Tumor-penetrating Nanocomplexes for Therapeutic siRNA Delivery to Pancreatic Cancer. Mol Cancer Ther 2018;17:2377-88. [PMID: 30097486 DOI: 10.1158/1535-7163.MCT-17-1090] [Cited by in Crossref: 27] [Cited by in F6Publishing: 17] [Article Influence: 6.8] [Reference Citation Analysis]
322 An JW, Choi EK, Park CH, Choi JB, Ko DK, Lee YW. Alternative Method of Retrocrural Approach during Celiac Plexus Block Using a Bent Tip Needle. Korean J Pain 2015;28:109-15. [PMID: 25852832 DOI: 10.3344/kjp.2015.28.2.109] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
323 Ansari D, Aronsson L, Fredriksson J, Andersson B, Andersson R. Safety of pancreatic resection in the elderly: a retrospective analysis of 556 patients. Ann Gastroenterol. 2016;29:221-225. [PMID: 27065736 DOI: 10.20524/aog.2016.0016] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
324 Nie F, Yu M, Zhang K, Yang L, Zhang Q, Liu S, Liu M, Shang M, Zeng F, Liu W. Association of MTHFR gene polymorphisms with pancreatic cancer: meta-analysis of 17 case-control studies. Int J Clin Oncol 2020;25:312-21. [PMID: 31701291 DOI: 10.1007/s10147-019-01571-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
325 Kang CM, Babicky ML, Lowy AM. The RON receptor tyrosine kinase in pancreatic cancer pathogenesis and its potential implications for future targeted therapies. Pancreas. 2014;43:183-189. [PMID: 24518495 DOI: 10.1097/mpa.0000000000000088] [Cited by in Crossref: 19] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
326 Cabrera MC, Tilahun E, Nakles R, Diaz-Cruz ES, Charabaty A, Suy S, Jackson P, Ley L, Slack R, Jha R. Human Pancreatic Cancer-Associated Stellate Cells Remain Activated after in vivo Chemoradiation. Front Oncol. 2014;4:102. [PMID: 24847445 DOI: 10.3389/fonc.2014.00102] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
327 McCarroll JA, Sharbeen G, Liu J, Youkhana J, Goldstein D, McCarthy N, Limbri LF, Dischl D, Ceyhan GO, Erkan M, Johns AL, Biankin AV, Kavallaris M, Phillips PA. βIII-tubulin: a novel mediator of chemoresistance and metastases in pancreatic cancer. Oncotarget 2015;6:2235-49. [PMID: 25544769 DOI: 10.18632/oncotarget.2946] [Cited by in Crossref: 44] [Cited by in F6Publishing: 41] [Article Influence: 7.3] [Reference Citation Analysis]
328 Gostimir M, Bennett S, Moyana T, Sekhon H, Martel G. Complete pathological response following neoadjuvant FOLFIRINOX in borderline resectable pancreatic cancer - a case report and review. BMC Cancer 2016;16:786. [PMID: 27724927 DOI: 10.1186/s12885-016-2821-0] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
329 Zhong Y, Naito Y, Cope L, Naranjo-Suarez S, Saunders T, Hong SM, Goggins MG, Herman JM, Wolfgang CL, Iacobuzio-Donahue CA. Functional p38 MAPK identified by biomarker profiling of pancreatic cancer restrains growth through JNK inhibition and correlates with improved survival. Clin Cancer Res. 2014;20:6200-6211. [PMID: 24963048 DOI: 10.1158/1078-0432.ccr-13-2823] [Cited by in Crossref: 26] [Cited by in F6Publishing: 16] [Article Influence: 3.3] [Reference Citation Analysis]
330 Wang T, Zhuang Z, Zhang P, Wang Y, Mu L, Jin H, Zhou L, Ma X, Liang R, Yuan Y. Effect of arenobufagin on human pancreatic carcinoma cells. Oncol Lett 2017;14:4971-6. [PMID: 29085509 DOI: 10.3892/ol.2017.6798] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
331 Joost S, Almada LL, Rohnalter V, Holz PS, Vrabel AM, Fernandez-Barrena MG, McWilliams RR, Krause M, Fernandez-Zapico ME, Lauth M. GLI1 inhibition promotes epithelial-to-mesenchymal transition in pancreatic cancer cells. Cancer Res 2012;72:88-99. [PMID: 22086851 DOI: 10.1158/0008-5472.CAN-10-4621] [Cited by in Crossref: 40] [Cited by in F6Publishing: 27] [Article Influence: 3.6] [Reference Citation Analysis]
332 Rovithi M, Avan A, Funel N, Leon LG, Gomez VE, Wurdinger T, Griffioen AW, Verheul HM, Giovannetti E. Development of bioluminescent chick chorioallantoic membrane (CAM) models for primary pancreatic cancer cells: a platform for drug testing. Sci Rep 2017;7:44686. [PMID: 28304379 DOI: 10.1038/srep44686] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 4.6] [Reference Citation Analysis]
333 Sudha T, Yalcin M, Lin HY, Elmetwally AM, Nazeer T, Arumugam T, Phillips P, Mousa SA. Suppression of pancreatic cancer by sulfated non-anticoagulant low molecular weight heparin. Cancer Lett 2014;350:25-33. [PMID: 24769074 DOI: 10.1016/j.canlet.2014.04.016] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
334 Mimeault M, Batra SK. Emergence of zebrafish models in oncology for validating novel anticancer drug targets and nanomaterials. Drug Discov Today 2013;18:128-40. [PMID: 22903142 DOI: 10.1016/j.drudis.2012.08.002] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
335 Zhao X, Chen M, Tan J. Knockdown of ZFR suppresses cell proliferation and invasion of human pancreatic cancer. Biol Res 2016;49:26. [PMID: 27177590 DOI: 10.1186/s40659-016-0086-3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
336 Manning AA, Zhao L, Zhu Z, Xiao H, Redington CG, Ding VA, Stewart-Hester T, Bai Q, Dunlap J, Wakefield MR, Fang Y. IL-39 acts as a friend to pancreatic cancer. Med Oncol 2018;36:12. [PMID: 30506430 DOI: 10.1007/s12032-018-1236-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
337 Kumar A, Dagar M, Herman J, Iacobuzio-Donahue C, Laheru D. CNS involvement in pancreatic adenocarcinoma: a report of eight cases from the Johns Hopkins Hospital and review of literature. J Gastrointest Cancer. 2015;46:5-8. [PMID: 25451139 DOI: 10.1007/s12029-014-9667-y] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
338 Quan M, Wang P, Cui J, Gao Y, Xie K. The roles of FOXM1 in pancreatic stem cells and carcinogenesis. Mol Cancer 2013;12:159. [PMID: 24325450 DOI: 10.1186/1476-4598-12-159] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 3.3] [Reference Citation Analysis]
339 Muniz VP, Askeland RW, Zhang X, Reed SM, Tompkins VS, Hagen J, McDowell BD, Button A, Smith BJ, Weydert JA, Mezhir JJ, Quelle DE. RABL6A Promotes Oxaliplatin Resistance in Tumor Cells and Is a New Marker of Survival for Resected Pancreatic Ductal Adenocarcinoma Patients. Genes Cancer 2013;4:273-84. [PMID: 24167655 DOI: 10.1177/1947601913501074] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
340 Shields MA, Dangi-Garimella S, Redig AJ, Munshi HG. Biochemical role of the collagen-rich tumour microenvironment in pancreatic cancer progression. Biochem J. 2012;441:541-552. [PMID: 22187935 DOI: 10.1042/bj20111240] [Cited by in Crossref: 128] [Cited by in F6Publishing: 89] [Article Influence: 12.8] [Reference Citation Analysis]
341 Jia Y, Li HY, Wang J, Wang Y, Zhang P, Ma N, Mo SJ. Phosphorylation of 14-3-3ζ links YAP transcriptional activation to hypoxic glycolysis for tumorigenesis. Oncogenesis 2019;8:31. [PMID: 31076568 DOI: 10.1038/s41389-019-0143-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
342 Ward ST, Dangi-Garimella S, Shields MA, Collander BA, Siddiqui MA, Krantz SB, Munshi HG. Ethanol differentially regulates snail family of transcription factors and invasion of premalignant and malignant pancreatic ductal cells. J Cell Biochem 2011;112:2966-73. [PMID: 21678462 DOI: 10.1002/jcb.23215] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
343 Tian J, Liu Y, Zhu B, Tian Y, Zhong R, Chen W, Lu X, Zou L, Shen N, Qian J, Li H, Miao X, Wang L. SF3A1 and pancreatic cancer: new evidence for the association of the spliceosome and cancer. Oncotarget 2015;6:37750-7. [PMID: 26498691 DOI: 10.18632/oncotarget.5647] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
344 Huang X, Gao Y, Zhi X, Ta N, Jiang H, Zheng J. Association between vitamin A, retinol and carotenoid intake and pancreatic cancer risk: Evidence from epidemiologic studies. Sci Rep. 2016;6:38936. [PMID: 27941847 DOI: 10.1038/srep38936] [Cited by in Crossref: 30] [Cited by in F6Publishing: 22] [Article Influence: 5.0] [Reference Citation Analysis]
345 Brunetti O, Russo A, Scarpa A, Santini D, Reni M, Bittoni A, Azzariti A, Aprile G, Delcuratolo S, Signorile M, Gnoni A, Palermo L, Lorusso V, Cascinu S, Silvestris N. MicroRNA in pancreatic adenocarcinoma: predictive/prognostic biomarkers or therapeutic targets? Oncotarget 2015;6:23323-41. [PMID: 26259238 DOI: 10.18632/oncotarget.4492] [Cited by in Crossref: 43] [Cited by in F6Publishing: 48] [Article Influence: 7.2] [Reference Citation Analysis]
346 Han ML, Lv ZW. Serum and bile NGAL for clinically distinguishing malignant biliary strictures from benign biliary strictures. Shijie Huaren Xiaohua Zazhi 2014; 22(1): 133-139 [DOI: 10.11569/wcjd.v22.i1.133] [Reference Citation Analysis]
347 Wu C, Yang P, Liu B, Tang Y. Is there a CDKN2A-centric network in pancreatic ductal adenocarcinoma? Onco Targets Ther 2020;13:2551-62. [PMID: 32273725 DOI: 10.2147/OTT.S232464] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
348 Duong HQ, Yi YW, Kang HJ, Bae I, Jang YJ, Kwak SJ, Seong YS. Combination of dasatinib and gemcitabine reduces the ALDH1A1 expression and the proliferation of gemcitabine-resistant pancreatic cancer MIA PaCa-2 cells. Int J Oncol 2014;44:2132-8. [PMID: 24676703 DOI: 10.3892/ijo.2014.2357] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 1.9] [Reference Citation Analysis]
349 Guerra C, Collado M, Navas C, Schuhmacher AJ, Hernández-Porras I, Cañamero M, Rodriguez-Justo M, Serrano M, Barbacid M. Pancreatitis-induced inflammation contributes to pancreatic cancer by inhibiting oncogene-induced senescence. Cancer Cell 2011;19:728-39. [PMID: 21665147 DOI: 10.1016/j.ccr.2011.05.011] [Cited by in Crossref: 316] [Cited by in F6Publishing: 292] [Article Influence: 28.7] [Reference Citation Analysis]
350 Lee ES, Lee JM. Imaging diagnosis of pancreatic cancer: a state-of-the-art review. World J Gastroenterol. 2014;20:7864-7877. [PMID: 24976723 DOI: 10.3748/wjg.v20.i247864] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
351 Li YJ, Huang GL, Sun XL, Zhao XC, Li ZG. The combination therapy of high-intensity focused ultrasound with radiotherapy in locally advanced pancreatic carcinoma. World J Surg Oncol 2016;14:60. [PMID: 26927794 DOI: 10.1186/s12957-016-0809-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
352 Hong YB, Kim JS, Yi YW, Seong YS, Bae I. Exploring protein kinase inhibitors: potentiating gemcitabine efficacy in pancreatic cancer. Pancreas 2012;41:496-8. [PMID: 22415672 DOI: 10.1097/MPA.0b013e318230f71a] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
353 Knab LM, Grippo PJ, Bentrem DJ. Involvement of eicosanoids in the pathogenesis of pancreatic cancer: The roles of cyclooxygenase-2 and 5-lipoxygenase. World J Gastroenterol 2014; 20(31): 10729-10739 [PMID: 25152576 DOI: 10.3748/wjg.v20.i31.10729] [Cited by in CrossRef: 38] [Cited by in F6Publishing: 34] [Article Influence: 4.8] [Reference Citation Analysis]
354 García-Costela M, Escudero-Feliú J, Puentes-Pardo JD, San Juán SM, Morales-Santana S, Ríos-Arrabal S, Carazo Á, León J. Circadian Genes as Therapeutic Targets in Pancreatic Cancer. Front Endocrinol (Lausanne) 2020;11:638. [PMID: 33042011 DOI: 10.3389/fendo.2020.00638] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
355 Yang W, Liu H, Duan B, Xu X, Carmody D, Luo S, Walsh KM, Abbruzzese JL, Zhang X, Chen X, Wei Q. Three novel genetic variants in NRF2 signaling pathway genes are associated with pancreatic cancer risk. Cancer Sci 2019;110:2022-32. [PMID: 30972876 DOI: 10.1111/cas.14017] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
356 Broekgaarden M, Bulin AL, Frederick J, Mai Z, Hasan T. Tracking Photodynamic- and Chemotherapy-Induced Redox-State Perturbations in 3D Culture Models of Pancreatic Cancer: A Tool for Identifying Therapy-Induced Metabolic Changes. J Clin Med 2019;8:E1399. [PMID: 31500115 DOI: 10.3390/jcm8091399] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
357 Papa AL, Basu S, Sengupta P, Banerjee D, Sengupta S, Harfouche R. Mechanistic studies of Gemcitabine-loaded nanoplatforms in resistant pancreatic cancer cells. BMC Cancer 2012;12:419. [PMID: 22998550 DOI: 10.1186/1471-2407-12-419] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 2.5] [Reference Citation Analysis]
358 Khokhlova TD, Haider Y, Hwang JH. Therapeutic potential of ultrasound microbubbles in gastrointestinal oncology: recent advances and future prospects. Therap Adv Gastroenterol 2015;8:384-94. [PMID: 26557894 DOI: 10.1177/1756283X15592584] [Cited by in Crossref: 18] [Cited by in F6Publishing: 11] [Article Influence: 2.6] [Reference Citation Analysis]
359 Xu YP, Yang M. Advancement in treatment and diagnosis of pancreatic cancer with radiopharmaceuticals. World J Gastrointest Oncol 2016; 8(2): 165-172 [PMID: 26909131 DOI: 10.4251/wjgo.v8.i2.165] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
360 Peng J, Valeshabad AK, Li Q, Wang Y. Differential expression of RBM5 and KRAS in pancreatic ductal adenocarcinoma and their association with clinicopathological features. Oncol Lett 2013;5:1000-4. [PMID: 23425895 DOI: 10.3892/ol.2012.1080] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
361 Yoo IK, Lee HS, Kim CD, Chun HJ, Jeen YT, Keum B, Kim ES, Choi HS, Lee JM, Kim SH, Nam SJ, Hyun JJ. Rare case of pancreatic cancer with leptomeningeal carcinomatosis. World J Gastroenterol 2015; 21(3): 1020-1023 [PMID: 25624740 DOI: 10.3748/wjg.v21.i3.1020] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
362 Xie G, Lu L, Qiu Y, Ni Q, Zhang W, Gao YT, Risch HA, Yu H, Jia W. Plasma metabolite biomarkers for the detection of pancreatic cancer. J Proteome Res 2015;14:1195-202. [PMID: 25429707 DOI: 10.1021/pr501135f] [Cited by in Crossref: 49] [Cited by in F6Publishing: 42] [Article Influence: 6.1] [Reference Citation Analysis]
363 Li JL, Cai Y, Zhang SW, Xiao SW, Li XF, Duan YJ, Li YH, Xu B, Yan K. Combination of Recombinant Adenovirus-p53 with Radiochemotherapy in Unresectable Pancreatic Carcinoma. Chin J Cancer Res 2011;23:194-200. [PMID: 23467436 DOI: 10.1007/s11670-011-0194-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
364 Ernsting MJ, Hoang B, Lohse I, Undzys E, Cao P, Do T, Gill B, Pintilie M, Hedley D, Li SD. Targeting of metastasis-promoting tumor-associated fibroblasts and modulation of pancreatic tumor-associated stroma with a carboxymethylcellulose-docetaxel nanoparticle. J Control Release. 2015;206:122-130. [PMID: 25804872 DOI: 10.1016/j.jconrel.2015.03.023] [Cited by in Crossref: 67] [Cited by in F6Publishing: 69] [Article Influence: 9.6] [Reference Citation Analysis]
365 Brunson BA, Hawes R, Hoffman B, Vela S, Romagnuolo J. Poor 'real-life' negative predictive value of cross-sectional imaging in obstructive jaundice. Can J Gastroenterol Hepatol 2014;28:385-90. [PMID: 25157530 DOI: 10.1155/2014/797960] [Reference Citation Analysis]
366 Giordano G, Pancione M, Olivieri N, Parcesepe P, Velocci M, Di Raimo T, Coppola L, Toffoli G, D’Andrea MR. Nano albumin bound-paclitaxel in pancreatic cancer: Current evidences and future directions. World J Gastroenterol 2017; 23(32): 5875-5886 [PMID: 28932079 DOI: 10.3748/wjg.v23.i32.5875] [Cited by in CrossRef: 41] [Cited by in F6Publishing: 35] [Article Influence: 8.2] [Reference Citation Analysis]
367 Sharon E, Zhang J, Hollevoet K, Steinberg SM, Pastan I, Onda M, Gaedcke J, Ghadimi BM, Ried T, Hassan R. Serum mesothelin and megakaryocyte potentiating factor in pancreatic and biliary cancers. Clin Chem Lab Med. 2012;50:721-725. [PMID: 22149739 DOI: 10.1515/cclm.2011.816] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
368 Luo G, Jin K, Guo M, Cheng H, Liu Z, Xiao Z, Lu Y, Long J, Liu L, Xu J, Liu C, Gao Y, Ni Q, Yu X. Patients with normal-range CA19-9 levels represent a distinct subgroup of pancreatic cancer patients. Oncol Lett 2017;13:881-6. [PMID: 28356973 DOI: 10.3892/ol.2016.5501] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
369 Shields MA, Ebine K, Sahai V, Kumar K, Siddiqui K, Hwang RF, Grippo PJ, Munshi HG. Snail cooperates with KrasG12D to promote pancreatic fibrosis. Mol Cancer Res 2013;11:1078-87. [PMID: 23761168 DOI: 10.1158/1541-7786.MCR-12-0637] [Cited by in Crossref: 35] [Cited by in F6Publishing: 28] [Article Influence: 3.9] [Reference Citation Analysis]
370 Chu M, Wang T, Sun A, Chen Y. Nimesulide inhibits proliferation and induces apoptosis of pancreatic cancer cells by enhancing expression of PTEN. Exp Ther Med 2018;16:370-6. [PMID: 29896263 DOI: 10.3892/etm.2018.6191] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
371 Song J, Lee J, Kim J, Jo S, Kim YJ, Baek JE, Kwon ES, Lee KP, Yang S, Kwon KS, Kim DU, Kang TH, Park YY, Chang S, Cho HJ, Kim SC, Koh SS, Kim S. Pancreatic adenocarcinoma up-regulated factor (PAUF) enhances the accumulation and functional activity of myeloid-derived suppressor cells (MDSCs) in pancreatic cancer. Oncotarget 2016;7:51840-53. [PMID: 27322081 DOI: 10.18632/oncotarget.10123] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 5.8] [Reference Citation Analysis]
372 Berger AK, Haag GM, Ehmann M, Byl A, Jäger D, Springfeld C. Palliative chemotherapy for pancreatic adenocarcinoma: a retrospective cohort analysis of efficacy and toxicity of the FOLFIRINOX regimen focusing on the older patient. BMC Gastroenterol 2017;17:143. [PMID: 29207968 DOI: 10.1186/s12876-017-0709-3] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
373 Venkatasubbarao K, Peterson L, Zhao S, Hill P, Cao L, Zhou Q, Nawrocki ST, Freeman JW. Inhibiting signal transducer and activator of transcription-3 increases response to gemcitabine and delays progression of pancreatic cancer. Mol Cancer 2013;12:104. [PMID: 24025152 DOI: 10.1186/1476-4598-12-104] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 3.2] [Reference Citation Analysis]
374 Giovannetti E, van der Velde A, Funel N, Vasile E, Perrone V, Leon LG, De Lio N, Avan A, Caponi S, Pollina LE. High-throughput microRNA (miRNAs) arrays unravel the prognostic role of MiR-211 in pancreatic cancer. PLoS One. 2012;7:e49145. [PMID: 23155457 DOI: 10.1371/journal.pone.0049145] [Cited by in Crossref: 51] [Cited by in F6Publishing: 48] [Article Influence: 5.1] [Reference Citation Analysis]
375 Osuna de la Peña D, Trabulo SMD, Collin E, Liu Y, Sharma S, Tatari M, Behrens D, Erkan M, Lawlor RT, Scarpa A, Heeschen C, Mata A, Loessner D. Bioengineered 3D models of human pancreatic cancer recapitulate in vivo tumour biology. Nat Commun 2021;12:5623. [PMID: 34561461 DOI: 10.1038/s41467-021-25921-9] [Reference Citation Analysis]
376 Hilmer AJ, Jeffrey RB, Park WG, Khosla C. Cholestyramine as a promising, strong anion exchange resin for direct capture of genetic biomarkers from raw pancreatic fluids. Biotechnol Bioeng 2017;114:934-8. [PMID: 27800600 DOI: 10.1002/bit.26207] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
377 Liu S, Gandler HI, Tošić I, Ye DQ, Giaccone ZT, Frank DA. Mutant KRAS Downregulates the Receptor for Leukemia Inhibitory Factor (LIF) to Enhance a Signature of Glycolysis in Pancreatic Cancer and Lung Cancer. Mol Cancer Res 2021;19:1283-95. [PMID: 33931487 DOI: 10.1158/1541-7786.MCR-20-0633] [Reference Citation Analysis]
378 Smith JP, Whitcomb DC, Matters GL, Brand RE, Liao J, Huang YJ, Frazier ML. Distribution of cholecystokinin-B receptor genotype between patients with pancreatic cancer and controls and its impact on survival. Pancreas 2015;44:236-42. [PMID: 25469546 DOI: 10.1097/MPA.0000000000000263] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
379 Khalid M, Idichi T, Seki N, Wada M, Yamada Y, Fukuhisa H, Toda H, Kita Y, Kawasaki Y, Tanoue K, Kurahara H, Mataki Y, Maemura K, Natsugoe S. Gene Regulation by Antitumor miR-204-5p in Pancreatic Ductal Adenocarcinoma: The Clinical Significance of Direct RACGAP1 Regulation. Cancers (Basel) 2019;11:E327. [PMID: 30866526 DOI: 10.3390/cancers11030327] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
380 Polani F, Grierson PM, Lim KH. Stroma-targeting strategies in pancreatic cancer: Past lessons, challenges and prospects. World J Gastroenterol 2021; 27(18): 2105-2121 [PMID: 34025067 DOI: 10.3748/wjg.v27.i18.2105] [Reference Citation Analysis]
381 Sinkala M, Mulder N, Martin D. Machine Learning and Network Analyses Reveal Disease Subtypes of Pancreatic Cancer and their Molecular Characteristics. Sci Rep. 2020;10:1212. [PMID: 31988390 DOI: 10.1038/s41598-020-58290-2] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 9.0] [Reference Citation Analysis]
382 He C, Huang X, Zhang Y, Lin X, Li S. A Novel Prediction Tool Based on Large Cohorts to Determine the Cancer-Specific Survival Probability of Patients With Locally Advanced Pancreatic Cancer After Irreversible Electroporation Treatment. Front Oncol 2020;10:952. [PMID: 32695671 DOI: 10.3389/fonc.2020.00952] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
383 Abair T, Xu B, Ranganathan A, Quill T, Chu E, Cunningham D. The Annual Meeting of the American Society of Clinical Oncology. Clinical Colorectal Cancer 2010;9:195-204. [DOI: 10.3816/ccc.2010.n.029] [Reference Citation Analysis]
384 Lucero-Acuña A, Jeffery JJ, Abril ER, Nagle RB, Guzman R, Pagel MD, Meuillet EJ. Nanoparticle delivery of an AKT/PDK1 inhibitor improves the therapeutic effect in pancreatic cancer. Int J Nanomedicine 2014;9:5653-65. [PMID: 25516710 DOI: 10.2147/IJN.S68511] [Cited by in Crossref: 3] [Cited by in F6Publishing: 9] [Article Influence: 0.4] [Reference Citation Analysis]
385 Holub M, Bartáková E, Stráníková A, Koblihová E, Arientová S, Blahutová M, Máca J, Ryska M. Calprotectin and Calgranulin C as Biomarkers of Pancreatic Tumors: Baseline Levels and Level Changes after Surgery. Mediators Inflamm 2019;2019:6985703. [PMID: 31582902 DOI: 10.1155/2019/6985703] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
386 Koizumi M, Watanabe T, Masumoto J, Sunago K, Imamura Y, Kanemitsu K, Kumagi T, Hiasa Y. Apoptosis-associated speck-like protein containing a CARD regulates the growth of pancreatic ductal adenocarcinoma. Sci Rep 2021;11:22351. [PMID: 34785680 DOI: 10.1038/s41598-021-01465-2] [Reference Citation Analysis]
387 Lee JH, Kim SK, Khawar IA, Jeong SY, Chung S, Kuh HJ. Microfluidic co-culture of pancreatic tumor spheroids with stellate cells as a novel 3D model for investigation of stroma-mediated cell motility and drug resistance. J Exp Clin Cancer Res 2018;37:4. [PMID: 29329547 DOI: 10.1186/s13046-017-0654-6] [Cited by in Crossref: 67] [Cited by in F6Publishing: 66] [Article Influence: 16.8] [Reference Citation Analysis]
388 Parker LA, Porta M, Lumbreras B, López T, Guarner L, Hernández-Aguado I, Carrato A, Corominas JM, Rifà J, Fernandez E, Alguacil J, Malats N, Real FX. Clinical validity of detecting K-ras mutations for the diagnosis of exocrine pancreatic cancer: a prospective study in a clinically-relevant spectrum of patients. Eur J Epidemiol 2011;26:229-36. [PMID: 21298467 DOI: 10.1007/s10654-011-9547-8] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
389 García-Reyes B, Kretz AL, Ruff JP, von Karstedt S, Hillenbrand A, Knippschild U, Henne-Bruns D, Lemke J. The Emerging Role of Cyclin-Dependent Kinases (CDKs) in Pancreatic Ductal Adenocarcinoma. Int J Mol Sci 2018;19:E3219. [PMID: 30340359 DOI: 10.3390/ijms19103219] [Cited by in Crossref: 20] [Cited by in F6Publishing: 24] [Article Influence: 5.0] [Reference Citation Analysis]
390 Tang P, Tao L, Yuan C, Zhang L, Xiu D. Serum Derived Exosomes From Pancreatic Cancer Patients Promoted Metastasis: An iTRAQ-Based Proteomic Analysis. Onco Targets Ther 2019;12:9329-39. [PMID: 31807013 DOI: 10.2147/OTT.S229494] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
391 Li M, Li T, Ma W, Wang X, Zhao G. MicroRNA-608 promotes apoptosis via BRD4 downregulation in pancreatic ductal adenocarcinoma. Oncol Lett 2020;19:1418-26. [PMID: 32002032 DOI: 10.3892/ol.2019.11246] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
392 Roberts AS, Campa MJ, Gottlin EB, Jiang C, Owzar K, Kindler HL, Venook AP, Goldberg RM, O'Reilly EM, Patz EF Jr. Identification of potential prognostic biomarkers in patients with untreated, advanced pancreatic cancer from a phase 3 trial (Cancer and Leukemia Group B 80303). Cancer 2012;118:571-8. [PMID: 21713765 DOI: 10.1002/cncr.26270] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
393 Kim SY, Choi M, Hwang HK, Rho SY, Lee WJ, Kang CM. Intraoperative Transfusion is Independently Associated with a Worse Prognosis in Resected Pancreatic Cancer-a Retrospective Cohort Analysis. J Clin Med 2020;9:E689. [PMID: 32143434 DOI: 10.3390/jcm9030689] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
394 Liu L, Zhang N, Dou Y, Mao G, Bi C, Pang W, Liu X, Song D, Deng H. Lysosomal dysfunction and autophagy blockade contribute to IMB-6G-induced apoptosis in pancreatic cancer cells. Sci Rep 2017;7:41862. [PMID: 28139733 DOI: 10.1038/srep41862] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 5.0] [Reference Citation Analysis]
395 Rabelo-Gonçalves EM, Roesler BM, Zeitune JM. Extragastric manifestations of Helicobacter pylori infection: Possible role of bacterium in liver and pancreas diseases. World J Hepatol 2015; 7(30): 2968-2979 [PMID: 26730276 DOI: 10.4254/wjh.v7.i30.2968] [Cited by in Crossref: 30] [Cited by in F6Publishing: 24] [Article Influence: 4.3] [Reference Citation Analysis]
396 Xu X, Rao GS, Groh V, Spies T, Gattuso P, Kaufman HL, Plate J, Prinz RA. Major histocompatibility complex class I-related chain A/B (MICA/B) expression in tumor tissue and serum of pancreatic cancer: role of uric acid accumulation in gemcitabine-induced MICA/B expression. BMC Cancer 2011;11:194. [PMID: 21605422 DOI: 10.1186/1471-2407-11-194] [Cited by in Crossref: 48] [Cited by in F6Publishing: 45] [Article Influence: 4.4] [Reference Citation Analysis]
397 Mirus JE, Zhang Y, Li CI, Lokshin AE, Prentice RL, Hingorani SR, Lampe PD. Cross-species antibody microarray interrogation identifies a 3-protein panel of plasma biomarkers for early diagnosis of pancreas cancer. Clin Cancer Res. 2015;21:1764-1771. [PMID: 25589628 DOI: 10.1158/1078-0432.ccr-13-3474] [Cited by in Crossref: 34] [Cited by in F6Publishing: 19] [Article Influence: 4.9] [Reference Citation Analysis]
398 Murakami T, Hiroshima Y, Matsuyama R, Homma Y, Hoffman RM, Endo I. Role of the tumor microenvironment in pancreatic cancer. Ann Gastroenterol Surg 2019;3:130-7. [PMID: 30923782 DOI: 10.1002/ags3.12225] [Cited by in Crossref: 40] [Cited by in F6Publishing: 36] [Article Influence: 13.3] [Reference Citation Analysis]
399 Li M, Chen Q, Ma T, Yu X. Targeting reactive nitrogen species suppresses hereditary pancreatic cancer. Proc Natl Acad Sci U S A 2017;114:7106-11. [PMID: 28630313 DOI: 10.1073/pnas.1702156114] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
400 Kitano A, Shimasaki T, Chikano Y, Nakada M, Hirose M, Higashi T, Ishigaki Y, Endo Y, Takino T, Sato H, Sai Y, Miyamoto K, Motoo Y, Kawakami K, Minamoto T. Aberrant glycogen synthase kinase 3β is involved in pancreatic cancer cell invasion and resistance to therapy. PLoS One 2013;8:e55289. [PMID: 23408967 DOI: 10.1371/journal.pone.0055289] [Cited by in Crossref: 48] [Cited by in F6Publishing: 49] [Article Influence: 5.3] [Reference Citation Analysis]
401 Sun C, Rosendahl AH, Ansari D, Andersson R. Proteome-based biomarkers in pancreatic cancer. World J Gastroenterol 2011; 17(44): 4845-4852 [PMID: 22171124 DOI: 10.3748/wjg.v17.i44.4845] [Cited by in CrossRef: 26] [Cited by in F6Publishing: 25] [Article Influence: 2.4] [Reference Citation Analysis]
402 Kohan G, Ocampo CG, Zandalazini HI, Klappenbach R, Yazyi F, Ditulio O, Coturel A, Canullán C, Porras LT, Rodriguez JA. Laparoscopic hepaticojejunostomy and gastrojejunostomy for palliative treatment of pancreatic head cancer in 48 patients. Surg Endosc 2015;29:1970-5. [PMID: 25303913 DOI: 10.1007/s00464-014-3894-y] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
403 Liu Y, Zhu D, Xing H, Hou Y, Sun Y. A 6‑gene risk score system constructed for predicting the clinical prognosis of pancreatic adenocarcinoma patients. Oncol Rep 2019;41:1521-30. [PMID: 30747226 DOI: 10.3892/or.2019.6979] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
404 Tanaka T, Li TS, Urata Y, Goto S, Ono Y, Kawakatsu M, Matsushima H, Hirabaru M, Adachi T, Kitasato A, Takatsuki M, Kuroki T, Eguchi S. Increased expression of PHD3 represses the HIF-1 signaling pathway and contributes to poor neovascularization in pancreatic ductal adenocarcinoma. J Gastroenterol 2015;50:975-83. [PMID: 25542265 DOI: 10.1007/s00535-014-1030-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
405 Peng W, Gao W, Feng J. Long noncoding RNA HULC is a novel biomarker of poor prognosis in patients with pancreatic cancer. Med Oncol. 2014;31:346. [PMID: 25412939 DOI: 10.1007/s12032-014-0346-4] [Cited by in Crossref: 107] [Cited by in F6Publishing: 105] [Article Influence: 13.4] [Reference Citation Analysis]
406 Nakamura A, Itasaka S, Takaori K, Kawaguchi Y, Shibuya K, Yoshimura M, Matsuo Y, Mizowaki T, Uemoto S, Hiraoka M. Radiotherapy for patients with isolated local recurrence of primary resected pancreatic cancer. Prolonged disease-free interval associated with favorable prognosis. Strahlenther Onkol 2014;190:485-90. [PMID: 24599344 DOI: 10.1007/s00066-014-0610-8] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 3.1] [Reference Citation Analysis]
407 Yu X, Zhang Q, Gao F, Zhang M, Zheng Q, He Y, Guo W. Predictive value of m5C regulatory gene expression in pancreatic adenocarcinoma. Sci Rep 2021;11:17529. [PMID: 34471186 DOI: 10.1038/s41598-021-96470-w] [Reference Citation Analysis]
408 Zhang X, Xu J, Yan R, Zhang Y, Hu Z, Fu H, You Q, Cai Q, Yang D. FAM84B, amplified in pancreatic ductal adenocarcinoma, promotes tumorigenesis through the Wnt/β-catenin pathway. Aging (Albany NY) 2020;12:6808-22. [PMID: 32291380 DOI: 10.18632/aging.103044] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
409 Ying H, Dey P, Yao W, Kimmelman AC, Draetta GF, Maitra A, DePinho RA. Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev. 2016;30:355-385. [PMID: 26883357 DOI: 10.1101/gad.275776.115] [Cited by in Crossref: 241] [Cited by in F6Publishing: 226] [Article Influence: 40.2] [Reference Citation Analysis]
410 Ma WW, Xie H, Fetterly G, Pitzonka L, Whitworth A, LeVea C, Wilton J, Mantione K, Schihl S, Dy GK, Boland P, Iyer R, Tan W, Brady W, Straubinger RM, Adjei AA. A Phase Ib Study of the FGFR/VEGFR Inhibitor Dovitinib With Gemcitabine and Capecitabine in Advanced Solid Tumor and Pancreatic Cancer Patients. Am J Clin Oncol 2019;42:184-9. [PMID: 30418178 DOI: 10.1097/COC.0000000000000492] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
411 Goldsmith C, Plowman PN, Green MM, Dale RG, Price PM. Stereotactic ablative radiotherapy (SABR) as primary, adjuvant, consolidation and re-treatment option in pancreatic cancer: scope for dose escalation and lessons for toxicity. Radiat Oncol. 2018;13:204. [PMID: 30340643 DOI: 10.1186/s13014-018-1138-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
412 Chikhladze S, Lederer AK, Kousoulas L, Reinmuth M, Sick O, Fichtner-Feigl S, Wittel UA. Adjuvant chemotherapy after surgery for pancreatic ductal adenocarcinoma: retrospective real-life data. World J Surg Oncol 2019;17:185. [PMID: 31706323 DOI: 10.1186/s12957-019-1732-3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
413 Liao X, Huang K, Huang R, Liu X, Han C, Yu L, Yu T, Yang C, Wang X, Peng T. Genome-scale analysis to identify prognostic markers in patients with early-stage pancreatic ductal adenocarcinoma after pancreaticoduodenectomy. Onco Targets Ther 2017;10:4493-506. [PMID: 28979141 DOI: 10.2147/OTT.S142557] [Cited by in Crossref: 24] [Cited by in F6Publishing: 40] [Article Influence: 4.8] [Reference Citation Analysis]
414 Papademetrio DL, Lompardía SL, Simunovich T, Costantino S, Mihalez CY, Cavaliere V, Álvarez É. Inhibition of Survival Pathways MAPK and NF-kB Triggers Apoptosis in Pancreatic Ductal Adenocarcinoma Cells via Suppression of Autophagy. Target Oncol 2016;11:183-95. [PMID: 26373299 DOI: 10.1007/s11523-015-0388-3] [Cited by in Crossref: 37] [Cited by in F6Publishing: 39] [Article Influence: 7.4] [Reference Citation Analysis]
415 Morganti AG, Cellini F, Buwenge M, Arcelli A, Alfieri S, Calvo FA, Casadei R, Cilla S, Deodato F, Di Gioia G, Di Marco M, Fuccio L, Bertini F, Guido A, Herman JM, Macchia G, Maidment BW 3rd, Miller RC, Minni F, Passoni P, Valentini C, Re A, Regine WF, Reni M, Falconi M, Valentini V, Mattiucci GC. Adjuvant chemoradiation in pancreatic cancer: impact of radiotherapy dose on survival. BMC Cancer 2019;19:569. [PMID: 31185957 DOI: 10.1186/s12885-019-5790-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
416 Krantz SB, Shields MA, Dangi-Garimella S, Cheon EC, Barron MR, Hwang RF, Rao MS, Grippo PJ, Bentrem DJ, Munshi HG. MT1-MMP cooperates with Kras(G12D) to promote pancreatic fibrosis through increased TGF-β signaling. Mol Cancer Res. 2011;9:1294-1304. [PMID: 21856775 DOI: 10.1158/1541-7786.mcr-11-0023] [Cited by in Crossref: 46] [Cited by in F6Publishing: 30] [Article Influence: 4.2] [Reference Citation Analysis]
417 Lennon AM, Klein AP, Goggins M. ABO blood group and other genetic variants associated with pancreatic cancer. Genome Med 2010;2:39. [PMID: 20587082 DOI: 10.1186/gm160] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
418 Huang S, Li Y, Hu J, Li L, Liu Z, Guo H, Jiang B, Chen J, Li J, Xiang X, Deng J, Xiong J. LncRNA PWAR6 regulates proliferation and migration by epigenetically silencing YAP1 in tumorigenesis of pancreatic ductal adenocarcinoma. J Cell Mol Med 2021;25:4275-86. [PMID: 33834618 DOI: 10.1111/jcmm.16480] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
419 Yang J, Xu Y, Huo Y, Cai L, Hua R, Zhang J, Chen Z. ERO1L Promotes Hepatic Metastasis through Activating Epithelial-Mesenchymal Transition (EMT) in Pancreatic Cancer. J Immunol Res 2021;2021:5553425. [PMID: 33681386 DOI: 10.1155/2021/5553425] [Reference Citation Analysis]
420 Zheng S, Wang X, Weng YH, Jin X, Ji JL, Guo L, Hu B, Liu N, Cheng Q, Zhang J, Bai H, Yang T, Xia XH, Zhang HY, Gao S, Huang Y. siRNA Knockdown of RRM2 Effectively Suppressed Pancreatic Tumor Growth Alone or Synergistically with Doxorubicin. Mol Ther Nucleic Acids 2018;12:805-16. [PMID: 30153565 DOI: 10.1016/j.omtn.2018.08.003] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 6.3] [Reference Citation Analysis]
421 Hiroshima Y, Zhang Y, Murakami T, Maawy A, Miwa S, Yamamoto M, Yano S, Sato S, Momiyama M, Mori R, Matsuyama R, Chishima T, Tanaka K, Ichikawa Y, Bouvet M, Endo I, Zhao M, Hoffman RM. Efficacy of tumor-targeting Salmonella typhimurium A1-R in combination with anti-angiogenesis therapy on a pancreatic cancer patient-derived orthotopic xenograft (PDOX) and cell line mouse models. Oncotarget 2014;5:12346-57. [PMID: 25402324 DOI: 10.18632/oncotarget.2641] [Cited by in Crossref: 108] [Cited by in F6Publishing: 107] [Article Influence: 15.4] [Reference Citation Analysis]
422 Shimizu A, Hirono S, Tani M, Kawai M, Okada K, Miyazawa M, Kitahata Y, Nakamura Y, Noda T, Yokoyama S. Coexpression of MUC16 and mesothelin is related to the invasion process in pancreatic ductal adenocarcinoma. Cancer Sci. 2012;103:739-746. [PMID: 22320398 DOI: 10.1111/j.1349-7006.2012.02214.x] [Cited by in Crossref: 60] [Cited by in F6Publishing: 58] [Article Influence: 6.0] [Reference Citation Analysis]
423 Zhao L, Liu B. Identification of potential prognostic ceRNA module biomarkers in patients with pancreatic adenocarcinoma. Oncotarget 2017;8:94493-504. [PMID: 29212244 DOI: 10.18632/oncotarget.21783] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
424 Jung J, Yoon SM, Park JH, Seo DW, Lee SS, Kim MH, Lee SK, Park DH, Song TJ, Ryoo BY, Chang HM, Kim KP, Yoo C, Jeong JH, Kim SC, Hwang DW, Lee JH, Song KB, Jo YY, Park J, Kim JH. Stereotactic body radiation therapy for locally advanced pancreatic cancer. PLoS One. 2019;14:e0214970. [PMID: 30978229 DOI: 10.1371/journal.pone.0214970] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
425 Takahashi K, Ota Y, Kogure T, Suzuki Y, Iwamoto H, Yamakita K, Kitano Y, Fujii S, Haneda M, Patel T, Ota T. Circulating extracellular vesicle-encapsulated HULC is a potential biomarker for human pancreatic cancer. Cancer Sci 2020;111:98-111. [PMID: 31715081 DOI: 10.1111/cas.14232] [Cited by in Crossref: 28] [Cited by in F6Publishing: 31] [Article Influence: 9.3] [Reference Citation Analysis]
426 Toledo LI, Murga M, Fernandez-Capetillo O. Targeting ATR and Chk1 kinases for cancer treatment: a new model for new (and old) drugs. Mol Oncol. 2011;5:368-373. [PMID: 21820372 DOI: 10.1016/j.molonc.2011.07.002] [Cited by in Crossref: 132] [Cited by in F6Publishing: 124] [Article Influence: 12.0] [Reference Citation Analysis]
427 Awaji M, Singh RK. Cancer-Associated Fibroblasts' Functional Heterogeneity in Pancreatic Ductal Adenocarcinoma. Cancers (Basel) 2019;11:E290. [PMID: 30832219 DOI: 10.3390/cancers11030290] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 6.0] [Reference Citation Analysis]
428 Sharbeen G, McCarroll J, Goldstein D, Phillips PA. Exploiting base excision repair to improve therapeutic approaches for pancreatic cancer. Front Nutr. 2015;2:10. [PMID: 25988138 DOI: 10.3389/fnut.2015.00010] [Cited by in Crossref: 8] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
429 Li K, Yang J, Chen J, Shi Y, Zhang Z, Chen W. High mobility group AT-hook 2 and c-MYC as potential prognostic factors in pancreatic ductal adenocarcinoma. Oncol Lett 2020;19:1584-92. [PMID: 31966084 DOI: 10.3892/ol.2019.11205] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
430 Liu Y, Shao L, Chen K, Wang Z, Wang J, Jing W, Hu M. GDF11 restrains tumor growth by promoting apoptosis in pancreatic cancer. Onco Targets Ther 2018;11:8371-9. [PMID: 30568460 DOI: 10.2147/OTT.S181792] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
431 Geng R, Li Z, Li S, Gao J. Proteomics in pancreatic cancer research. Int J Proteomics 2011;2011:365350. [PMID: 22084685 DOI: 10.1155/2011/365350] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
432 Li J, Ma Q, Liu H, Guo K, Li F, Li W, Han L, Wang F, Wu E. Relationship between neural alteration and perineural invasion in pancreatic cancer patients with hyperglycemia. PLoS One. 2011;6:e17385. [PMID: 21386984 DOI: 10.1371/journal.pone.0017385] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 2.6] [Reference Citation Analysis]
433 Mousa DS, El-Far AH, Saddiq AA, Sudha T, Mousa SA. Nanoformulated Bioactive Compounds Derived from Different Natural Products Combat Pancreatic Cancer Cell Proliferation. Int J Nanomedicine 2020;15:2259-68. [PMID: 32280218 DOI: 10.2147/IJN.S238256] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 4.5] [Reference Citation Analysis]
434 Wilson JM, Fokas E, Dutton SJ, Patel N, Hawkins MA, Eccles C, Chu KY, Durrant L, Abraham AG, Partridge M, Woodward M, O'Neill E, Maughan T, McKenna WG, Mukherjee S, Brunner TB. ARCII: A phase II trial of the HIV protease inhibitor Nelfinavir in combination with chemoradiation for locally advanced inoperable pancreatic cancer. Radiother Oncol 2016;119:306-11. [PMID: 27117177 DOI: 10.1016/j.radonc.2016.03.021] [Cited by in Crossref: 37] [Cited by in F6Publishing: 34] [Article Influence: 6.2] [Reference Citation Analysis]
435 Bauer I, Grozio A, Lasigliè D, Basile G, Sturla L, Magnone M, Sociali G, Soncini D, Caffa I, Poggi A, Zoppoli G, Cea M, Feldmann G, Mostoslavsky R, Ballestrero A, Patrone F, Bruzzone S, Nencioni A. The NAD+-dependent histone deacetylase SIRT6 promotes cytokine production and migration in pancreatic cancer cells by regulating Ca2+ responses. J Biol Chem 2012;287:40924-37. [PMID: 23086953 DOI: 10.1074/jbc.M112.405837] [Cited by in Crossref: 107] [Cited by in F6Publishing: 60] [Article Influence: 10.7] [Reference Citation Analysis]
436 Byrne JD, Jajja MR, O'Neill AT, Bickford LR, Keeler AW, Hyder N, Wagner K, Deal A, Little RE, Moffitt RA, Stack C, Nelson M, Brooks CR, Lee W, Luft JC, Napier ME, Darr D, Anders CK, Stack R, Tepper JE, Wang AZ, Zamboni WC, Yeh JJ, DeSimone JM. Local iontophoretic administration of cytotoxic therapies to solid tumors. Sci Transl Med 2015;7:273ra14. [PMID: 25653220 DOI: 10.1126/scitranslmed.3009951] [Cited by in Crossref: 41] [Cited by in F6Publishing: 31] [Article Influence: 5.9] [Reference Citation Analysis]
437 Duan Y, Yin X, Lai X, Liu C, Nie W, Li D, Xie Z, Li Z, Meng F. Upregulation of DAB2IP Inhibits Ras Activity and Tumorigenesis in Human Pancreatic Cancer Cells. Technol Cancer Res Treat 2020;19:1533033819895494. [PMID: 32336215 DOI: 10.1177/1533033819895494] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
438 Hori S, Shimada K, Ino Y, Oguro S, Esaki M, Nara S, Kishi Y, Kosuge T, Hattori Y, Sukeda A, Kitagawa Y, Kanai Y, Hiraoka N. Macroscopic features predict outcome in patients with pancreatic ductal adenocarcinoma. Virchows Arch 2016;469:621-34. [PMID: 27709361 DOI: 10.1007/s00428-016-2026-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
439 Zhang L, Tao L, Guo L, Zhan J, Yuan C, Ma Z, Jiang B, Xiu D. G-CSF associates with neurogenesis and predicts prognosis and sensitivity to chemotherapy in pancreatic ductal adenocarcinoma. Cancer Manag Res 2018;10:2767-75. [PMID: 30147373 DOI: 10.2147/CMAR.S165226] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
440 Shannon HE, Fishel ML, Xie J, Gu D, McCarthy BP, Riley AA, Sinn AL, Silver JM, Peterman K, Kelley MR, Hanenberg H, Korc M, Pollok KE, Territo PR. Longitudinal Bioluminescence Imaging of Primary Versus Abdominal Metastatic Tumor Growth in Orthotopic Pancreatic Tumor Models in NSG Mice. Pancreas 2015;44:64-75. [PMID: 25406955 DOI: 10.1097/MPA.0000000000000238] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
441 Zhu G, Song J, Chen W, Yuan D, Wang W, Chen X, Liu H, Su H, Zhu J. Expression and Role of Dickkopf-1 (Dkk1) in Tumors: From the Cells to the Patients. Cancer Manag Res 2021;13:659-75. [PMID: 33536782 DOI: 10.2147/CMAR.S275172] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
442 Jamieson NB, Chan NI, Foulis AK, Dickson EJ, McKay CJ, Carter CR. The prognostic influence of resection margin clearance following pancreaticoduodenectomy for pancreatic ductal adenocarcinoma. J Gastrointest Surg. 2013;17:511-521. [PMID: 23297028 DOI: 10.1007/s11605-012-2131-z] [Cited by in Crossref: 57] [Cited by in F6Publishing: 47] [Article Influence: 6.3] [Reference Citation Analysis]
443 Fujiwara M, Kanayama K, Hirokawa YS, Shiraishi T. ASF-4-1 fibroblast-rich culture increases chemoresistance and mTOR expression of pancreatic cancer BxPC-3 cells at the invasive front in vitro, and promotes tumor growth and invasion in vivo. Oncol Lett 2016;11:2773-9. [PMID: 27073551 DOI: 10.3892/ol.2016.4289] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
444 Reichert M, Bakir B, Moreira L, Pitarresi JR, Feldmann K, Simon L, Suzuki K, Maddipati R, Rhim AD, Schlitter AM, Kriegsmann M, Weichert W, Wirth M, Schuck K, Schneider G, Saur D, Reynolds AB, Klein-Szanto AJ, Pehlivanoglu B, Memis B, Adsay NV, Rustgi AK. Regulation of Epithelial Plasticity Determines Metastatic Organotropism in Pancreatic Cancer. Dev Cell 2018;45:696-711.e8. [PMID: 29920275 DOI: 10.1016/j.devcel.2018.05.025] [Cited by in Crossref: 61] [Cited by in F6Publishing: 61] [Article Influence: 15.3] [Reference Citation Analysis]
445 Kosmidis C, Sapalidis K, Kotidis E, Mixalopoulos N, Zarogoulidis P, Tsavlis D, Baka S, Man YG, Kanellos J. Pancreatic cancer from bench to bedside: molecular pathways and treatment options. Ann Transl Med 2016;4:165. [PMID: 27275478 DOI: 10.21037/atm.2016.05.11] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
446 Zhang L, Lv Y, Rong Y, Chen W, Fang Y, Mao W, Lou W, Jin D, Xu X. Downregulated expression of RACK1 results in pancreatic cancer growth and metastasis. Onco Targets Ther 2019;12:1007-20. [PMID: 30774385 DOI: 10.2147/OTT.S176101] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
447 Rees DO, Crick PJ, Jenkins GJ, Wang Y, Griffiths WJ, Brown TH, Al-Sarireh B. Comparison of the composition of bile acids in bile of patients with adenocarcinoma of the pancreas and benign disease. J Steroid Biochem Mol Biol 2017;174:290-5. [PMID: 29031685 DOI: 10.1016/j.jsbmb.2017.10.011] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
448 Argyros O, Wong SP, Gowers K, Harbottle RP. Genetic modification of cancer cells using non-viral, episomal S/MAR vectors for in vivo tumour modelling. PLoS One 2012;7:e47920. [PMID: 23110132 DOI: 10.1371/journal.pone.0047920] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
449 Guerrero PE, Miró L, Wong BS, Massaguer A, Martínez-Bosch N, Llorens R, Navarro P, Konstantopoulos K, Llop E, Peracaula R. Knockdown of α2,3-Sialyltransferases Impairs Pancreatic Cancer Cell Migration, Invasion and E-selectin-Dependent Adhesion. Int J Mol Sci 2020;21:E6239. [PMID: 32872308 DOI: 10.3390/ijms21176239] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
450 Diaferia GR, Balestrieri C, Prosperini E, Nicoli P, Spaggiari P, Zerbi A, Natoli G. Dissection of transcriptional and cis-regulatory control of differentiation in human pancreatic cancer. EMBO J 2016;35:595-617. [PMID: 26769127 DOI: 10.15252/embj.201592404] [Cited by in Crossref: 74] [Cited by in F6Publishing: 64] [Article Influence: 12.3] [Reference Citation Analysis]
451 Martín AM, Hidalgo M, Alvarez R, Arrazubi V, Martínez-Galán J, Salgado M, Macarulla T, Carrato A. From First Line to Sequential Treatment in the Management of Metastatic Pancreatic Cancer. J Cancer 2018;9:1978-88. [PMID: 29896283 DOI: 10.7150/jca.23716] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
452 Wei F, Zhang Y, Geng L, Zhang P, Wang G, Liu Y. mTOR inhibition induces EGFR feedback activation in association with its resistance to human pancreatic cancer. Int J Mol Sci 2015;16:3267-82. [PMID: 25654224 DOI: 10.3390/ijms16023267] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 3.7] [Reference Citation Analysis]
453 Shukla SK, Gebregiworgis T, Purohit V, Chaika NV, Gunda V, Radhakrishnan P, Mehla K, Pipinos II, Powers R, Yu F. Metabolic reprogramming induced by ketone bodies diminishes pancreatic cancer cachexia. Cancer Metab. 2014;2:18. [PMID: 25228990 DOI: 10.1186/2049-3002-2-18] [Cited by in Crossref: 116] [Cited by in F6Publishing: 116] [Article Influence: 14.5] [Reference Citation Analysis]
454 Kishikawa T, Otsuka M, Yoshikawa T, Ohno M, Yamamoto K, Yamamoto N, Kotani A, Koike K. Quantitation of circulating satellite RNAs in pancreatic cancer patients. JCI Insight 2016;1:e86646. [PMID: 27699267 DOI: 10.1172/jci.insight.86646] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 3.3] [Reference Citation Analysis]
455 Cooper C, Burden ST, Molassiotis A. An explorative study of the views and experiences of food and weight loss in patients with operable pancreatic cancer perioperatively and following surgical intervention. Support Care Cancer 2015;23:1025-33. [PMID: 25277960 DOI: 10.1007/s00520-014-2455-1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
456 Carstens JL, Yang S, Correa de Sampaio P, Zheng X, Barua S, McAndrews KM, Rao A, Burks JK, Rhim AD, Kalluri R. Stabilized epithelial phenotype of cancer cells in primary tumors leads to increased colonization of liver metastasis in pancreatic cancer. Cell Rep 2021;35:108990. [PMID: 33852841 DOI: 10.1016/j.celrep.2021.108990] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
457 Wartenberg M, Zlobec I, Perren A, Koelzer VH, Gloor B, Lugli A, Karamitopoulou E. Accumulation of FOXP3+T-cells in the tumor microenvironment is associated with an epithelial-mesenchymal-transition-type tumor budding phenotype and is an independent prognostic factor in surgically resected pancreatic ductal adenocarcinoma. Oncotarget 2015;6:4190-201. [PMID: 25669968 DOI: 10.18632/oncotarget.2775] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 4.5] [Reference Citation Analysis]
458 Takasawa A, Murata M, Takasawa K, Ono Y, Osanai M, Tanaka S, Nojima M, Kono T, Hirata K, Kojima T, Sawada N. Nuclear localization of tricellulin promotes the oncogenic property of pancreatic cancer. Sci Rep 2016;6:33582. [PMID: 27641742 DOI: 10.1038/srep33582] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.2] [Reference Citation Analysis]
459 Kaistha BP, Krattenmacher A, Fredebohm J, Schmidt H, Behrens D, Widder M, Hackert T, Strobel O, Hoheisel JD, Gress TM, Buchholz M. The deubiquitinating enzyme USP5 promotes pancreatic cancer via modulating cell cycle regulators. Oncotarget 2017;8:66215-25. [PMID: 29029505 DOI: 10.18632/oncotarget.19882] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 3.6] [Reference Citation Analysis]
460 Pausch TM, Aue E, Wirsik NM, Freire Valls A, Shen Y, Radhakrishnan P, Hackert T, Schneider M, Schmidt T. Metastasis-associated fibroblasts promote angiogenesis in metastasized pancreatic cancer via the CXCL8 and the CCL2 axes. Sci Rep 2020;10:5420. [PMID: 32214219 DOI: 10.1038/s41598-020-62416-x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 27] [Article Influence: 11.0] [Reference Citation Analysis]
461 Kong L, Liu P, Zheng M, Wang Z, Gao Y, Liang K, Wang H, Tan X. The miR-1224-5p/ELF3 Axis Regulates Malignant Behaviors of Pancreatic Cancer via PI3K/AKT/Notch Signaling Pathways. Onco Targets Ther 2020;13:3449-66. [PMID: 32368099 DOI: 10.2147/OTT.S248507] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
462 Alexander BE, Sun S, Palframan MJ, Kociok-Köhn G, Dibwe DF, Watanabe S, Caggiano L, Awale S, Lewis SE. Sidechain Diversification of Grandifloracin Allows Identification of Analogues with Enhanced Anti-Austerity Activity against Human PANC-1 Pancreatic Cancer Cells. ChemMedChem 2020;15:125-35. [PMID: 31821731 DOI: 10.1002/cmdc.201900549] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
463 Meng Q, Shi S, Liang C, Xiang J, Liang D, Zhang B, Qin Y, Ji S, Xu W, Xu J, Ni Q, Yu X. Diagnostic Accuracy of a CA125-Based Biomarker Panel in Patients with Pancreatic Cancer: A Systematic Review and Meta-Analysis. J Cancer. 2017;8:3615-3622. [PMID: 29151947 DOI: 10.7150/jca.18901] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
464 Gu JF, Fu W, Qian HX, Gu WX, Zong Y, Chen Q, Lu L. TBL1XR1 induces cell proliferation and inhibit cell apoptosis by the PI3K/AKT pathway in pancreatic ductal adenocarcinoma. World J Gastroenterol 2020; 26(25): 3586-3602 [PMID: 32742128 DOI: 10.3748/wjg.v26.i25.3586] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
465 Ghasemi R, Rapposelli IG, Capone E, Rossi C, Lattanzio R, Piantelli M, Sala G, Iacobelli S. Dual targeting of ErbB-2/ErbB-3 results in enhanced antitumor activity in preclinical models of pancreatic cancer. Oncogenesis 2014;3:e117. [PMID: 25133484 DOI: 10.1038/oncsis.2014.31] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
466 Yin Z, Zhou Y, Ma T, Chen S, Shi N, Zou Y, Hou B, Zhang C. Down-regulated lncRNA SBF2-AS1 in M2 macrophage-derived exosomes elevates miR-122-5p to restrict XIAP, thereby limiting pancreatic cancer development. J Cell Mol Med 2020;24:5028-38. [PMID: 32301277 DOI: 10.1111/jcmm.15125] [Cited by in Crossref: 26] [Cited by in F6Publishing: 31] [Article Influence: 13.0] [Reference Citation Analysis]
467 Moutinho-Ribeiro P, Macedo G, Melo SA. Pancreatic Cancer Diagnosis and Management: Has the Time Come to Prick the Bubble? Front Endocrinol (Lausanne) 2018;9:779. [PMID: 30671023 DOI: 10.3389/fendo.2018.00779] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 5.3] [Reference Citation Analysis]
468 Azad A, Yin Lim S, D'Costa Z, Jones K, Diana A, Sansom OJ, Kruger P, Liu S, McKenna WG, Dushek O, Muschel RJ, Fokas E. PD-L1 blockade enhances response of pancreatic ductal adenocarcinoma to radiotherapy. EMBO Mol Med 2017;9:167-80. [PMID: 27932443 DOI: 10.15252/emmm.201606674] [Cited by in Crossref: 77] [Cited by in F6Publishing: 75] [Article Influence: 15.4] [Reference Citation Analysis]
469 Lei J, Ma J, Ma Q, Li X, Liu H, Xu Q, Duan W, Sun Q, Xu J, Wu Z. Hedgehog signaling regulates hypoxia induced epithelial to mesenchymal transition and invasion in pancreatic cancer cells via a ligand-independent manner. Mol Cancer. 2013;12:66. [PMID: 23786654 DOI: 10.1186/1476-4598-12-66] [Cited by in Crossref: 87] [Cited by in F6Publishing: 86] [Article Influence: 9.7] [Reference Citation Analysis]
470 Cheng XB, Kohi S, Koga A, Hirata K, Sato N. Hyaluronan stimulates pancreatic cancer cell motility. Oncotarget. 2016;7:4829-4840. [PMID: 26684359 DOI: 10.18632/oncotarget.6617] [Cited by in Crossref: 39] [Cited by in F6Publishing: 46] [Article Influence: 6.5] [Reference Citation Analysis]
471 Ozkan M, Cakiroglu M, Kocaman O, Kurt M, Yilmaz B, Can G, Korkmaz U, Dandil E, Eksi Z. Age-based computer-aided diagnosis approach for pancreatic cancer on endoscopic ultrasound images. Endosc Ultrasound. 2016;5:101-107. [PMID: 27080608 DOI: 10.4103/2303-9027.180473] [Cited by in Crossref: 16] [Cited by in F6Publishing: 21] [Article Influence: 2.7] [Reference Citation Analysis]
472 Li C, Wang Z, Chen Y, Zhou M, Zhang H, Chen R, Shi F, Wang C, Rui Z. Transcriptional silencing of ETS-1 abrogates epithelial-mesenchymal transition resulting in reduced motility of pancreatic cancer cells. Oncol Rep 2015;33:559-65. [PMID: 25421630 DOI: 10.3892/or.2014.3613] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 2.5] [Reference Citation Analysis]
473 Dangi-Garimella S, Sahai V, Ebine K, Kumar K, Munshi HG. Three-dimensional collagen I promotes gemcitabine resistance in vitro in pancreatic cancer cells through HMGA2-dependent histone acetyltransferase expression. PLoS One. 2013;8:e64566. [PMID: 23696899 DOI: 10.1371/journal.pone.0064566] [Cited by in Crossref: 34] [Cited by in F6Publishing: 36] [Article Influence: 3.8] [Reference Citation Analysis]
474 Xu DF, Wang LS, Zhou JH. Long non‑coding RNA CASC2 suppresses pancreatic cancer cell growth and progression by regulating the miR‑24/MUC6 axis. Int J Oncol 2020;56:494-507. [PMID: 31894271 DOI: 10.3892/ijo.2019.4937] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
475 Boldrini L, Cusumano D, Cellini F, Azario L, Mattiucci GC, Valentini V. Online adaptive magnetic resonance guided radiotherapy for pancreatic cancer: state of the art, pearls and pitfalls. Radiat Oncol 2019;14:71. [PMID: 31036034 DOI: 10.1186/s13014-019-1275-3] [Cited by in Crossref: 47] [Cited by in F6Publishing: 42] [Article Influence: 15.7] [Reference Citation Analysis]
476 Tian F, Dai MH, Jia CW, Liu ZW, Li BL. Retrospective analysis of seven cases of pancreatic mixed adenoneuroendocrine carcinoma from a high-volume center and review of the literature. BMC Surg 2019;19:89. [PMID: 31296197 DOI: 10.1186/s12893-019-0546-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
477 Vennin C, Chin VT, Warren SC, Lucas MC, Herrmann D, Magenau A, Melenec P, Walters SN, Del Monte-Nieto G, Conway JR, Nobis M, Allam AH, McCloy RA, Currey N, Pinese M, Boulghourjian A, Zaratzian A, Adam AA, Heu C, Nagrial AM, Chou A, Steinmann A, Drury A, Froio D, Giry-Laterriere M, Harris NL, Phan T, Jain R, Weninger W, McGhee EJ, Whan R, Johns AL, Samra JS, Chantrill L, Gill AJ, Kohonen-Corish M, Harvey RP, Biankin AV, Evans TR, Anderson KI, Grey ST, Ormandy CJ, Gallego-Ortega D, Wang Y, Samuel MS, Sansom OJ, Burgess A, Cox TR, Morton JP, Pajic M, Timpson P; Australian Pancreatic Cancer Genome Initiative (APGI). Transient tissue priming via ROCK inhibition uncouples pancreatic cancer progression, sensitivity to chemotherapy, and metastasis. Sci Transl Med 2017;9:eaai8504. [PMID: 28381539 DOI: 10.1126/scitranslmed.aai8504] [Cited by in Crossref: 139] [Cited by in F6Publishing: 136] [Article Influence: 27.8] [Reference Citation Analysis]
478 Maekawa T, Kamada Y, Ebisutani Y, Ueda M, Hata T, Kawamoto K, Takamatsu S, Mizutani K, Shimomura M, Sobajima T, Fujii H, Nakayama K, Nishino K, Yamada M, Kumada T, Ito T, Eguchi H, Nagano H, Miyoshi E. Serum Mac-2 binding protein is a novel biomarker for chronic pancreatitis. World J Gastroenterol 2016; 22(17): 4403-4410 [PMID: 27158210 DOI: 10.3748/wjg.v22.i17.4403] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
479 Krishna S, Palm W, Lee Y, Yang W, Bandyopadhyay U, Xu H, Florey O, Thompson CB, Overholtzer M. PIKfyve Regulates Vacuole Maturation and Nutrient Recovery following Engulfment. Dev Cell 2016;38:536-47. [PMID: 27623384 DOI: 10.1016/j.devcel.2016.08.001] [Cited by in Crossref: 58] [Cited by in F6Publishing: 53] [Article Influence: 11.6] [Reference Citation Analysis]
480 Hui B, Xu Y, Zhao B, Ji H, Ma Z, Xu S, He Z, Wang K, Lu J. Overexpressed long noncoding RNA TUG1 affects the cell cycle, proliferation, and apoptosis of pancreatic cancer partly through suppressing RND3 and MT2A. Onco Targets Ther 2019;12:1043-57. [PMID: 30787623 DOI: 10.2147/OTT.S188396] [Cited by in Crossref: 22] [Cited by in F6Publishing: 14] [Article Influence: 7.3] [Reference Citation Analysis]
481 Wang D, Liu C, Zhou Y, Yan T, Li C, Yang Q, Xu Y, Zhao L, Pei Q, Tan F, Güngör C, Li Y. Effect of neoadjuvant radiotherapy on survival of non-metastatic pancreatic ductal adenocarcinoma: a SEER database analysis. Radiat Oncol 2020;15:107. [PMID: 32404114 DOI: 10.1186/s13014-020-01561-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
482 Mohamadkhani A, Naderi E, Sharafkhah M, Fazli HR, Moradzadeh M, Pourshams A. Detection of TP53 R249 Mutation in Iranian Patients with Pancreatic Cancer. J Oncol 2013;2013:738915. [PMID: 24489544 DOI: 10.1155/2013/738915] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
483 Baumgart S, Chen NM, Siveke JT, König A, Zhang JS, Singh SK, Wolf E, Bartkuhn M, Esposito I, Heßmann E, Reinecke J, Nikorowitsch J, Brunner M, Singh G, Fernandez-Zapico ME, Smyrk T, Bamlet WR, Eilers M, Neesse A, Gress TM, Billadeau DD, Tuveson D, Urrutia R, Ellenrieder V. Inflammation-induced NFATc1-STAT3 transcription complex promotes pancreatic cancer initiation by KrasG12D. Cancer Discov 2014;4:688-701. [PMID: 24694735 DOI: 10.1158/2159-8290.CD-13-0593] [Cited by in Crossref: 75] [Cited by in F6Publishing: 55] [Article Influence: 9.4] [Reference Citation Analysis]
484 Beatty GL, Torigian DA, Chiorean EG, Saboury B, Brothers A, Alavi A, Troxel AB, Sun W, Teitelbaum UR, Vonderheide RH, O'Dwyer PJ. A phase I study of an agonist CD40 monoclonal antibody (CP-870,893) in combination with gemcitabine in patients with advanced pancreatic ductal adenocarcinoma. Clin Cancer Res. 2013;19:6286-6295. [PMID: 23983255 DOI: 10.1158/1078-0432.ccr-13-1320] [Cited by in Crossref: 272] [Cited by in F6Publishing: 171] [Article Influence: 30.2] [Reference Citation Analysis]
485 Peng Z, Ji Z, Mei F, Lu M, Ou Y, Cheng X. Lithium inhibits tumorigenic potential of PDA cells through targeting hedgehog-GLI signaling pathway. PLoS One. 2013;8:e61457. [PMID: 23626687 DOI: 10.1371/journal.pone.0061457] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 2.8] [Reference Citation Analysis]
486 Shen WD, Chen HL, Liu PF. XRCC1 Polymorphisms and Pancreatic Cancer: A Meta-Analysis. Chin J Cancer Res 2011;23:165-70. [PMID: 23467456 DOI: 10.1007/s11670-011-0165-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
487 Lemke J, Scheele J, Kapapa T, von Karstedt S, Wirtz CR, Henne-Bruns D, Kornmann M. Brain metastases in gastrointestinal cancers: is there a role for surgery? Int J Mol Sci 2014;15:16816-30. [PMID: 25247579 DOI: 10.3390/ijms150916816] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
488 Zhou W, Jubb AM, Lyle K, Xiao Q, Ong CC, Desai R, Fu L, Gnad F, Song Q, Haverty PM. PAK1 mediates pancreatic cancer cell migration and resistance to MET inhibition. J Pathol. 2014;234:502-513. [PMID: 25074413 DOI: 10.1002/path.4412] [Cited by in Crossref: 27] [Cited by in F6Publishing: 30] [Article Influence: 3.4] [Reference Citation Analysis]
489 Yu X, Song Y, Di Y, He H, Fu D, Jin C. Enhanced tumor targeting of cRGD peptide-conjugated albumin nanoparticles in the BxPC-3 cell line. Sci Rep 2016;6:31539. [PMID: 27515795 DOI: 10.1038/srep31539] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
490 Amantini C, Morelli MB, Nabissi M, Piva F, Marinelli O, Maggi F, Bianchi F, Bittoni A, Berardi R, Giampieri R, Santoni G. Expression Profiling of Circulating Tumor Cells in Pancreatic Ductal Adenocarcinoma Patients: Biomarkers Predicting Overall Survival.Front Oncol. 2019;9:874. [PMID: 31552188 DOI: 10.3389/fonc.2019.00874] [Cited by in Crossref: 19] [Cited by in F6Publishing: 25] [Article Influence: 6.3] [Reference Citation Analysis]
491 Proctor A, Herrera-Loeza SG, Wang Q, Lawrence DS, Yeh JJ, Allbritton NL. Measurement of protein kinase B activity in single primary human pancreatic cancer cells. Anal Chem 2014;86:4573-80. [PMID: 24716819 DOI: 10.1021/ac500616q] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 3.3] [Reference Citation Analysis]
492 Clauss D, Tjaden C, Hackert T, Schneider L, Ulrich CM, Wiskemann J, Steindorf K. Cardiorespiratory fitness and muscle strength in pancreatic cancer patients. Support Care Cancer 2017;25:2797-807. [PMID: 28417202 DOI: 10.1007/s00520-017-3694-8] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 3.6] [Reference Citation Analysis]
493 Noel M, O'Reilly EM, Wolpin BM, Ryan DP, Bullock AJ, Britten CD, Linehan DC, Belt BA, Gamelin EC, Ganguly B, Yin D, Joh T, Jacobs IA, Taylor CT, Lowery MA. Phase 1b study of a small molecule antagonist of human chemokine (C-C motif) receptor 2 (PF-04136309) in combination with nab-paclitaxel/gemcitabine in first-line treatment of metastatic pancreatic ductal adenocarcinoma. Invest New Drugs 2020;38:800-11. [PMID: 31297636 DOI: 10.1007/s10637-019-00830-3] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 11.3] [Reference Citation Analysis]
494 Huang C, Xie K. Crosstalk of Sp1 and Stat3 signaling in pancreatic cancer pathogenesis. Cytokine Growth Factor Rev 2012;23:25-35. [PMID: 22342309 DOI: 10.1016/j.cytogfr.2012.01.003] [Cited by in Crossref: 40] [Cited by in F6Publishing: 38] [Article Influence: 4.0] [Reference Citation Analysis]
495 Pranger BK, Tseng DSJ, Ubels S, van Santvoort HC, Nieuwenhuijs VB, de Jong KP, Patijn G, Molenaar IQ, Erdmann JI, de Meijer VE. How to Approach Para-Aortic Lymph Node Metastases During Exploration for Suspected Periampullary Carcinoma: Resection or Bypass? Ann Surg Oncol 2020;27:2949-58. [PMID: 32157526 DOI: 10.1245/s10434-020-08304-0] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
496 Iacobuzio-Donahue CA. Genetic evolution of pancreatic cancer: lessons learnt from the pancreatic cancer genome sequencing project. Gut. 2012;61:1085-1094. [PMID: 21749982 DOI: 10.1136/gut.2010.236026] [Cited by in Crossref: 89] [Cited by in F6Publishing: 82] [Article Influence: 8.1] [Reference Citation Analysis]
497 Ishikawa M, Okamoto C, Shinoda K, Komagata H, Iwamoto C, Ohuchida K, Hashizume M, Shimizu A, Kobayashi N. Detection of pancreatic tumor cell nuclei via a hyperspectral analysis of pathological slides based on stain spectra. Biomed Opt Express 2019;10:4568-88. [PMID: 31565510 DOI: 10.1364/BOE.10.004568] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
498 Torres JB, Knight JC, Mosley MJ, Kersemans V, Koustoulidou S, Allen D, Kinchesh P, Smart S, Cornelissen B. Imaging of Claudin-4 in Pancreatic Ductal Adenocarcinoma Using a Radiolabelled Anti-Claudin-4 Monoclonal Antibody. Mol Imaging Biol 2018;20:292-9. [PMID: 28842811 DOI: 10.1007/s11307-017-1112-8] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
499 Gogate PN, Kurenova EV, Ethirajan M, Liao J, Yemma M, Sen A, Pandey RK, Cance WG. Targeting the C-terminal focal adhesion kinase scaffold in pancreatic cancer. Cancer Lett 2014;353:281-9. [PMID: 25067788 DOI: 10.1016/j.canlet.2014.07.032] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
500 Kohi S, Sato N, Koga A, Matayoshi N, Hirata K. KIAA1199 is induced by inflammation and enhances malignant phenotype in pancreatic cancer. Oncotarget 2017;8:17156-63. [PMID: 28179576 DOI: 10.18632/oncotarget.15052] [Cited by in Crossref: 12] [Cited by in F6Publishing: 16] [Article Influence: 2.4] [Reference Citation Analysis]
501 Sun Q, Zhang B, Hu Q, Qin Y, Xu W, Liu W, Yu X, Xu J. The impact of cancer-associated fibroblasts on major hallmarks of pancreatic cancer. Theranostics 2018;8:5072-87. [PMID: 30429887 DOI: 10.7150/thno.26546] [Cited by in Crossref: 64] [Cited by in F6Publishing: 72] [Article Influence: 16.0] [Reference Citation Analysis]
502 Yin H, Chen N, Guo R, Wang H, Li W, Wang G, Cui J, Jin H, Hu JF. Antitumor potential of a synthetic interferon-alpha/PLGF-2 positive charge peptide hybrid molecule in pancreatic cancer cells. Sci Rep 2015;5:16975. [PMID: 26584517 DOI: 10.1038/srep16975] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
503 Dotan E, Alpaugh RK, Ruth K, Negin BP, Denlinger CS, Hall MJ, Astsaturov I, McAleer C, Fittipaldi P, Thrash-Bingham C, Meropol NJ, Cohen SJ. Prognostic Significance of MUC-1 in Circulating Tumor Cells in Patients With Metastatic Pancreatic Adenocarcinoma. Pancreas 2016;45:1131-5. [PMID: 26967453 DOI: 10.1097/MPA.0000000000000619] [Cited by in Crossref: 31] [Cited by in F6Publishing: 16] [Article Influence: 7.8] [Reference Citation Analysis]
504 Zhang ZX, Zhou J, Zhang Y, Zhu DM, Li DC, Zhao H. Knockdown of angiopoietin-2 suppresses metastasis in human pancreatic carcinoma by reduced matrix metalloproteinase-2. Mol Biotechnol 2013;53:336-44. [PMID: 22457202 DOI: 10.1007/s12033-012-9532-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
505 Sielaff CM, Mousa SA. Status and future directions in the management of pancreatic cancer: potential impact of nanotechnology. J Cancer Res Clin Oncol 2018;144:1205-17. [PMID: 29721665 DOI: 10.1007/s00432-018-2651-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
506 Chan A, Diamandis EP, Blasutig IM. Strategies for discovering novel pancreatic cancer biomarkers. J Proteomics 2013;81:126-34. [PMID: 23026552 DOI: 10.1016/j.jprot.2012.09.025] [Cited by in Crossref: 37] [Cited by in F6Publishing: 33] [Article Influence: 3.7] [Reference Citation Analysis]
507 Link A, Becker V, Goel A, Wex T, Malfertheiner P. Feasibility of fecal microRNAs as novel biomarkers for pancreatic cancer. PLoS One. 2012;7:e42933. [PMID: 22905187 DOI: 10.1371/journal.pone.0042933] [Cited by in Crossref: 47] [Cited by in F6Publishing: 47] [Article Influence: 4.7] [Reference Citation Analysis]
508 Dong R, Chen P, Chen Q. Inhibition of pancreatic cancer stem cells by Rauwolfia vomitoria extract. Oncol Rep 2018;40:3144-54. [PMID: 30272287 DOI: 10.3892/or.2018.6713] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
509 Schimmack S, Kneller S, Dadabaeva N, Bergmann F, Taylor A, Hackert T, Werner J, Strobel O. Epithelial to Stromal Re-Distribution of Primary Cilia during Pancreatic Carcinogenesis. PLoS One 2016;11:e0164231. [PMID: 27783689 DOI: 10.1371/journal.pone.0164231] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
510 Borazanci E, Millis SZ, Korn R, Han H, Whatcott CJ, Gatalica Z, Barrett MT, Cridebring D, Hoff DDV. Adenosquamous carcinoma of the pancreas: Molecular characterization of 23 patients along with a literature review. World J Gastrointest Oncol 2015; 7(9): 132-140 [PMID: 26380056 DOI: 10.4251/wjgo.v7.i9.132] [Cited by in CrossRef: 30] [Cited by in F6Publishing: 24] [Article Influence: 4.3] [Reference Citation Analysis]
511 Kawase T, Yasui Y, Nishina S, Hara Y, Yanatori I, Tomiyama Y, Nakashima Y, Yoshida K, Kishi F, Nakamura M, Hino K. Fibroblast activation protein-α-expressing fibroblasts promote the progression of pancreatic ductal adenocarcinoma. BMC Gastroenterol 2015;15:109. [PMID: 26330349 DOI: 10.1186/s12876-015-0340-0] [Cited by in Crossref: 38] [Cited by in F6Publishing: 40] [Article Influence: 5.4] [Reference Citation Analysis]
512 Garrido-Laguna I, Hidalgo M. Pancreatic cancer: from state-of-the-art treatments to promising novel therapies. Nat Rev Clin Oncol. 2015;12:319-334. [PMID: 25824606 DOI: 10.1038/nrclinonc.2015.53] [Cited by in Crossref: 350] [Cited by in F6Publishing: 325] [Article Influence: 50.0] [Reference Citation Analysis]
513 Greer JB, Brand RE. New developments in pancreatic cancer. Curr Gastroenterol Rep. 2011;13:131-139. [PMID: 21258973 DOI: 10.1007/s11894-011-0175-y] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
514 Brabez N, Nguyen KL, Saunders K, Lacy R, Xu L, Gillies RJ, Lynch RM, Chassaing G, Lavielle S, Hruby VJ. Synthesis and evaluation of cholecystokinin trimers: a multivalent approach to pancreatic cancer detection and treatment. Bioorg Med Chem Lett 2013;23:2422-5. [PMID: 23489620 DOI: 10.1016/j.bmcl.2013.02.022] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
515 Kaistha BP, Honstein T, Müller V, Bielak S, Sauer M, Kreider R, Fassan M, Scarpa A, Schmees C, Volkmer H, Gress TM, Buchholz M. Key role of dual specificity kinase TTK in proliferation and survival of pancreatic cancer cells. Br J Cancer 2014;111:1780-7. [PMID: 25137017 DOI: 10.1038/bjc.2014.460] [Cited by in Crossref: 46] [Cited by in F6Publishing: 43] [Article Influence: 5.8] [Reference Citation Analysis]
516 Palmarocchi MC, Balzarotti Canger RC, Saletti P. Neoadjuvant chemotherapy in borderline resectable pancreatic cancer: A case report. Oncol Lett 2017;13:4445-52. [PMID: 28588713 DOI: 10.3892/ol.2017.6026] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
517 Gündoğdu E, Emekli E, Kebapçı M. Relationship among CT-based abdominal adipose tissue areas and pancreatic ductal adenocarcinoma in male. Aging Male 2020;23:1455-9. [PMID: 33191832 DOI: 10.1080/13685538.2020.1793940] [Reference Citation Analysis]
518 Scott SJ, Adams MS, Salgaonkar V, Sommer FG, Diederich CJ. Theoretical investigation of transgastric and intraductal approaches for ultrasound-based thermal therapy of the pancreas. J Ther Ultrasound 2017;5:10. [PMID: 28469915 DOI: 10.1186/s40349-017-0090-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
519 Sharen G, Peng Y, Cheng H, Liu Y, Shi Y, Zhao J. Prognostic value of GLUT-1 expression in pancreatic cancer: results from 538 patients. Oncotarget 2017;8:19760-7. [PMID: 28178665 DOI: 10.18632/oncotarget.15035] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 4.0] [Reference Citation Analysis]
520 Payne SN, Maher ME, Tran NH, Van De Hey DR, Foley TM, Yueh AE, Leystra AA, Pasch CA, Jeffrey JJ, Clipson L, Matkowskyj KA, Deming DA. PIK3CA mutations can initiate pancreatic tumorigenesis and are targetable with PI3K inhibitors. Oncogenesis 2015;4:e169. [PMID: 26436951 DOI: 10.1038/oncsis.2015.28] [Cited by in Crossref: 21] [Cited by in F6Publishing: 27] [Article Influence: 3.0] [Reference Citation Analysis]
521 Wang J, Guo XJ, Ding YM, Jiang JX. miR-1181 inhibits invasion and proliferation via STAT3 in pancreatic cancer. World J Gastroenterol 2017; 23(9): 1594-1601 [PMID: 28321160 DOI: 10.3748/wjg.v23.i9.1594] [Cited by in CrossRef: 20] [Cited by in F6Publishing: 21] [Article Influence: 4.0] [Reference Citation Analysis]
522 Hall M, Liu H, Malafa M, Centeno B, Hodul PJ, Pimiento J, Pilon-Thomas S, Sarnaik AA. Expansion of tumor-infiltrating lymphocytes (TIL) from human pancreatic tumors. J Immunother Cancer 2016;4:61. [PMID: 27777771 DOI: 10.1186/s40425-016-0164-7] [Cited by in Crossref: 47] [Cited by in F6Publishing: 45] [Article Influence: 7.8] [Reference Citation Analysis]
523 Lanki M, Seppänen H, Mustonen H, Hagström J, Haglund C. Toll-like receptor 1 predicts favorable prognosis in pancreatic cancer. PLoS One 2019;14:e0219245. [PMID: 31314777 DOI: 10.1371/journal.pone.0219245] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
524 Slapak EJ, Duitman J, Tekin C, Bijlsma MF, Spek CA. Matrix Metalloproteases in Pancreatic Ductal Adenocarcinoma: Key Drivers of Disease Progression? Biology (Basel) 2020;9:E80. [PMID: 32325664 DOI: 10.3390/biology9040080] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
525 Chang J, Tian J, Zhu Y, Zhong R, Zhai K, Li J, Ke J, Han Q, Lou J, Chen W, Zhu B, Shen N, Zhang Y, Gong Y, Yang Y, Zou D, Peng X, Zhang Z, Zhang X, Huang K, Yang M, Wang L, Wu C, Lin D, Miao X. Exome-wide analysis identifies three low-frequency missense variants associated with pancreatic cancer risk in Chinese populations. Nat Commun 2018;9:3688. [PMID: 30206226 DOI: 10.1038/s41467-018-06136-x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 4.5] [Reference Citation Analysis]
526 Ho WJ, Jaffee EM, Zheng L. The tumour microenvironment in pancreatic cancer - clinical challenges and opportunities. Nat Rev Clin Oncol 2020;17:527-40. [PMID: 32398706 DOI: 10.1038/s41571-020-0363-5] [Cited by in Crossref: 82] [Cited by in F6Publishing: 97] [Article Influence: 41.0] [Reference Citation Analysis]
527 Yip-Schneider MT, Carr RA, Wu H, Schmidt CM. Prostaglandin E2: A Pancreatic Fluid Biomarker of Intraductal Papillary Mucinous Neoplasm Dysplasia. J Am Coll Surg 2017;225:481-7. [PMID: 28739154 DOI: 10.1016/j.jamcollsurg.2017.07.521] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
528 Schober M, Jesenofsky R, Faissner R, Weidenauer C, Hagmann W, Michl P, Heuchel RL, Haas SL, Löhr JM. Desmoplasia and chemoresistance in pancreatic cancer. Cancers (Basel) 2014;6:2137-54. [PMID: 25337831 DOI: 10.3390/cancers6042137] [Cited by in Crossref: 72] [Cited by in F6Publishing: 68] [Article Influence: 9.0] [Reference Citation Analysis]
529 Lecuelle J, Aarnink A, Tharin Z, Truntzer C, Ghiringhelli F. Using Exome Sequencing to Improve Prediction of FOLFIRINOX First Efficacy for Pancreatic Adenocarcinoma. Cancers (Basel) 2021;13:1851. [PMID: 33924443 DOI: 10.3390/cancers13081851] [Reference Citation Analysis]
530 Mishra VK, Wegwitz F, Kosinsky RL, Sen M, Baumgartner R, Wulff T, Siveke JT, Schildhaus HU, Najafova Z, Kari V. Histone deacetylase class-I inhibition promotes epithelial gene expression in pancreatic cancer cells in a BRD4- and MYC-dependent manner. Nucleic Acids Res. 2017;45:6334-6349. [PMID: 28369619 DOI: 10.1093/nar/gkx212] [Cited by in Crossref: 47] [Cited by in F6Publishing: 42] [Article Influence: 9.4] [Reference Citation Analysis]
531 Wang F, Huang L, Zhang J, Fan J, Wu H, Xu J. Dyslipidemia in Chinese Pancreatic Cancer Patients: A Two-Center Retrospective Study. J Cancer 2021;12:5338-44. [PMID: 34335950 DOI: 10.7150/jca.60340] [Reference Citation Analysis]
532 Quaresima P, Saccone G, Pellegrino R, Vaccarisi S, Taranto L, Mazzulla R, Bernardo S, Venturella R, Di Carlo C, Morelli M. Incidental diagnosis of a pancreatic adenocarcinoma in a woman affected by gestational diabetes mellitus: case report and literature review. Am J Obstet Gynecol MFM 2021;3:100471. [PMID: 34454160 DOI: 10.1016/j.ajogmf.2021.100471] [Reference Citation Analysis]
533 Garofano F, Gonzalez-Carmona MA, Skowasch D, Schmidt-Wolf R, Abramian A, Hauser S, Strassburg CP, Schmidt-Wolf IGH. Clinical Trials with Combination of Cytokine-Induced Killer Cells and Dendritic Cells for Cancer Therapy. Int J Mol Sci 2019;20:E4307. [PMID: 31484350 DOI: 10.3390/ijms20174307] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
534 Alagesan B, Contino G, Guimaraes AR, Corcoran RB, Deshpande V, Wojtkiewicz GR, Hezel AF, Wong KK, Loda M, Weissleder R. Combined MEK and PI3K inhibition in a mouse model of pancreatic cancer. Clin Cancer Res. 2015;21:396-404. [PMID: 25348516 DOI: 10.1158/1078-0432.ccr-14-1591] [Cited by in Crossref: 83] [Cited by in F6Publishing: 58] [Article Influence: 10.4] [Reference Citation Analysis]
535 Zhang K, Lu Z, Zhu Y, Tian L, Zhang J, Xi C, Gao W, Jiang K, Miao Y. The clinical value, regulatory mechanisms, and gene network of the cancer-testis gene STK31 in pancreatic cancer. Oncotarget 2017;8:35154-64. [PMID: 28422722 DOI: 10.18632/oncotarget.16814] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
536 Smith AL, Bascuñana C, Hall A, Salman A, Andrei AZ, Volenik A, Rothenmund H, Ferland D, Lamoussenery D, Kamath AS, Amre R, Caglar D, Gao ZH, Haegert DG, Kanber Y, Michel RP, Omeroglu-Altinel G, Asselah J, Bouganim N, Kavan P, Arena G, Barkun J, Chaudhury P, Gallinger S, Foulkes WD, Omeroglu A, Metrakos P, Zogopoulos G. Establishing a clinic-based pancreatic cancer and periampullary tumour research registry in Quebec. Curr Oncol 2015;22:113-21. [PMID: 25908910 DOI: 10.3747/co.22.2300] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
537 Khan MA, Azim S, Zubair H, Bhardwaj A, Patel GK, Khushman M, Singh S, Singh AP. Molecular Drivers of Pancreatic Cancer Pathogenesis: Looking Inward to Move Forward. Int J Mol Sci 2017;18:E779. [PMID: 28383487 DOI: 10.3390/ijms18040779] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 7.2] [Reference Citation Analysis]
538 Chen Z, Sangwan V, Banerjee S, Chugh R, Dudeja V, Vickers SM, Saluja AK. Triptolide sensitizes pancreatic cancer cells to TRAIL-induced activation of the death receptor pathway. Cancer Lett 2014;348:156-66. [PMID: 24662747 DOI: 10.1016/j.canlet.2014.03.016] [Cited by in Crossref: 42] [Cited by in F6Publishing: 42] [Article Influence: 5.3] [Reference Citation Analysis]
539 Djurec M, Graña O, Lee A, Troulé K, Espinet E, Cabras L, Navas C, Blasco MT, Martín-Díaz L, Burdiel M, Li J, Liu Z, Vallespinós M, Sanchez-Bueno F, Sprick MR, Trumpp A, Sainz B Jr, Al-Shahrour F, Rabadan R, Guerra C, Barbacid M. Saa3 is a key mediator of the protumorigenic properties of cancer-associated fibroblasts in pancreatic tumors. Proc Natl Acad Sci U S A 2018;115:E1147-56. [PMID: 29351990 DOI: 10.1073/pnas.1717802115] [Cited by in Crossref: 70] [Cited by in F6Publishing: 67] [Article Influence: 17.5] [Reference Citation Analysis]
540 Maier HJ, Wirth T, Beug H. Epithelial-mesenchymal transition in pancreatic carcinoma. Cancers (Basel) 2010;2:2058-83. [PMID: 24281218 DOI: 10.3390/cancers2042058] [Cited by in Crossref: 40] [Cited by in F6Publishing: 42] [Article Influence: 3.3] [Reference Citation Analysis]
541 Malsy M, Gebhardt K, Gruber M, Wiese C, Graf B, Bundscherer A. Effects of ketamine, s-ketamine, and MK 801 on proliferation, apoptosis, and necrosis in pancreatic cancer cells. BMC Anesthesiol. 2015;15:111. [PMID: 26219286 DOI: 10.1186/s12871-015-0076-y] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 3.1] [Reference Citation Analysis]
542 Meng Q, Shi S, Liang C, Liang D, Xu W, Ji S, Zhang B, Ni Q, Xu J, Yu X. Diagnostic and prognostic value of carcinoembryonic antigen in pancreatic cancer: a systematic review and meta-analysis. Onco Targets Ther. 2017;10:4591-4598. [PMID: 28979147 DOI: 10.2147/ott.s145708] [Cited by in Crossref: 42] [Cited by in F6Publishing: 29] [Article Influence: 8.4] [Reference Citation Analysis]
543 Li X, Wang M, Jiang JX, Tian R, Shi CJ, Qin RY. Clinical significance of expression of DYRK2 in pancreatic cancer. Shijie Huaren Xiaohua Zazhi 2013; 21(15): 1442-1447 [DOI: 10.11569/wcjd.v21.i15.1442] [Reference Citation Analysis]
544 Čeponytė U, Paškevičiūtė M, Petrikaitė V. Comparison of NSAIDs activity in COX-2 expressing and non-expressing 2D and 3D pancreatic cancer cell cultures. Cancer Manag Res 2018;10:1543-51. [PMID: 29942156 DOI: 10.2147/CMAR.S163747] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
545 Bournet B, Gayral M, Torrisani J, Selves J, Cordelier P, Buscail L. Role of endoscopic ultrasound in the molecular diagnosis of pancreatic cancer. World J Gastroenterol 2014; 20(31): 10758-10768 [PMID: 25152579 DOI: 10.3748/wjg.v20.i31.10758] [Cited by in CrossRef: 25] [Cited by in F6Publishing: 23] [Article Influence: 3.1] [Reference Citation Analysis]
546 Karamitopoulou E. Tumor budding cells, cancer stem cells and epithelial-mesenchymal transition-type cells in pancreatic cancer. Front Oncol. 2012;2:209. [PMID: 23316479 DOI: 10.3389/fonc.2012.00209] [Cited by in Crossref: 18] [Cited by in F6Publishing: 31] [Article Influence: 2.0] [Reference Citation Analysis]
547 Lamarca A, Feliu J. Pancreatic biomarkers: Could they be the answer? World J Gastroenterol 2014; 20(24): 7819-7829 [PMID: 24976720 DOI: 10.3748/wjg.v20.i24.7819] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
548 Ostios-Garcia L, Villamayor J, Garcia-Lorenzo E, Vinal D, Feliu J. Understanding the immune response and the current landscape of immunotherapy in pancreatic cancer. World J Gastroenterol 2021; 27(40): 6775-6793 [PMID: 34790007 DOI: 10.3748/wjg.v27.i40.6775] [Reference Citation Analysis]
549 Sumiyoshi H, Matsushita A, Nakamura Y, Matsuda Y, Ishiwata T, Naito Z, Uchida E. Suppression of STAT5b in pancreatic cancer cells leads to attenuated gemcitabine chemoresistance, adhesion and invasion. Oncol Rep 2016;35:3216-26. [PMID: 27035235 DOI: 10.3892/or.2016.4727] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
550 Song J, Sokoll LJ, Pasay JJ, Rubin AL, Li H, Bach DM, Chan DW, Zhang Z. Identification of Serum Biomarker Panels for the Early Detection of Pancreatic Cancer. Cancer Epidemiol Biomarkers Prev 2019;28:174-82. [PMID: 30333219 DOI: 10.1158/1055-9965.EPI-18-0483] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
551 Coveler AL, Mizrahi J, Eastman B, Apisarnthanarax SJ, Dalal S, McNearney T, Pant S; Precision Promise Consortium. Pancreas Cancer-Associated Pain Management. Oncologist 2021;26:e971-82. [PMID: 33885205 DOI: 10.1002/onco.13796] [Reference Citation Analysis]
552 Zhang D, Lei J, Ma J, Chen X, Sheng L, Jiang Z, Nan L, Xu Q, Duan W, Wang Z, Li X, Wu Z, Wu E, Ma Q, Huo X. β2-adrenogenic signaling regulates NNK-induced pancreatic cancer progression via upregulation of HIF-1α. Oncotarget 2016;7:17760-72. [PMID: 26497365 DOI: 10.18632/oncotarget.5677] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
553 Duan L, Ying G, Danzer B, Perez RE, Shariat-Madar Z, Levenson VV, Maki CG. The prolyl peptidases PRCP/PREP regulate IRS-1 stability critical for rapamycin-induced feedback activation of PI3K and AKT. J Biol Chem 2014;289:21694-705. [PMID: 24936056 DOI: 10.1074/jbc.M114.550038] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
554 Kunzmann V, Ramanathan RK, Goldstein D, Liu H, Ferrara S, Lu B, Renschler MF, Von Hoff DD. Tumor Reduction in Primary and Metastatic Pancreatic Cancer Lesions With nab-Paclitaxel and Gemcitabine: An Exploratory Analysis From a Phase 3 Study. Pancreas. 2017;46:203-208. [PMID: 27841795 DOI: 10.1097/mpa.0000000000000742] [Cited by in Crossref: 18] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
555 Namba T, Kodama R. Avarol induces apoptosis in pancreatic ductal adenocarcinoma cells by activating PERK-eIF2α-CHOP signaling. Mar Drugs 2015;13:2376-89. [PMID: 25894488 DOI: 10.3390/md13042376] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.1] [Reference Citation Analysis]
556 Sarsour EH, Son JM, Kalen AL, Xiao W, Du J, Alexander MS, O'Leary BR, Cullen JJ, Goswami PC. Arachidonate 12-lipoxygenase and 12-hydroxyeicosatetraenoic acid contribute to stromal aging-induced progression of pancreatic cancer. J Biol Chem 2020;295:6946-57. [PMID: 32265301 DOI: 10.1074/jbc.RA120.012798] [Reference Citation Analysis]
557 Cui J, Shi M, Xie D, Wei D, Jia Z, Zheng S, Gao Y, Huang S, Xie K. FOXM1 promotes the warburg effect and pancreatic cancer progression via transactivation of LDHA expression. Clin Cancer Res. 2014;20:2595-2606. [PMID: 24634381 DOI: 10.1158/1078-0432.ccr-13-2407] [Cited by in Crossref: 118] [Cited by in F6Publishing: 88] [Article Influence: 14.8] [Reference Citation Analysis]
558 Diersch S, Wenzel P, Szameitat M, Eser P, Paul MC, Seidler B, Eser S, Messer M, Reichert M, Pagel P, Esposito I, Schmid RM, Saur D, Schneider G. Efemp1 and p27(Kip1) modulate responsiveness of pancreatic cancer cells towards a dual PI3K/mTOR inhibitor in preclinical models. Oncotarget 2013;4:277-88. [PMID: 23470560 DOI: 10.18632/oncotarget.859] [Cited by in Crossref: 28] [Cited by in F6Publishing: 22] [Article Influence: 3.5] [Reference Citation Analysis]
559 Ooi M, Phan A, Nguyen NQ. Future role of endoscopic ultrasound in personalized management of pancreatic cancer. Endosc Ultrasound 2017;6:300-7. [PMID: 29063873 DOI: 10.4103/eus.eus_84_17] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
560 Whittle MC, Izeradjene K, Rani PG, Feng L, Carlson MA, DelGiorno KE, Wood LD, Goggins M, Hruban RH, Chang AE, Calses P, Thorsen SM, Hingorani SR. RUNX3 Controls a Metastatic Switch in Pancreatic Ductal Adenocarcinoma. Cell 2015;161:1345-60. [PMID: 26004068 DOI: 10.1016/j.cell.2015.04.048] [Cited by in Crossref: 112] [Cited by in F6Publishing: 113] [Article Influence: 16.0] [Reference Citation Analysis]
561 Karanikas M, Esempidis A, Chasan ZT, Deftereou T, Antonopoulou M, Bozali F, Amarantidis K, Man YG. Pancreatic Cancer from Molecular Pathways to Treatment Opinion. J Cancer 2016;7:1328-39. [PMID: 27390608 DOI: 10.7150/jca.15419] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 2.2] [Reference Citation Analysis]
562 Basso D, Fogar P, Falconi M, Fadi E, Sperti C, Frasson C, Greco E, Tamburrino D, Teolato S, Moz S. Pancreatic tumors and immature immunosuppressive myeloid cells in blood and spleen: role of inhibitory co-stimulatory molecules PDL1 and CTLA4. An in vivo and in vitro study. PLoS One. 2013;8:e54824. [PMID: 23359812 DOI: 10.1371/journal.pone.0054824] [Cited by in Crossref: 32] [Cited by in F6Publishing: 35] [Article Influence: 3.6] [Reference Citation Analysis]
563 Argentiero A, Calabrese A, Sciacovelli AM, Delcuratolo S, Solimando AG, Brunetti O. Complete Response of Synchronous Liver Metastasis in a Pancreatic Ductal Adenocarcinoma, When Surgery Could Represent a Therapeutic Option. Can J Gastroenterol Hepatol 2020;2020:8679751. [PMID: 33102398 DOI: 10.1155/2020/8679751] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
564 Yuen A, Díaz B. The impact of hypoxia in pancreatic cancer invasion and metastasis. Hypoxia (Auckl) 2014;2:91-106. [PMID: 27774469 DOI: 10.2147/HP.S52636] [Cited by in Crossref: 16] [Cited by in F6Publishing: 25] [Article Influence: 2.0] [Reference Citation Analysis]
565 Thomas SK, Lee J, Beatty GL. Paracrine and cell autonomous signalling in pancreatic cancer progression and metastasis. EBioMedicine. 2020;53:102662. [PMID: 32139180 DOI: 10.1016/j.ebiom.2020.102662] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]
566 Dal Molin M, Zhang M, de Wilde RF, Ottenhof NA, Rezaee N, Wolfgang CL, Blackford A, Vogelstein B, Kinzler KW, Papadopoulos N, Hruban RH, Maitra A, Wood LD. Very Long-term Survival Following Resection for Pancreatic Cancer Is Not Explained by Commonly Mutated Genes: Results of Whole-Exome Sequencing Analysis. Clin Cancer Res 2015;21:1944-50. [PMID: 25623214 DOI: 10.1158/1078-0432.CCR-14-2600] [Cited by in Crossref: 52] [Cited by in F6Publishing: 28] [Article Influence: 7.4] [Reference Citation Analysis]
567 Sun Z, Zhang B, Cui T. Long non-coding RNA XIST exerts oncogenic functions in pancreatic cancer via miR-34a-5p. Oncol Rep 2018;39:1591-600. [PMID: 29393501 DOI: 10.3892/or.2018.6245] [Cited by in Crossref: 6] [Cited by in F6Publishing: 24] [Article Influence: 1.5] [Reference Citation Analysis]
568 Lin X, Huang M, Xie F, Zhou H, Yang J, Huang Q. Gemcitabine inhibits immune escape of pancreatic cancer by down regulating the soluble ULBP2 protein. Oncotarget 2016;7:70092-9. [PMID: 27602753 DOI: 10.18632/oncotarget.11780] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
569 Parisi S, Ferini G, Cacciola A, Lillo S, Tamburella C, Santacaterina A, Bottari A, Brogna A, Ferrantelli G, Pontoriero A, Minutoli F, Pergolizzi S. A non-surgical COMBO-therapy approach for locally advanced unresectable pancreatic adenocarcinoma: preliminary results of a prospective study. Radiol Med 2022. [PMID: 35034325 DOI: 10.1007/s11547-021-01441-w] [Reference Citation Analysis]
570 Zhang J, Peng CS, Tian YH. Primary site surgery for elderly patients with distant metastatic pancreatic neuroendocrine tumor: to do or not to do? Clin Interv Aging 2019;14:1419-32. [PMID: 31496669 DOI: 10.2147/CIA.S209428] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
571 Fu Z, Cheng X, Kuang J, Feng H, Chen L, Liang J, Shen X, Yuen S, Peng C, Shen B, Jin Z, Qiu W. CQ sensitizes human pancreatic cancer cells to gemcitabine through the lysosomal apoptotic pathway via reactive oxygen species. Mol Oncol 2018;12:529-44. [PMID: 29453806 DOI: 10.1002/1878-0261.12179] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 5.3] [Reference Citation Analysis]
572 Zhang S, Shi W, Hu W, Ma D, Yan D, Yu K, Zhang G, Cao Y, Wu J, Jiang C, Wang Z. DEP Domain-Containing Protein 1B (DEPDC1B) Promotes Migration and Invasion in Pancreatic Cancer Through the Rac1/PAK1-LIMK1-Cofilin1 Signaling Pathway. Onco Targets Ther 2020;13:1481-96. [PMID: 32110046 DOI: 10.2147/OTT.S229055] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
573 Hagiwara K, Harimoto N, Araki K, Watanabe A, Kubo N, Nakazawa S, Yajima T, Uchida N, Shirabe K. Long-term survival of two patients with pancreatic cancer after resection of liver and lung oligometastases: a case report.Surg Case Rep. 2020;6:309. [PMID: 33284401 DOI: 10.1186/s40792-020-01029-y] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
574 Osborne N, Sundseth R, Burks J, Cao H, Liu X, Kroemer AH, Sutton L, Cato A, Smith JP. Gastrin vaccine improves response to immune checkpoint antibody in murine pancreatic cancer by altering the tumor microenvironment. Cancer Immunol Immunother 2019;68:1635-48. [PMID: 31549214 DOI: 10.1007/s00262-019-02398-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
575 Treviño JG, Verma M, Singh S, Pillai S, Zhang D, Pernazza D, Sebti SM, Lawrence NJ, Centeno BA, Chellappan SP. Selective disruption of rb-raf-1 kinase interaction inhibits pancreatic adenocarcinoma growth irrespective of gemcitabine sensitivity. Mol Cancer Ther 2013;12:2722-34. [PMID: 24107447 DOI: 10.1158/1535-7163.MCT-12-0719] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
576 Palchetti S, Caputo D, Digiacomo L, Capriotti AL, Coppola R, Pozzi D, Caracciolo G. Protein Corona Fingerprints of Liposomes: New Opportunities for Targeted Drug Delivery and Early Detection in Pancreatic Cancer. Pharmaceutics 2019;11:E31. [PMID: 30650541 DOI: 10.3390/pharmaceutics11010031] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 8.0] [Reference Citation Analysis]
577 Chen J, Xiao-Zhong G, Qi XS. Clinical Outcomes of Specific Immunotherapy in Advanced Pancreatic Cancer: A Systematic Review and Meta-Analysis. J Immunol Res 2017;2017:8282391. [PMID: 28265583 DOI: 10.1155/2017/8282391] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
578 Diana A, Wang LM, D'Costa Z, Allen P, Azad A, Silva MA, Soonawalla Z, Liu S, McKenna WG, Muschel RJ, Fokas E. Prognostic value, localization and correlation of PD-1/PD-L1, CD8 and FOXP3 with the desmoplastic stroma in pancreatic ductal adenocarcinoma. Oncotarget. 2016;7:40992-41004. [PMID: 27329602 DOI: 10.18632/oncotarget.10038] [Cited by in Crossref: 41] [Cited by in F6Publishing: 43] [Article Influence: 10.3] [Reference Citation Analysis]
579 Wang X, Zhang YB, Liu JW, Li P. Expression of metastasis related genes S100A4 and MMP-9 in pancreatic cancer cells treated with metformin. Shijie Huaren Xiaohua Zazhi 2017; 25(4): 334-339 [DOI: 10.11569/wcjd.v25.i4.334] [Reference Citation Analysis]
580 Liu Q, Zhao G, Zhang X, Jiang N, Zhao Z, Wang Y, Xu S, Zhu L, Lau WY, Dai G, Liu R. Nab-paclitaxel plus S-1 with or without PD-1 inhibitor in pancreatic ductal adenocarcinoma with only hepatic metastases: a retrospective cohort study. Langenbecks Arch Surg 2021. [PMID: 34518900 DOI: 10.1007/s00423-021-02321-7] [Reference Citation Analysis]
581 Ishii N, Araki K, Yokobori T, Gantumur D, Yamanaka T, Altan B, Tsukagoshi M, Igarashi T, Watanabe A, Kubo N, Hosouchi Y, Kuwano H, Shirabe K. Reduced FBXW7 expression in pancreatic cancer correlates with poor prognosis and chemotherapeutic resistance via accumulation of MCL1. Oncotarget 2017;8:112636-46. [PMID: 29348852 DOI: 10.18632/oncotarget.22634] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
582 Taniuchi K, Tsuboi M, Sakaguchi M, Saibara T. Measurement of serum PODXL concentration for detection of pancreatic cancer. Onco Targets Ther 2018;11:1433-45. [PMID: 29588598 DOI: 10.2147/OTT.S155367] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
583 Balak JRA, Juksar J, Carlotti F, Lo Nigro A, de Koning EJP. Organoids from the Human Fetal and Adult Pancreas. Curr Diab Rep 2019;19:160. [PMID: 31828551 DOI: 10.1007/s11892-019-1261-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
584 Immervoll H, Hoem D, Steffensen OJ, Miletic H, Molven A. Visualization of CD44 and CD133 in normal pancreas and pancreatic ductal adenocarcinomas: non-overlapping membrane expression in cell populations positive for both markers. J Histochem Cytochem. 2011;59:441-455. [PMID: 21411814 DOI: 10.1369/0022155411398275] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 2.8] [Reference Citation Analysis]
585 Wang L, Xiong L, Wu Z, Miao X, Liu Z, Li D, Zou Q, Yang Z. Expression of UGP2 and CFL1 expression levels in benign and malignant pancreatic lesions and their clinicopathological significance. World J Surg Oncol 2018;16:11. [PMID: 29347944 DOI: 10.1186/s12957-018-1316-7] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
586 Jiao F, Hu H, Han T, Zhuo M, Yuan C, Yang H, Wang L, Wang L. Aberrant expression of nuclear HDAC3 and cytoplasmic CDH1 predict a poor prognosis for patients with pancreatic cancer. Oncotarget 2016;7:16505-16. [PMID: 26918727 DOI: 10.18632/oncotarget.7663] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 3.2] [Reference Citation Analysis]
587 Guo K, Cui J, Quan M, Xie D, Jia Z, Wei D, Wang L, Gao Y, Ma Q, Xie K. The Novel KLF4/MSI2 Signaling Pathway Regulates Growth and Metastasis of Pancreatic Cancer. Clin Cancer Res 2017;23:687-96. [PMID: 27449499 DOI: 10.1158/1078-0432.CCR-16-1064] [Cited by in Crossref: 40] [Cited by in F6Publishing: 30] [Article Influence: 6.7] [Reference Citation Analysis]
588 Bosetti C, Lucenteforte E, Silverman DT, Petersen G, Bracci PM, Ji BT, Negri E, Li D, Risch HA, Olson SH, Gallinger S, Miller AB, Bueno-de-Mesquita HB, Talamini R, Polesel J, Ghadirian P, Baghurst PA, Zatonski W, Fontham E, Bamlet WR, Holly EA, Bertuccio P, Gao YT, Hassan M, Yu H, Kurtz RC, Cotterchio M, Su J, Maisonneuve P, Duell EJ, Boffetta P, La Vecchia C. Cigarette smoking and pancreatic cancer: an analysis from the International Pancreatic Cancer Case-Control Consortium (Panc4). Ann Oncol. 2012;23:1880-1888. [PMID: 22104574 DOI: 10.1093/annonc/mdr541] [Cited by in Crossref: 183] [Cited by in F6Publishing: 161] [Article Influence: 16.6] [Reference Citation Analysis]
589 Yuan Y, Yang Z, Miao X, Li D, Liu Z, Zou Q. The clinical significance of FRAT1 and ABCG2 expression in pancreatic ductal adenocarcinoma. Tumour Biol 2015;36:9961-8. [PMID: 26178481 DOI: 10.1007/s13277-015-3752-0] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
590 Polvani S, Tarocchi M, Tempesti S, Bencini L, Galli A. Peroxisome proliferator activated receptors at the crossroad of obesity, diabetes, and pancreatic cancer. World J Gastroenterol 2016; 22(8): 2441-2459 [PMID: 26937133 DOI: 10.3748/wjg.v22.i8.2441] [Cited by in CrossRef: 48] [Cited by in F6Publishing: 47] [Article Influence: 8.0] [Reference Citation Analysis]
591 Rajeshkumar NV, Yabuuchi S, Pai SG, Tong Z, Hou S, Bateman S, Pierce DW, Heise C, Von Hoff DD, Maitra A. Superior therapeutic efficacy of nab-paclitaxel over cremophor-based paclitaxel in locally advanced and metastatic models of human pancreatic cancer. Br J Cancer. 2016;115:442-453. [PMID: 27441498 DOI: 10.1038/bjc.2016.215] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 3.7] [Reference Citation Analysis]
592 Li BQ, Huang S, Shao QQ, Sun J, Zhou L, You L, Zhang TP, Liao Q, Guo JC, Zhao YP. WT1-associated protein is a novel prognostic factor in pancreatic ductal adenocarcinoma. Oncol Lett 2017;13:2531-8. [PMID: 28454430 DOI: 10.3892/ol.2017.5784] [Cited by in Crossref: 17] [Cited by in F6Publishing: 22] [Article Influence: 3.4] [Reference Citation Analysis]
593 Stenzinger A, Endris V, Klauschen F, Sinn B, Lorenz K, Warth A, Goeppert B, Ehemann V, Muckenhuber A, Kamphues C, Bahra M, Neuhaus P, Weichert W. High SIRT1 expression is a negative prognosticator in pancreatic ductal adenocarcinoma. BMC Cancer 2013;13:450. [PMID: 24088390 DOI: 10.1186/1471-2407-13-450] [Cited by in Crossref: 35] [Cited by in F6Publishing: 30] [Article Influence: 3.9] [Reference Citation Analysis]
594 Drifka CR, Loeffler AG, Mathewson K, Mehta G, Keikhosravi A, Liu Y, Lemancik S, Ricke WA, Weber SM, Kao WJ, Eliceiri KW. Comparison of Picrosirius Red Staining With Second Harmonic Generation Imaging for the Quantification of Clinically Relevant Collagen Fiber Features in Histopathology Samples. J Histochem Cytochem 2016;64:519-29. [PMID: 27449741 DOI: 10.1369/0022155416659249] [Cited by in Crossref: 43] [Cited by in F6Publishing: 44] [Article Influence: 7.2] [Reference Citation Analysis]
595 Yu X, Li H, Fu D, Jin C, Li JI. Characterization of the role of the photosensitizer, deuteporfin, in the detection of lymphatic metastases in a pancreatic cancer xenograft model. Oncol Lett 2015;10:1430-6. [PMID: 26622685 DOI: 10.3892/ol.2015.3441] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
596 Durrant DE, Das A, Dyer S, Tavallai S, Dent P, Kukreja RC. Targeted Inhibition of Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Sensitizes Pancreatic Cancer Cells to Doxorubicin without Exacerbating Cardiac Toxicity. Mol Pharmacol 2015;88:512-23. [PMID: 26101222 DOI: 10.1124/mol.115.099143] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
597 Brunet LR, Hagemann T, Andrew G, Mudan S, Marabelle A. Have lessons from past failures brought us closer to the success of immunotherapy in metastatic pancreatic cancer? Oncoimmunology. 2016;5:e1112942. [PMID: 27141395 DOI: 10.1080/2162402x.2015.1112942] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
598 Ball CR, Oppel F, Ehrenberg KR, Dubash TD, Dieter SM, Hoffmann CM, Abel U, Herbst F, Koch M, Werner J, Bergmann F, Ishaque N, Schmidt M, von Kalle C, Scholl C, Fröhling S, Brors B, Weichert W, Weitz J, Glimm H. Succession of transiently active tumor-initiating cell clones in human pancreatic cancer xenografts. EMBO Mol Med 2017;9:918-32. [PMID: 28526679 DOI: 10.15252/emmm.201607354] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 6.3] [Reference Citation Analysis]
599 Liang K, Liu F, Fan J, Sun D, Liu C, Lyon CJ, Bernard DW, Li Y, Yokoi K, Katz MH, Koay EJ, Zhao Z, Hu Y. Nanoplasmonic Quantification of Tumor-derived Extracellular Vesicles in Plasma Microsamples for Diagnosis and Treatment Monitoring. Nat Biomed Eng 2017;1:0021. [PMID: 28791195 DOI: 10.1038/s41551-016-0021] [Cited by in Crossref: 158] [Cited by in F6Publishing: 155] [Article Influence: 31.6] [Reference Citation Analysis]
600 Cheng Z, Rosati LM, Chen L, Mian OY, Cao Y, Villafania M, Nakatsugawa M, Moore JA, Robertson SP, Jackson J, Hacker-Prietz A, He J, Wolfgang CL, Weiss MJ, Herman JM, Narang AK, McNutt TR. Improving prediction of surgical resectability over current staging guidelines in patients with pancreatic cancer who receive stereotactic body radiation therapy. Adv Radiat Oncol 2018;3:601-10. [PMID: 30370361 DOI: 10.1016/j.adro.2018.07.002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
601 Fassan M, Rusev B, Corbo V, Gasparini P, Luchini C, Vicentini C, Mafficini A, Paiella S, Salvia R, Cataldo I, Scarpa A, Huebner K. Fhit down-regulation is an early event in pancreatic carcinogenesis. Virchows Arch 2017;470:647-53. [PMID: 28289900 DOI: 10.1007/s00428-017-2105-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
602 Nishizawa N, Harada H, Kumamoto Y, Kaizu T, Katoh H, Tajima H, Ushiku H, Yokoi K, Igarashi K, Fujiyama Y, Okuwaki K, Iwai T, Watanabe M, Yamashita K. Diagnostic potential of hypermethylation of the cysteine dioxygenase 1 gene (CDO1) promoter DNA in pancreatic cancer.Cancer Sci. 2019;110:2846-2855. [PMID: 31325200 DOI: 10.1111/cas.14134] [Cited by in Crossref: 11] [Cited by in F6Publishing: 15] [Article Influence: 3.7] [Reference Citation Analysis]
603 Guo JC, Li J, Yang YC, Zhou L, Zhang TP, Zhao YP. Oligonucleotide microarray identifies genes differentially expressed during tumorigenesis of DMBA-induced pancreatic cancer in rats. PLoS One. 2013;8:e82910. [PMID: 24376604 DOI: 10.1371/journal.pone.0082910] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
604 Long Y, Sun Q, Wu J, Wang Y, Jiao S. Allogeneic cell-based immunotherapy combined with chemotherapy and targeted therapy in advanced pancreatic cancer with metastases: A case report. Oncol Lett 2014;7:1594-8. [PMID: 24765183 DOI: 10.3892/ol.2014.1908] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
605 Xie X, Tu J, You H, Hu B. Design, synthesis, and biological evaluation of novel EF24 and EF31 analogs as potential IκB kinase β inhibitors for the treatment of pancreatic cancer. Drug Des Devel Ther 2017;11:1439-51. [PMID: 28553074 DOI: 10.2147/DDDT.S133172] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
606 Christenson ES, Jaffee E, Azad NS. Current and emerging therapies for patients with advanced pancreatic ductal adenocarcinoma: a bright future. Lancet Oncol. 2020;21:e135-e145. [PMID: 32135117 DOI: 10.1016/s1470-2045(19)30795-8] [Cited by in Crossref: 41] [Cited by in F6Publishing: 34] [Article Influence: 20.5] [Reference Citation Analysis]
607 Ansari D, Gustafsson A, Andersson R. Update on the management of pancreatic cancer: Surgery is not enough. World J Gastroenterol 2015; 21(11): 3157-3165 [PMID: 25805920 DOI: 10.3748/wjg.v21.i11.3157] [Cited by in CrossRef: 86] [Cited by in F6Publishing: 80] [Article Influence: 12.3] [Reference Citation Analysis]
608 Sy MS, Altekruse SF, Li C, Lynch CF, Goodman MT, Hernandez BY, Zhou L, Saber MS, Hewitt SM, Xin W. Association of prion protein expression with pancreatic adenocarcinoma survival in the SEER residual tissue repository. Cancer Biomark 2011-2012;10:251-8. [PMID: 22820080 DOI: 10.3233/CBM-2012-0256] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
609 Rozanov D, Cheltsov A, Nilsen A, Boniface C, Forquer I, Korkola J, Gray J, Tyner J, Tognon CE, Mills GB, Spellman P. Targeting mitochondria in cancer therapy could provide a basis for the selective anti-cancer activity. PLoS One 2019;14:e0205623. [PMID: 30908483 DOI: 10.1371/journal.pone.0205623] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
610 Spadi R, Brusa F, Ponzetti A, Chiappino I, Birocco N, Ciuffreda L, Satolli MA. Current therapeutic strategies for advanced pancreatic cancer: A review for clinicians. World J Clin Oncol 2016; 7(1): 27-43 [PMID: 26862489 DOI: 10.5306/wjco.v7.i1.27] [Cited by in CrossRef: 50] [Cited by in F6Publishing: 47] [Article Influence: 8.3] [Reference Citation Analysis]
611 Zhu Y, Zhai K, Ke J, Li J, Gong Y, Yang Y, Tian J, Zhang Y, Zou D, Peng X, Gong J, Zhong R, Huang K, Chang J, Miao X. BRCA1 missense polymorphisms are associated with poor prognosis of pancreatic cancer patients in a Chinese population. Oncotarget 2017;8:36033-9. [PMID: 28415599 DOI: 10.18632/oncotarget.16422] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
612 Paik WH, Ryu JK, Jeong KS, Park JM, Song BJ, Lee SH, Kim YT, Yoon YB. Clobenpropit enhances anti-tumor effect of gemcitabine in pancreatic cancer. World J Gastroenterol 2014; 20(26): 8545-8557 [PMID: 25024609 DOI: 10.3748/wjg.v20.i26.8545] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
613 Matsubara T, Nishida T, Hayashi S, Shimakoshi H, Tomimaru Y, Takahashi K, Nakamatsu D, Matsumoto K, Yamamoto M, Inada M. Comparison of double-layer large-diameter and conventional small-diameter plastic stents for preoperative biliary drainage in resectable distal malignant biliary obstruction. Sci Rep 2020;10:13222. [PMID: 32764666 DOI: 10.1038/s41598-020-70183-y] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
614 Sun S, Osterman MD, Li M. Tissue specificity of DNA damage response and tumorigenesis. Cancer Biol Med 2019;16:396-414. [PMID: 31565474 DOI: 10.20892/j.issn.2095-3941.2019.0097] [Cited by in F6Publishing: 9] [Reference Citation Analysis]
615 Kumar R, Chaudhary K, Singla D, Gautam A, Raghava GP. Designing of promiscuous inhibitors against pancreatic cancer cell lines. Sci Rep 2014;4:4668. [PMID: 24728108 DOI: 10.1038/srep04668] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
616 Guo X, Hollander L, MacPherson D, Wang L, Velazquez H, Chang J, Safirstein R, Cha C, Gorelick F, Desir GV. Inhibition of renalase expression and signaling has antitumor activity in pancreatic cancer. Sci Rep 2016;6:22996. [PMID: 26972355 DOI: 10.1038/srep22996] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
617 Gerritsen A, Besselink MG, Cieslak KP, Vriens MR, Steenhagen E, van Hillegersberg R, Borel Rinkes IH, Molenaar IQ. Efficacy and complications of nasojejunal, jejunostomy and parenteral feeding after pancreaticoduodenectomy. J Gastrointest Surg. 2012;16:1144-1151. [PMID: 22528573 DOI: 10.1007/s11605-012-1887-5] [Cited by in Crossref: 57] [Cited by in F6Publishing: 48] [Article Influence: 5.7] [Reference Citation Analysis]
618 Cui L, Deng Y, Rong Y, Lou W, Mao Z, Feng Y, Xie D, Jin D. IRF-2 is over-expressed in pancreatic cancer and promotes the growth of pancreatic cancer cells. Tumour Biol 2012;33:247-55. [PMID: 22119988 DOI: 10.1007/s13277-011-0273-3] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 2.2] [Reference Citation Analysis]
619 Chu Z, Abu-Baker S, Palascak MB, Ahmad SA, Franco RS, Qi X. Targeting and cytotoxicity of SapC-DOPS nanovesicles in pancreatic cancer. PLoS One. 2013;8:e75507. [PMID: 24124494 DOI: 10.1371/journal.pone.0075507] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 3.4] [Reference Citation Analysis]
620 Gopinathan A, Morton JP, Jodrell DI, Sansom OJ. GEMMs as preclinical models for testing pancreatic cancer therapies. Dis Model Mech 2015;8:1185-200. [PMID: 26438692 DOI: 10.1242/dmm.021055] [Cited by in Crossref: 62] [Cited by in F6Publishing: 59] [Article Influence: 10.3] [Reference Citation Analysis]
621 Mo J, Lin M, He B, Tan K, Jin C, Jiang H, Pan X, Lin W. Recombinant human adenovirus-p53 improves the outcome of mid-late stage pancreatic cancer via arterial infusion. Oncol Lett 2017;14:6829-32. [PMID: 29181104 DOI: 10.3892/ol.2017.7058] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
622 Zhao J, Li J, Schlößer HA, Popp F, Popp MC, Alakus H, Jauch KW, Bruns CJ, Zhao Y. Targeting Cancer Stem Cells and Their Niche: Current Therapeutic Implications and Challenges in Pancreatic Cancer. Stem Cells Int 2017;2017:6012810. [PMID: 28845161 DOI: 10.1155/2017/6012810] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
623 Han DY, Fu D, Xi H, Li QY, Feng LJ, Zhang W, Ji G, Xiao JC, Wei Q. Genomic expression profiling and bioinformatics analysis of pancreatic cancer. Mol Med Rep 2015;12:4133-40. [PMID: 26062681 DOI: 10.3892/mmr.2015.3917] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
624 Nishikawa Y, Tsuji Y, Isoda H, Kodama Y, Chiba T. Perfusion in the tissue surrounding pancreatic cancer and the patient's prognosis. Biomed Res Int 2014;2014:648021. [PMID: 25302302 DOI: 10.1155/2014/648021] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
625 Arnone A, Laudicella R, Caobelli F, Guglielmo P, Spallino M, Abenavoli E, Martini AL, Filice R, Comis AD, Cuzzocrea M, Linguanti F, Evangelista L, Alongi P. Clinical Impact of 18F-FDG PET/CT in the Diagnostic Workup of Pancreatic Ductal Adenocarcinoma: A Systematic Review. Diagnostics (Basel). 2020;10. [PMID: 33287195 DOI: 10.3390/diagnostics10121042] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
626 Prasad KS, Abugalyon Y, Li C, Xu F, Li X. A new method to amplify colorimetric signals of paper-based nanobiosensors for simple and sensitive pancreatic cancer biomarker detection. Analyst 2020;145:5113-7. [PMID: 32589169 DOI: 10.1039/d0an00704h] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 4.5] [Reference Citation Analysis]
627 Walker EJ, Ko AH. Beyond first-line chemotherapy for advanced pancreatic cancer: An expanding array of therapeutic options? World J Gastroenterol 2014; 20(9): 2224-2236 [PMID: 24605022 DOI: 10.3748/wjg.v20.i9.2224] [Cited by in CrossRef: 38] [Cited by in F6Publishing: 33] [Article Influence: 4.8] [Reference Citation Analysis]
628 Zhang LX, Chen L, Xu AM. A Simple Model Established by Blood Markers Predicting Overall Survival After Radical Resection of Pancreatic Ductal Adenocarcinoma. Front Oncol 2020;10:583. [PMID: 32426277 DOI: 10.3389/fonc.2020.00583] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
629 Zhou Z, Ma Z, Li Z, Zhuang H, Liu C, Gong Y, Huang S, Zhang C, Hou B. CMTM3 Overexpression Predicts Poor Survival and Promotes Proliferation and Migration in Pancreatic Cancer. J Cancer 2021;12:5797-806. [PMID: 34475993 DOI: 10.7150/jca.57082] [Reference Citation Analysis]
630 Miyashita T, Miki K, Kamigaki T, Makino I, Tajima H, Nakanuma S, Hayashi H, Takamura H, Fushida S, Ahmed AK, Harmon JW, Ohta T. Low-dose valproic acid with low-dose gemcitabine augments MHC class I-related chain A/B expression without inducing the release of soluble MHC class I-related chain A/B. Oncol Lett 2017;14:5918-26. [PMID: 29113227 DOI: 10.3892/ol.2017.6943] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
631 Yan HH, Jung KH, Son MK, Fang Z, Kim SJ, Ryu YL, Kim J, Kim MH, Hong SS. Crizotinib exhibits antitumor activity by targeting ALK signaling not c-MET in pancreatic cancer. Oncotarget. 2014;5:9150-9168. [PMID: 25193856 DOI: 10.18632/oncotarget.2363] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
632 Yang J, Zhou Y, Zhao B. Isolation of circulating tumor cells in pancreatic cancer patients by immunocytochemical assay. J Clin Lab Anal 2018;32. [PMID: 28523756 DOI: 10.1002/jcla.22156] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
633 Ghidini M, Lampis A, Mirchev MB, Okuducu AF, Ratti M, Valeri N, Hahne JC. Immune-Based Therapies and the Role of Microsatellite Instability in Pancreatic Cancer. Genes (Basel) 2020;12:33. [PMID: 33383713 DOI: 10.3390/genes12010033] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
634 Zhang YH, Zhang CW, Hu ZM, Hong DF. Pancreatic cancer: Open or minimally invasive surgery? World J Gastroenterol 2016; 22(32): 7301-7310 [PMID: 27621576 DOI: 10.3748/wjg.v22.i32.7301] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
635 Ishiguro S, Kawabata A, Zulbaran-Rojas A, Monson K, Uppalapati D, Ohta N, Inui M, Pappas CG, Tzakos AG, Tamura M. Co-treatment with a C1B5 peptide of protein kinase Cγ and a low dose of gemcitabine strongly attenuated pancreatic cancer growth in mice through T cell activation. Biochem Biophys Res Commun 2018;495:962-8. [PMID: 29155177 DOI: 10.1016/j.bbrc.2017.11.102] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
636 Zhu S, Zhou HY, Deng SC, Deng SJ, He C, Li X, Chen JY, Jin Y, Hu ZL, Wang F, Wang CY, Zhao G. ASIC1 and ASIC3 contribute to acidity-induced EMT of pancreatic cancer through activating Ca2+/RhoA pathway. Cell Death Dis 2017;8:e2806. [PMID: 28518134 DOI: 10.1038/cddis.2017.189] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 6.4] [Reference Citation Analysis]
637 Matsumoto H, Yoshida Y. Brain metastasis from pancreatic cancer: A case report and literature review. Asian J Neurosurg 2015;10:35-9. [PMID: 25767574 DOI: 10.4103/1793-5482.151507] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
638 Lu P, Geng J, Zhang L, Wang Y, Niu N, Fang Y, Liu F, Shi J, Zhang ZG, Sun YW, Wang LW, Tang Y, Xue J. THZ1 reveals CDK7-dependent transcriptional addictions in pancreatic cancer. Oncogene 2019;38:3932-45. [PMID: 30692639 DOI: 10.1038/s41388-019-0701-1] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 7.3] [Reference Citation Analysis]
639 Smith JP, Fonkoua LK, Moody TW. The Role of Gastrin and CCK Receptors in Pancreatic Cancer and other Malignancies. Int J Biol Sci 2016;12:283-91. [PMID: 26929735 DOI: 10.7150/ijbs.14952] [Cited by in Crossref: 36] [Cited by in F6Publishing: 30] [Article Influence: 6.0] [Reference Citation Analysis]
640 Teicher BA. Perspective: Opportunities in recalcitrant, rare and neglected tumors. Oncol Rep 2013;30:1030-4. [PMID: 23820887 DOI: 10.3892/or.2013.2581] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
641 Spring BQ, Abu-Yousif AO, Palanisami A, Rizvi I, Zheng X, Mai Z, Anbil S, Sears RB, Mensah LB, Goldschmidt R, Erdem SS, Oliva E, Hasan T. Selective treatment and monitoring of disseminated cancer micrometastases in vivo using dual-function, activatable immunoconjugates. Proc Natl Acad Sci U S A 2014;111:E933-42. [PMID: 24572574 DOI: 10.1073/pnas.1319493111] [Cited by in Crossref: 67] [Cited by in F6Publishing: 67] [Article Influence: 8.4] [Reference Citation Analysis]
642 Li M, Wang MM, Guo XW, Wu CY, Li DR, Zhang X, Zhang PT. Different Survival Benefits of Chinese Medicine for Pancreatic Cancer: How to Choose? Chin J Integr Med 2018;24:178-84. [PMID: 29063468 DOI: 10.1007/s11655-017-2971-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
643 Xiao MB, Jiang F, Ni WK, Chen BY, Lu CH, Li XY, Ni RZ. High expression of S100A11 in pancreatic adenocarcinoma is an unfavorable prognostic marker. Med Oncol. 2012;29:1886-1891. [PMID: 21912994 DOI: 10.1007/s12032-011-0058-y] [Cited by in Crossref: 29] [Cited by in F6Publishing: 33] [Article Influence: 2.6] [Reference Citation Analysis]
644 Yang J, Jiang Y, He R, Liu W, Yang M, Tao L, Fu X, Shen Y, Li J, Liu D, Huo Y, Zhang J, Hua R, Zhang Z, Sun Y. DKK2 Impairs Tumor Immunity Infiltration and Correlates with Poor Prognosis in Pancreatic Ductal Adenocarcinoma. J Immunol Res 2019;2019:8656282. [PMID: 31583260 DOI: 10.1155/2019/8656282] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
645 Ye H, Zhou Q, Zheng S, Li G, Lin Q, Wei L, Fu Z, Zhang B, Liu Y, Li Z, Chen R. Tumor-associated macrophages promote progression and the Warburg effect via CCL18/NF-kB/VCAM-1 pathway in pancreatic ductal adenocarcinoma. Cell Death Dis 2018;9:453. [PMID: 29670110 DOI: 10.1038/s41419-018-0486-0] [Cited by in Crossref: 59] [Cited by in F6Publishing: 61] [Article Influence: 14.8] [Reference Citation Analysis]
646 Provenzano PP, Hingorani SR. Hyaluronan, fluid pressure, and stromal resistance in pancreas cancer. Br J Cancer. 2013;108:1-8. [PMID: 23299539 DOI: 10.1038/bjc.2012.569] [Cited by in Crossref: 173] [Cited by in F6Publishing: 165] [Article Influence: 19.2] [Reference Citation Analysis]
647 Li YH, Wang X, Pan Y, Lee DH, Chowdhury D, Kimmelman AC. Inhibition of non-homologous end joining repair impairs pancreatic cancer growth and enhances radiation response. PLoS One. 2012;7:e39588. [PMID: 22724027 DOI: 10.1371/journal.pone.0039588] [Cited by in Crossref: 41] [Cited by in F6Publishing: 45] [Article Influence: 4.1] [Reference Citation Analysis]
648 Zhao F, Wei C, Cui MY, Xia QQ, Wang SB, Zhang Y. Prognostic value of microRNAs in pancreatic cancer: a meta-analysis. Aging (Albany NY) 2020;12:9380-404. [PMID: 32420903 DOI: 10.18632/aging.103214] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
649 Burks J, Nadella S, Mahmud A, Mankongpaisarnrung C, Wang J, Hahm JI, Tucker RD, Shivapurkar N, Stern ST, Smith JP. Cholecystokinin Receptor-Targeted Polyplex Nanoparticle Inhibits Growth and Metastasis of Pancreatic Cancer. Cell Mol Gastroenterol Hepatol 2018;6:17-32. [PMID: 29928669 DOI: 10.1016/j.jcmgh.2018.02.013] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
650 Balázs A, Németh BC, Ördög B, Hegyi E, Hritz I, Czakó L, Czimmer J, Gódi S, Csiszkó A, Rakonczay Z Jr, Párniczky A, Izbéki F, Halász A, Kahán Z, Hegyi P, Sahin-Tóth M; Hungarian Pancreatic Study Group. A Common CCK-B Receptor Intronic Variant in Pancreatic Adenocarcinoma in a Hungarian Cohort. Pancreas 2016;45:541-5. [PMID: 26646278 DOI: 10.1097/MPA.0000000000000539] [Reference Citation Analysis]
651 Suzuki S, Okada M, Shibuya K, Seino M, Sato A, Takeda H, Seino S, Yoshioka T, Kitanaka C. JNK suppression of chemotherapeutic agents-induced ROS confers chemoresistance on pancreatic cancer stem cells. Oncotarget. 2015;6:458-470. [PMID: 25473894 DOI: 10.18632/oncotarget.2693] [Cited by in Crossref: 50] [Cited by in F6Publishing: 46] [Article Influence: 8.3] [Reference Citation Analysis]
652 Zhu D, Yang Z, Liu Z, Zou Q, Yuan Y, Hu C. Association between Wnt inhibitory factor 1 and receptor tyrosine kinase-like orphan receptor 2 protein expression and the clinical pathological significance in benign and malignant pancreatic lesions. Oncol Lett 2017;13:2244-52. [PMID: 28454387 DOI: 10.3892/ol.2017.5704] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
653 Haider S, Wang J, Nagano A, Desai A, Arumugam P, Dumartin L, Fitzgibbon J, Hagemann T, Marshall JF, Kocher HM, Crnogorac-Jurcevic T, Scarpa A, Lemoine NR, Chelala C. A multi-gene signature predicts outcome in patients with pancreatic ductal adenocarcinoma. Genome Med 2014;6:105. [PMID: 25587357 DOI: 10.1186/s13073-014-0105-3] [Cited by in Crossref: 64] [Cited by in F6Publishing: 64] [Article Influence: 8.0] [Reference Citation Analysis]
654 Heinrich EL, Arrington AK, Ko ME, Luu C, Lee W, Lu J, Kim J. Paracrine Activation of Chemokine Receptor CCR9 Enhances The Invasiveness of Pancreatic Cancer Cells. Cancer Microenviron 2013;6:241-5. [PMID: 23371851 DOI: 10.1007/s12307-013-0130-6] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.1] [Reference Citation Analysis]
655 Van Sciver RE, Lee MP, Lee CD, Lafever AC, Svyatova E, Kanda K, Colliver AL, Siewertsz van Reesema LL, Tang-Tan AM, Zheleva V, Bwayi MN, Bian M, Schmidt RL, Matrisian LM, Petersen GM, Tang AH. A New Strategy to Control and Eradicate "Undruggable" Oncogenic K-RAS-Driven Pancreatic Cancer: Molecular Insights and Core Principles Learned from Developmental and Evolutionary Biology. Cancers (Basel) 2018;10:E142. [PMID: 29757973 DOI: 10.3390/cancers10050142] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
656 Gong JH, Zheng YB, Zhang MR, Wang YX, Yang SQ, Wang RH, Miao QF, Liu XJ, Zhen YS. Dexamethasone enhances the antitumor efficacy of Gemcitabine by glucocorticoid receptor signaling. Cancer Biol Ther 2020;21:332-43. [PMID: 31906826 DOI: 10.1080/15384047.2019.1702399] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
657 Provenzano PP, Cuevas C, Chang AE, Goel VK, Von Hoff DD, Hingorani SR. Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell. 2012;21:418-429. [PMID: 22439937 DOI: 10.1016/j.ccr.2012.01.007] [Cited by in Crossref: 1156] [Cited by in F6Publishing: 1136] [Article Influence: 115.6] [Reference Citation Analysis]
658 Khawaja MR, Kleyman S, Yu Z, Howard T, Burns M, Nakeeb A, Loehrer PJ Sr, Cardenes HR, Chiorean EG. Adjuvant Gemcitabine and Gemcitabine-based Chemoradiotherapy Versus Gemcitabine Alone After Pancreatic Cancer Resection: The Indiana University Experience. Am J Clin Oncol 2017;40:42-6. [PMID: 25121637 DOI: 10.1097/COC.0000000000000115] [Cited by in Crossref: 3] [Article Influence: 0.4] [Reference Citation Analysis]
659 Guddati AK, Komiya T, Patel SJ, Sharma N, Powell E. Impact of immunotherapy use in patients with stage IV pancreatic carcinoma. J Gastrointest Oncol 2020;11:654-62. [PMID: 32953149 DOI: 10.21037/jgo-20-191] [Reference Citation Analysis]
660 Berry W, Lundy J, Croagh D, Jenkins BJ. Reviewing the Utility of EUS FNA to Advance Precision Medicine in Pancreatic Cancer. Cancers (Basel) 2018;10:E35. [PMID: 29382047 DOI: 10.3390/cancers10020035] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
661 Giannis D, Moris D, Barbas AS. Diagnostic, Predictive and Prognostic Molecular Biomarkers in Pancreatic Cancer: An Overview for Clinicians. Cancers (Basel) 2021;13:1071. [PMID: 33802340 DOI: 10.3390/cancers13051071] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
662 Schultz NA, Andersen KK, Roslind A, Willenbrock H, Wøjdemann M, Johansen JS. Prognostic microRNAs in cancer tissue from patients operated for pancreatic cancer--five microRNAs in a prognostic index. World J Surg. 2012;36:2699-2707. [PMID: 22851141 DOI: 10.1007/s00268-012-1705-y] [Cited by in Crossref: 57] [Cited by in F6Publishing: 62] [Article Influence: 6.3] [Reference Citation Analysis]
663 Song X, Shao Z, Liang H. Using the new INTRABEAM mobile intraoperative radiotherapy system during surgery for pancreatic cancer: a case report. J Med Case Rep 2019;13:23. [PMID: 30683151 DOI: 10.1186/s13256-018-1906-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
664 Cai L, Michelakos T, Ferrone CR, Zhang L, Deshpande V, Shen Q, DeLeo A, Yamada T, Zhang G, Ferrone S, Wang X. Expression status of folate receptor alpha is a predictor of survival in pancreatic ductal adenocarcinoma. Oncotarget 2017;8:37646-56. [PMID: 28430580 DOI: 10.18632/oncotarget.16841] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
665 Liu L, Liu Y, Liu X, Zhang N, Mao G, Zeng Q, Yin M, Song D, Deng H. Resibufogenin suppresses transforming growth factor-β-activated kinase 1-mediated nuclear factor-κB activity through protein kinase C-dependent inhibition of glycogen synthase kinase 3. Cancer Sci 2018;109:3611-22. [PMID: 30168902 DOI: 10.1111/cas.13788] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
666 Chen J, Li H, Xu W, Guo X. Evaluation of serum ATX and LPA as potential diagnostic biomarkers in patients with pancreatic cancer. BMC Gastroenterol 2021;21:58. [PMID: 33568105 DOI: 10.1186/s12876-021-01635-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
667 Ikematsu Y, Tamura H, Hayashi T, Tokunaga Y, Misawa Y, Mori H, Hasegawa S, Okawada T, Ozawa T, Momiki S, Nishiwaki Y. Metachronous double cancer after curative resection for pancreatic adenocarcinoma: report of four cases. Clin J Gastroenterol 2012;5:108-12. [PMID: 26182152 DOI: 10.1007/s12328-011-0280-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]